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3... Since then I never pay any attention to anything by ‘experts.’
I calculate everything myself.
I’ll never make that mistake again, reading the experts’ opinions.
Of course, you only live one life, and you make all your mistakes,
and learn what not to do, and that’s the end of you.
Richard Feynman, 1985
"Surely You're Joking, Mr. Feynman"
Have no respect whatsoever for authority;
forget who said it and instead look at what he starts with, where he ends up,
and ask yourself, "is it reasonable?"
Richard Feynman, 1988
"What Do You Care What Other People Think?"
When an old and distinguished person speaks to you, listen to him carefully and with respect - but do not
believe him. Never put your trust in anything but your own intellect. Your elder, no matter whether he has
grey hair or has lost his hair, no matter whether he is a Nobel Laureate, may be wrong. The world progresses,
year by year, century by century, as the members of the younger generation find out what was wrong among
the things that their elders said. So you must always be skeptical - always think for yourself.
There are, of course, exceptional circumstances: when you are taking an examination, it is smart to answer
the questions not by saying what you think is right, but rather what you think the professor thinks is right.
Linus Pauling, 1955
Advice to Students
I wish to propose for the reader’s favourable consideration a doctrine which may, I fear, appear wildly
paradoxical and subversive. The doctrine in question is this: that it is undesirable to believe a proposition
when there is no ground whatever for supposing it true, I must, of course, admit that if such an opinion
became common it would completely transform our social life and our political system; since both are at
present faultless, this must weight against it. I am also aware (what is more serious) that it would tend to
diminish the incomes of clairvoyants, bookmakers, bishops and others who live on the irrational hopes of
those who have done nothing to deserve good fortune here or hereafter.
Bertrand Russell, 1928
Sceptical Essays
… Where I have been necessarily led, in this disagreeable part of the work, to criticise the sentiments of
eminent and learned authors, I have not done it with a malignant view of depreciating their labours, or their
names; but from a regard to truth, and to the good of mankind. I hope such motives will, to the candid,
and to the most judicious, be a sufficient apology for the liberties I have assumed.
James Lind, 1753
A Treatise of the Scurvy
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5ABSTRACT
Deficiency of vitamin C causes a specific deficiency disease, scurvy, which led to the deaths of numer-
ous seamen in the Age of Sail because they had no access to fruit or vegetables during long voyages.
Nowadays scurvy is very rare in the Western countries. Vitamin E is found in such a great variety of
foods and is stored in the body for such long periods that deficiency of this vitamin hardly ever results
from poor diet.
Since a large number of studies found that vitamins C and E affect the immune system, it has been
suggested that these vitamins might affect infectious diseases. Numerous animal studies found that
vitamins C and E reduce the incidence and severity of various viral and bacterial infections. These
findings justify research into whether these two vitamins affect the incidence and severity of respira-
tory infections in humans.
The earlier medical literature contains suggestions that vitamin C may be beneficial against respira-
tory infections, but this topic achieved wider popular interest only after 1970 when Linus Pauling, a
dual Nobel Laureate, wrote a book in which he concluded that large doses of vitamin C prevent and
alleviate colds. Pauling’s proposal led to a large series of new placebo-controlled trials. It is shown in
this thesis that these new trials consistently found that regular vitamin C supplementation shortens the
duration and alleviates the symptoms of the common cold, partly confirming Pauling’s hypothesis. The
new trials did not find reduction of common cold incidence in the ordinary Western population with
vitamin C supplementation. Nevertheless, in this thesis it is shown that there may be sub-populations,
such as people undergoing heavy acute physical stress and young males with low dietary vitamin C
intakes, in which regular vitamin C supplementation may reduce the incidence of the common cold.
While the trials carried out since 1970 have shown that vitamin C alleviates common cold symp-
toms, it is strange that major medical textbooks state that this vitamin has no effect on colds. In this
thesis it is shown that the most influential reviews on vitamin C and the common cold cited in the major
textbooks contain numerous erroneous statements, and that they even present data that are inconsistent
with the original study reports. Consequently, the negative statements in the medical textbooks are
based on biased reviews. It is also shown that the most influential vitamin C common cold trial carried
out at the National Institutes of Health in the USA and published in JAMA in 1975 was erroneously
analyzed.
Overall, the analyses of the vitamin C common cold trials indicate that further therapeutic trials
examining the effect of vitamin C on the common cold are warranted, in particular among children.
Proper understanding of the restricted subgroups or particular living conditions in which daily vitamin
C supplementation might be beneficial also requires further study.
The second part of this thesis consists of analyses of the ATBC (Alpha-Tocopherol, Beta-Carotene
Cancer Prevention) Study with 29,133 male smokers. The current analysis focuses on the question of
whether vitamin E might affect respiratory infections.
In the ATBC Study, vitamin E supplementation had no overall effect on the incidence of the com-
mon cold or pneumonia, but in both cases there was substantial modification of the vitamin E effect,
suggesting benefit in restricted sub-populations. Common cold incidence was reduced by vitamin E in
a small group of elderly city-dwellers who smoked 5-14 cigarettes per day. Although the effect was
statistically highly significant, it was small and the assessment of its practical importance requires
further study. The incidence of pneumonia was reduced among participants who started cigarette smoking
at later ages. This effect was also statistically highly significant, but further work is needed to evaluate
its practical significance. Vitamin E supplementation had no effect on the risk of tuberculosis.
The intake level of vitamin C in diet was estimated at the baseline of the ATBC Study. It was found
that the level of vitamin C in diet had no association with the risk of the common cold or tuberculosis.
A major finding in this thesis is heterogeneity in the effects of daily vitamin C and vitamin E supple-
mentation. While there is no evidence that ordinary people might benefit from supplementation of
these two vitamins, the heterogeneity in effects indicates that further study should be carried out to
identify and characterize the population groups or living conditions in which these vitamins might be
beneficial.
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9ABBREVIATIONS
Abbreviations that are used only in one chapter and defined within the same chapter are not listed here
except when the term may need more explicit definition.
ATBC Study The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study with 29,133 participants
(p 52; ATBC 1994a,b)
CI Confidence Interval; a measure of the accuracy of a result
DB double blind
EBM Evidence-Based Medicine
FDA US Food and Drug Administration; regulates prescription and non-prescription drugs, and the
labeling of products under its jurisdiction
FNB Food and Nutrition Board of the NRC; sets up committees to establish RDA levels;  NRC:  National
Research Council; the principal operating agency of the US National Academy of Sciences, adminis-
tered jointly by the Academy and the Institute of Medicine (the latter established in 1970 by the US
National Academy of Sciences to secure the services of eminent members of appropriate professions
in the examination of policy matters pertaining to public health)
NIH National Institutes of Health of the USA
NNT Number Needed to Treat; how many people need to be treated to produce benefit for a single person
RCT Randomized Controlled Trial
RDA Recommended Dietary Allowance; the dietary intake level sufficient to meet the nutrient require-
ment of nearly all healthy individuals (FNB 1989a, 1994a, 2000)
OR Odds Ratio; an approximation of the RR
RR Risk Ratio; the ratio of risk in two populations; e.g., if 10% of the study population and 40% of the
control population contract a disease, then RR = 0.25
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1INTRODUCTION
Overview of vitamin C
History of vitamin C and its deficiency, scurvy, is fascinat-
ing and it is briefly summarized in Appendix 1.
Scurvy, the deficiency of vitamin C, was a serious dis-
ease in particular of sailors in the Age of Sail. James Lind
(1753) wrote the classic monograph A Treatise of the Scurvy
in which he reported a systematic review of all the earlier
literature. In the literature before Lind, the clinical defini-
tion of scurvy had become ambiguous and in many cases
the name was used for diseases unrelated to our current defi-
nition. Lind’s own clinical definition was based on "putrid
gums, swelled legs, and spots, accompanying each other,
and in their progress usually attended with rigid tendons in
the ham … observed in no other distemper".
In 1747, Lind (1753) carried out the first well described
controlled trial in medicine, on HMS Salisbury. Lind treated
two patients with scurvy with 2 oranges and 1 lemon per
day, and to the other groups of scorbutic patients he admin-
istered other supposed anti-scurvy remedies. The patients
administered oranges and lemons recovered rapidly whereas
the other patients did not. In addition to providing direct
evidence that oranges and lemons cured scurvy, Lind’s trial
was a milestone in medical research methodology. For ex-
ample, Hampton (2002) commented that "the elegant trial
of the use of oranges and lemons for the treatment of scurvy
was hardly bettered until the trial of streptomycin for tuber-
culosis designed by Austin Bradford Hill [in 1948]."
In spite of his own trial showing that fruit cured scurvy,
Lind was convinced that lack of fruit and vegetables was not
the primary etiological cause of scurvy, and proposed that the
primary cause was moisture of air (see Appendix 1). It seems
that the correct explanation of the etiology of scurvy was first
proposed in 1734 by John Bachstrom, a physician in Holland
who proposed that scurvy was caused by the absence of fresh
vegetable food from the diet for a considerable time. About a
century later, John Elliotson (1831), professor of medicine in
London, also proposed that scurvy was caused by the defi-
ciency of some substances in diet. However, the concept of
necessary minor constituents of diet started to be accepted in
main-line medicine only in the early twentieth century, in par-
ticular, because of the work of Sir Frederick Hopkins who was
awarded the 1929 Nobel Prize for his discovery of the growth-
stimulating substances, which he called ‘accessory food fac-
tors’, that were later named vitamins (NF 2005a).
Although there was strong evidence that fruit cured
scurvy, there was no biological rationalization for fruit, and
a large number of false theories about scurvy prevailed long
after Lind’s 1747 trial (Table 1). Since vitamin C is synthe-
sized by all mammals with the few exceptions of primates,
the guinea pig and fruit-eating bats, a practical animal model
for scurvy was not easy to find. Holst and Frölich (1907)
were able to produce scurvy in guinea pigs and thereby an
animal model for vitamin C deficiency was identified; how-
ever, see footnote to Table 1. Vitamin C was first isolated
by Albert Szent-Györgyi, who was awarded the Nobel Prize
in Medicine or Physiology in 1937 partly for identifying
vitamin C (NF 2005b). The chemical structure of vitamin C
was solved by Haworth, who was awarded the Nobel Prize
in Chemistry in 1937 (NF 2005c).
Typical symptoms of classical scurvy include swollen
and bleeding gums, dropping teeth, and poor healing of
wounds (Hess 1920; Kalaja 1939; Crandon et al. 1940; Pe-
ters et al. 1948; Krebs 1953; Hodges et al. 1971; Carpenter
1986; Forsius 1997; Harvie 2002; Bown 2003). Since these
symptoms are explained by the participation of vitamin C
in the synthesis of collagen, major textbooks of biochemis-
try mention only the role of vitamin C in proline
hydroxylation (e.g., Berg et al. 2002). Vitamin C, however,
also participates in the enzymatic synthesis of dopamine,
carnitine, and a number of neuroendocrine peptides (Englard
& Seifter 1986; Levine 1986; Hughes 1988; Padh 1990;
Hemilä & Antila 1993b; Rebouche 1991; Rice 2000). In
addition, vitamin C participates in the transformation of cho-
lesterol into bile acids (Ginter 1973, 1989; Hemilä 1990d,
1992c, 1993). The survival time of vitamin C deficient
guinea pigs is extended by carnitine (Jones & Hughes 1982)
and glutathione (Mårtensson et al. 1993), indicating that
scurvy is not explained simply by the defects in collagen
hydroxylation. Furthermore, vitamin C is a powerful reduc-
ing agent, antioxidant, and reacts with oxidants produced
by phagocytes, through which it may affect the functions of
the immune system (Hemilä et al. 1984; Hemilä 1992a,b,
1997a, 2003a). Thus the notion presented in the textbooks
that vitamin C participates only in the hydroxylation of pro-
line in collagen is grossly oversimplified and misleading.
A number of early animal studies indicated that vitamin
C may affect susceptibility to infection (Perla & Marmorston
1937). After James Lind’s treatise on scurvy, the next Eng-
lish treatise was written by Alfred Hess (1920; Darby &
Woodruff 1962; Wiedemann 1993), a pediatrician in New
York. In various parts of his monograph, Hess noted the
increased risk of infection, in particular pneumonia, in vita-
min C deficiency. A decade later, in a major medical jour-
nal, Hess (1932) commented that in "infantile scurvy …
a lack of the antiscorbutic factor which leads to scurvy, at
the same time predisposes to infections [particularly of the
respiratory tract].  … Similar susceptibility to infections goes
hand in hand with adult scurvy." Such opinions did not leave
traces in mainstream medicine and, according to the cur-
rent widespread consensus, vitamin C has relevance only in
preventing and curing classical scurvy.
The current world production of vitamin C is about
100,000,000 kg per year, i.e., 15 grams per year per each
inhabitant of the globe (Hancock & Viola 2002; Baier 2004).
Approximately half of the vitamin C produced is used in
vitamin supplements and pharmaceutical preparations. A
survey of female physicians in the USA found that 18% of
21 See Appendix 1.
2 McCollum discovered vitamin A and was "one of the giants of nutritional biochemistry" (Simoni et al. 2002). For the work of McCollum, see
McCollum (1953, 1967), Rider (1970), Day (1974, 1979, 1997), Schneider (1986), Carpenter (2003b), JHBSPH (2005).
Each year the E.V. McCollum Award is given by the American Society of Clinical Nutrition to a clinical investigator currently perceived as a
major creative force, actively generating new concepts in nutrition, and personally seeing to the execution of studies testing the validity of these
concepts (ASCN 2005). In 1972, the McCollum award was given to Victor Herbert (see pp 62-4 of this thesis), and in 1990 to Ranjit K.
Chandra (see pp 16-8 of this thesis).
In 1917, McCollum and Pitz published the results of a series of experiments with guinea pigs in a paper which was recently categorized as a
"classic paper" by the Journal of Biological Chemistry (Simoni et al. 2002).
McCollum and Pitz (1917) stated in the Journal of Biological Chemistry paper that "the experimental data presented in this paper form a
conclusive line of evidence which proves that scurvy in the guinea pig is not a deficiency disease in the sense in which Holst, Funk, Hess and
others have regarded it … The efficiency of orange juice as an antiscorbutic may well be accounted for by its content of sodium and potassium
citrates, both of which possess laxative properties"  (p 234), "chart 7 offers definite and convincing evidence that scurvy is in reality the sequel
to retention of feces in the cecum" (p 235), "we are inclined to attribute the beneficial effects of orange juice to its laxative action" (p 237), "the
observations reported in this paper furnish definite support for the idea that scurvy in the guinea pig is not the result of the deficiency of a spe-
cific protective substance… it becomes necessary to offer a new interpretation as to the etiology of experimental scurvy in the guinea pig. Our
interpretation, that the first cause of the disease is associated with the retention of feces … is we believe supported by adequate experimental
data" (pp 238-9). "The significance of this interpretation is far reaching. It removes from the list one of the syndromes (scurvy) which has long
been generally accepted as being due to dietary deficiency" (p 239). "This fact, together with convincing evidence that scurvy is not in reality a
deficiency disease in the sense of being caused by a lack of specific protective substance, warrants an attitude of skepticism regarding the valid-
ity of the ‘vitamine’ theory of the etiology of such other diseases as pellagra, rickets, etc., which have been attributed to specific dietary defi-
ciency" (p 239-40). “… There is therefore no reason whatever why we should assume as Voegtlin, Goldberger, Funk, and other have done that
pellagra is due to a lack of a specific unidentified dietary factor, a ‘vitamine’ ” (p 241).
McCollum (1917) repeated his conclusions in JAMA: "Scurvy in the guinea-pig is the result of the retention of feces…  I am inclined to
attribute the protective power of orange juice as an antiscorbutic to its content of certain salts of citric acid, rather than to the presence of an
unidentified organic substance of the class of the so-called vitamins" (p 1385).
Table 1. Erroneous theories of scurvy by eminent people maintained after James Lind’s controlled trial
in 1747, which showed that citrus fruit cured scurvy
________________________________________________________________________________________________
Person and his position Theory of scurvy
___________________ ______________
James Lind (1716-1794) 1 Caused by moisture,
Carried out the first systematic review prevented and cured by dry air 1
and the first well documented controlled trial
Sir John Pringle (1707-1787) Caused by putrefaction,
President of the Royal Society correctable by foods fermenting to yield
Physician to King George III carbon dioxide (wort of malt)
Sir Robert Christison (1797-1882) Caused by protein deficiency
President of the British Medical Association,
Physician to Queen Victoria
Lord Lister (1827-1912) Caused by ptomaine intoxication
President of the Royal Society, (substances in spoiled food)
Surgeon to Queen Victoria
Jean-Antoine Villemin (1827-1892) Caused by a contagious miasm
Member of the Academy of  Medicine, Paris
William Hammond (1828-1900) Caused by deficiency of potassium and/or iron
US Army Surgeon-General
Elmer McCollum (1879-1967) 2 Caused by constipation and cured by laxatives 2
The most important US nutrition scientist in the early 1900s
________________________________________________________________________________________________
Modified of Carpenter (1986) Table 10.4
3them were regularly using vitamin C supplements (Frank et
al. 2000), and about 30% of the general US adult popula-
tion takes vitamin C supplements (FNB 2000). This high
level consumption of vitamin C by people’s own initiative
makes the health effects of supplementation of consider-
able public health interest, be they positive or negative.
Overview of vitamin E
The history of vitamin E is much less dramatic than that of
vitamin C (Mason 1977; Raacke 1983; Ames 1984). Vitamin
E deficiency caused sterility in male and female rats (Evans
& Bishop 1922), and vitamin E was isolated from wheat germ
oil using the ‘ability of rats to bear litters’ as the biological
test. Its chemical name, tocopherol, was derived from tocos
(‘childbirth’ in Greek) and phero (‘bringing’ birth in Greek).
Because of the ubiquitous distribution of vitamin E in grain,
vegetable oil and animal fat, vitamin E deficiency is virtually
nonexistent as a result of poor diet (FNB 2000). Vitamin E
deficiency can occur because of malabsorption of dietary vi-
tamin E resulting from various gastrointestinal disorders that
interfere with the digestion or absorption of lipids. In hu-
mans, vitamin E deficiency causes various neurological symp-
toms such as ataxia and myopathy (Sokol 1993).
Vitamin E is a fat-soluble antioxidant that prevents the
propagation of free-radical reactions, which seems to be its
main biochemical function (FNB 2000). In particular, vita-
min E protects polyunsaturated fatty acids within membrane
phospholipids and in plasma lipoproteins. Vitamin E also
inhibits protein kinase C activity, but the physiological sig-
nificance of this is not clear (FNB 2000; Ricciarelli et al.
2001; Azzi et al. 2002).
The first report suggesting that vitamin E might affect
the severity of infections was published in the 1940s (Sabin
& Duffy 1940; p 131), but wider interest in its possible ef-
fects on the immune system and susceptibility to infection
was initiated in the 1970s with studies on chickens (Tengerdy
et al. 1972; Nockels 1979).
A survey of female physicians in the USA found that
16% were regularly using vitamin E supplements (Frank et
al. 2000), and about 25% of the general US adult popula-
tion take vitamin E supplements (FNB 2000). This high pro-
portion of people using vitamin E supplements makes the
health effects of such supplementation of considerable public
health interest irrespective of whether the effects are ben-
eficial or harmful.
4REVIEW OF THE LITERATURE
Infections studied in the present work
The common cold
The term ‘the common cold’ does not denote any precisely
defined disease, but this illness is personally familiar to prac-
tically everybody. Typically the symptoms of the common
cold consist of some combination of nasal discharge and ob-
struction, sore throat, cough, lethargy, and malaise, with or
without fever. On average, young children have 6 colds per
year, and the incidence decreases with age so that elderly
people have about one per year (Monto 1994). The common
cold is the leading cause of acute morbidity and of visits to a
physician in the Western countries, and a major cause of
absenteeism from work and school (Gwaltney 2005).
The common cold is usually caused by respiratory vi-
ruses (rhino, corona, adeno, parainfluenza, influenza, res-
piratory syncytial), which overall have some 200 serotypes
(Gwaltney 2005; Puhakka 1999; Mäkelä et al. 1998; West
2002; Heikkinen & Järvinen 2003). Thus, the term ‘com-
mon cold’ does not refer to a single entity but to a group of
diseases caused by numerous unrelated etiological agents.
The most frequent agent causing the common cold is rhino-
virus, which is found in some 30-50% of sufferers. In sub-
jects with cold symptoms, the etiology remains undefined
in some third of subjects even when extensive virological
tests are used. It is not clear to what extent this latter group
is explained by the low sensitivity of the tests, unidentified
viruses, or similar symptoms arising from non-viral etiology.
Different respiratory viruses have different symptom pro-
files, but the patterns are not consistent enough to validate
etiological conclusions from the patients’ symptoms.
Although the great majority of common cold episodes
are caused by the respiratory virus group, the symptom-
based definition of the ‘common cold’ also covers some
diseases caused by other viruses (varicella, measles, rubella,
cytomegalo, Epstein-Barr) and some bacterial infections.
For example, since streptococcal pharyngitis cannot be dif-
ferentiated from viral pharyngitis on clinical grounds, it can
also be included within the broad definition of the common
cold. Symptoms of illnesses caused by Mycoplasma
pneumoniae and Chlamydia pneumoniae may also be simi-
lar to the symptoms caused by the respiratory viruses.
The large number of etiological agents, the mild charac-
ter of the disease, and the high cost of the virological tests
(e.g., $ 700 per patient in Mäkelä et al. 1998) mean that a
functional everyday definition of the ‘common cold’ can-
not be based on laboratory tests, but must be based on symp-
toms. A chest x-ray has no relevance in excluding pneumo-
nia when the symptoms are mild and the patient is not seri-
ously ill. The manifestations of the common cold are so
typical that self-diagnosis by the patient is usually correct.
Hay fever and vasomotor rhinitis may give similar nasal
symptoms, but the recurrent and chronic nature of these dis-
eases is soon recognized by the patient and easily diagnosed
by the physician from the patient’s history (Gwaltney 2005).
In several common cold trials an explicit definition of
the common cold has been used for logistic reasons; for
example, based on the duration and the set of symptoms to
yield an explicitly defined outcome. Such limits are, how-
ever, biologically arbitrary. There is no exact minimum du-
ration or combination of symptoms which is meaningful
when drawing a conclusion as to whether the symptoms
should be explained by a viral infection or by allergic or
mechanical irritation of nasal airways or throat.
The use of antibiotics for a typical acute common cold
episode is useless since the vast majority of colds are caused
by viruses (Arroll & Kenealy 2005). Nevertheless, about
half of common cold patients in the USA received antibiot-
ics according to some surveys (Mainous et al. 1996;
Gonzales et al. 1997). In this respect, the alternative treat-
ment options for the common cold are of substantial public
health interest (Turow 1997).
Pneumonia
Pneumonia denotes infection of the lungs, i.e., an infection
defined by an anatomical region. ‘Community-acquired pneu-
monia’ means pneumonia cases occurring at home, and ‘hos-
pital acquired (nosocomial) pneumonia’ means pneumonia
cases initiating in hospitals. The practical reason for this di-
vision is that the spectrum of etiological agents causing these
two types of pneumonia is different, and consequently the
selection of antibiotics and prognosis is different.
Pneumonia can be caused by bacteria, viruses, Rickettsia,
fungi, or parasites, and close to 100 species in these groups
have been identified as etiological agents (Donowitz &
Mandell 2005). The majority of diagnosed pneumonia cases
are caused by bacteria, the most common being Streptococ-
cus pneumoniae which causes 15-40% of the acute commu-
nity-acquired pneumonia (Fine 2003). In various studies, vi-
ruses caused about 8-18% of community-acquired pneumo-
nia episodes while the etiological agent remained unidenti-
fied in 20-45% of cases. In the case of pneumonia which is
not severe, it is impractical to try to identify the etiological
agent. Different bacteria generally have differences in the sets
of symptoms which are relevant in choosing a proper antibi-
otic as the susceptibility of bacteria to antibiotics varies. Pneu-
monia caused by fungi and parasites is rare and usually af-
fects subjects with serious background diseases.
The suspicion that a patient has pneumonia usually arises
when the general condition of the subject has been declin-
ing in association with respiratory symptoms such as cough,
chest pain, and difficulty in breathing, often associated with
fever. Diagnosis of pneumonia is usually based on new in-
filtrates in a chest x-ray, but high resolution computed tom-
ography can sometimes identify pulmonary changes caused
5by pneumonia even when the chest x-ray is normal (Syrjälä
et al. 1998).
The risk of pneumonia is elevated in young children and
the aged (Graham 1990). It has been estimated that in de-
veloping countries pneumonia causes annually about 2 mil-
lion deaths in children under 5 (Graham 1990; Jones et al.
2003; Rudan et al. 2004). In Finland, the annual rate of pneu-
monia-related hospital treatment is 2.7 per 1,000 men and
1.1 per 1,000 women in the age group of 15-64 years, and
26 per 1,000 men and 18 per 1,000 women among people
aged ≥65 years (Säynäjäkangas et al. 1997a,b;
Säynäjäkangas 1999).
Tuberculosis
In contrast to the common cold and pneumonia, tuberculo-
sis has an exact etiological definition as a disease caused by
Mycobacterium tuberculosis (Fitzgerald & Haas 2005). Nev-
ertheless, it is important to differentiate tuberculosis infec-
tion from tuberculosis disease. Infection implies seeding of
some anatomic focus with the bacterium, which may or may
not cause clinical disease. It has been estimated that one
third of world’s population is infected with M. tuberculosis
(Corbett et al. 2003). Tuberculosis infection can be detected
by the tuberculin test (Mantoux) in countries where BCG
(Bacille Calmette-Guerin) vaccination is not used, and con-
sequently it is not a practicable method in Finland where
children are generally BCG vaccinated.
A latent tuberculosis infection can be activated into dis-
ease by various factors affecting the immune system such as
aging, chronic diseases, and malnutrition. The most common
form of tuberculosis disease is pulmonary tuberculosis, i.e.,
a specific type of pneumonia, but the tuberculosis bacterium
can also affect various other organs, in which case the term
‘extrapulmonary tuberculosis’ is used. The best method of
diagnosing tuberculosis disease is to culture or stain the bac-
teria, or to detect the DNA by the polymerase chain reaction
(PCR) method. Pulmonary tuberculosis can usually be iden-
tified by typical changes in the chest x-ray.
It has been estimated that tuberculosis causes the death
of some 2 million people per year in the developing coun-
tries (Corbett et al. 2003). In Finland, tuberculosis was a
major problem in the early twentieth century, but its inci-
dence dramatically decreased towards the end of the cen-
tury. In 1940 there were 7,842 deaths caused by tuberculo-
sis in Finland, but in 1995 there were only 135. In 1995
there were 561 new cases of tuberculosis, 391 cases being
pulmonary tuberculosis and 170 cases extrapulmonary tu-
berculosis (Härö 1998).
Vitamin C and infections
Effects on the immune system
In the intensive search for specific molecules participating
in the defense against viruses and bacteria, vitamin C has
not been particularly interesting as it is not specifically and
firmly linked to any single immunological mechanism. Still,
it is possible that as an efficient reducing agent vitamin C
has non-specific effects on diverse parts of the immune sys-
tem (Hemilä 1992a, 1997a, 2003a).
Upon activation, phagocytes release a set of oxidizing
agents intended to kill viruses and bacteria. Many of these
oxidants appear to be harmful to the host cells, and in some
cases the oxidizing agents produced during viral and bacte-
rial infections seem to play a substantial role in the
pathogenesis (Goode & Webster 1993; Akaike et al. 1998;
Peterhans 1997). Vitamin C is an efficient water-soluble
antioxidant and may protect host cells against the oxidants
released by phagocytes, for example (Hemilä et al. 1984;
Frei et al. 1989; Hemilä 1990a, 1992a,b, 1997a). Phagocytes
have a specific transport system by which the oxidized form
of vitamin C (dehydroascorbic acid) is imported into the
cells, where reduced vitamin C is regenerated (Wang et al.
1997; Nualart et al. 2003). If the major role of vitamin C in
the immune system is that of a physiological antioxidant
protecting various host cells against oxidative stress during
an infection, it could have important effects in certain con-
ditions even though the mechanisms are apparently non-
specific.
A number of authors have reviewed the literature on vi-
tamin C and the immune system (Bourne 1949; Thomas &
Holt 1978; Gross & Newberne 1980; Beisel 1982; Leibovitz
& Siegel 1981; Cunningham-Rundles et al. 1993; Jariwalla
& Harakeh 1996; Hemilä 1992a, 1997a). Overall, more than
100 studies have examined the effect of vitamin C on vari-
ous parts of the immune system (Hemilä 1997a). The con-
centration of vitamin C in phagocytes and lymphocytes is
far higher than in plasma, indicating that it may have func-
tional roles in these immune system cells. In various ex-
perimental settings, vitamin C has affected random migra-
tion and chemotaxis of phagocytes (Goetzl et al. 1974),
transformation of influenza virus-infected lymphocytes
(Manzella & Roberts 1979), production of interferon (Siegel
1974), and replication of viruses (Atherton et al. 1978;
Bissell et al. 1980; Harakeh et al. 1990). In guinea pigs,
vitamin C deficiency suppressed the development of tuber-
culin skin reactivity (Mueller & Kies 1962; Zweiman et al.
1966). Recently, vitamin C was reported to affect the gene
expression of monocyte adhesion molecules (Rayment et
al. 2003). In some studies it affected complement and im-
munoglobulin levels, but the literature is quite inconsistent
on these topics.
Although the great majority of studies found effects sug-
gesting benefits from vitamin C on the immune system, one
study with 5 subjects found that 2 g/day vitamin C impaired
in vitro bactericidal activity of leukocytes when using
E. coli as the test organism (Shilotri & Bhat 1977). The
significance of this solitary report is unclear.
Even if vitamin C had a role in the immune system, it is
possible that the level of vitamin C intake is important only
in particular conditions. For example, if vitamin C intake is
important only in the low range of intakes, it is possible that
the variation in intake does not affect the immune system in
6the ordinary Western population. Still, it might be a limit-
ing factor in populations with low vitamin C intakes.
If the fundamental question is whether vitamin C intake
affects the incidence and severity of infections, then labo-
ratory measures of the immune system are only surrogate
markers. Since there are quite a few examples where the
effect on a clinical outcome diverged from the effect on a
surrogate end point (Fleming & DeMets 1996; DeGruttola
et al. 1997), the effects on surrogate end points should be
considered cautiously. Neither are the physiological mecha-
nisms usually crucial in epidemiological reasoning when
considering potential cause and effect relationships, since
what is biologically plausible depends upon the biological
knowledge of the day and in many cases this understanding
is quite limited and changes with time (Hill 1965). Never-
theless, the extensive literature on the effects of vitamin C
on the immune system provides a meaningful conceptual
framework to consider whether this vitamin might have ef-
fects on infections.
Vitamin C metabolism during infections
In guinea pigs, tuberculosis and other infections lead to a
decrease in vitamin C concentration in the adrenals and urine
(Abbasy et al. 1937a,b; Harris et al. 1937; Birkhaug 1938).
In rats, Trypanosoma infection decreased the concentration
of reduced vitamin C in spleen and adrenals, and increased
the proportion of vitamin C in the oxidized dehydroascor-
bic acid form (Nyden 1948). In mice, influenza A infection
resulted in a decrease in vitamin C concentration in
bronchoalveolar lavage fluid, concomitant with an increase
in dehydroascorbic acid (Buffinton et al. 1992). In macaque
monkeys, malaria caused a reduced vitamin C level in
plasma (McKee & Geiman 1946). In cows, intramammary
infusion of E. coli (Weiss et al. 2004) and clinical mastitis
(Kleczkowski et al. 2005) decreased plasma vitamin C con-
centration. Furthermore, bacterial toxins cause loss of vita-
min C from many tissues (Harde 1934; Lyman & King 1936;
Harris et al. 1937; Torrance 1940; Garcia et al. 1990; Rojas
et al. 1996; Benito & Bosch 1997; Yamaguchi et al. 1997;
Armour et al. 2001; Victor et al. 2002), but one study found
an increase in vitamin C level in the livers of mice adminis-
tered endotoxin (Jeffries 1965).
A large number of studies with human subjects found that
vitamin C levels decrease in plasma, leucocytes and urine
during various infections, including pneumonia and tubercu-
losis (Leppo 1939; Banerjee et al. 1940; Sweany et al. 1941;
Sinha et al. 1984; Tanzer & Özalp 1993; Hunt et al. 1994;
Galley et al. 1996, 1997; Pfitzenmeyer et al. 1997; Plit et al.
1998; Bakaev et al. 2004; for further refs., see Hemilä 1997a;
Hemilä & Douglas 1999). Moreover, several reports noted
that more severe forms of tuberculosis are more often associ-
ated with lower vitamin C levels than milder forms of the
disease (Hemilä 1997a).
In the common cold infections, plasma, leukocyte and urine
vitamin C levels decrease (for refs., see Hemilä 1992a, 1997a).
Hume and Weyers (1973; see also Pauling 1973) reported
that vitamin C level in leukocytes was reduced to half when
their subjects contracted a cold, but the level returned to the
original level in about a week after the episode. Vitamin C
supplementation (6 g/day) essentially abolished the fall in
leukocyte vitamin C level caused by colds (Fig. 1).
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Fig. 1. The effect of the common cold infection on leucocyte vitamin
C level. In 7 control participants, the vitamin C level in leucocytes
(µg/108 cells) is indicated by triangles. Vitamin C level is indicated by
squares in 3 vitamin C participants supplemented regularly with
1 g/day and, after the onset of the cold, with 6 g/day for 3 days, and
thereafter with 1 g/day again. Day 0 indicates pre-cold level. The
figure is based on tables I and III of Hume & Weyers (1973).
Although low vitamin C levels in patients with infec-
tions may partly be explained by low dietary intakes, there
are several studies in which the dietary intake of vitamin C
was comparable between the patients and healthy controls,
indicating that low dietary intake cannot be the only cause
of low vitamin C levels in the patients with infections
(Hemilä 1997a). Increased levels of dehydroascorbic acid
have also been reported in patients with various infections,
consistent with the notion that vitamin C may be oxidized
during infections (Banerjee & Belavady 1953; Chakrabarti
& Banerjee 1955).
7Endotoxin administration reduced plasma vitamin C con-
centration in human subjects (Pleiner et al. 2002, 2003),
and vitamin C supplementation abolished the exercise-in-
duced increase in plasma endotoxin level (Ashton et al.
2003).
Infections in animals
When you can measure what you are speaking about,
and express it in numbers, you know something about it;
but when you cannot measure it, when you cannot express
it in numbers, your knowledge of it is of a meager and
unsatisfactory kind.
Lord Kelvin (1883)
Since primates and the guinea pig have lost their capability
to synthesize vitamin C (Burns 1957; Pauling 1970b;
Chatterjee 1973; Sato & Udenfriend 1978; Nishikimi & Yagi
1996; Nandi et al. 1997; Smirnoff 2001), these animals are
of primary interest when considering the possible effects of
low vitamin C intake on susceptibility to infection.
In the early studies on vitamin C deficiency in the guinea
pig, bacteria were so often found in histological sections to
indicate the infectious nature of scurvy to some authors.
Hess (1920 pp 133-4) concluded that such results show
merely that the tissues of scorbutic animals frequently harbor
bacteria, but "There is no doubt that invasion of the blood-
stream does occur readily in the course of scurvy, but this
takes place generally after the disease has developed and
must be regarded as a secondary phenomenon and there-
fore unessential from an etiological standpoint. Indeed one
of the striking and important symptoms of scurvy is the
marked susceptibility to infection" (p 32). Summarizing
autopsy findings of experimental scurvy in the guinea pig,
Hess also noted that "Pneumonia is met with very frequently
and constitutes a common terminal infection" (p 123) and
"The superficial lymphatic glands are frequently palpable
in scurvy, especially those in the inguinal region… It has
seemed to us attributable less to the nutritional condition
than to the infections which so frequently complicate the
disorder" (p 141).
A large number of studies have reported that guinea pigs
fed a vitamin C deficient diet have low resistance to vari-
ous infections (for review, see Höjer 1924; Clausen 1934;
Robertson 1934; Perla & Marmorston 1937; Birkhaug 1938;
McCullough 1938; Scrimshaw et al. 1968; Hemilä 1997a,
1998). Most of the early animal studies did not examine the
effect of pure vitamin C, the ‘vitamin C group’ being ad-
ministered oranges or other fruit or vegetables containing
vitamin C. Even though the positive findings in such stud-
ies are consistent with the notion that vitamin C intake may
affect susceptibility to infection, the effect may be caused
by other substances in fruit and vegetables as well (see Pa-
per IV). The studies in which pure vitamin C was adminis-
tered to the ‘vitamin C group’ are thus presented separately
(Appendix 2) from those in which the ‘vitamin C group’
was administered fruit or vegetables as the source of the
vitamin (Appendix 3). Studies in which animals were ad-
ministered diphtheria toxin, tetanus toxin, or endotoxin are
included in the tables, since these toxins are essential com-
ponents in the pathogenesis of the bacteria concerned. A
meta-analytic summary of the animal studies with pure vi-
tamin C is shown in Table 2.
The studies in Appendix 2 are ordered with respect to
the importance of the animal model to human beings so that
those with primates are first, followed by guinea pigs, and
thereafter studies with animals producing vitamin C, first
mammals and then birds. At the end of Appendix 2 there
are studies with fish, which are incapable of synthesizing
vitamin C, yet in evolutionary terms they are most distant
from humans.
In a series of studies with rhesus monkeys infected with
poliovirus, Jungeblut (1937a,b, 1939) found significant ben-
efit from vitamin C in several settings, but there was con-
siderable variation in the results. In a small study, Albert
Sabin (1939) found no effect using vitamin C. The studies
by Jungeblut and Sabin differ in the method of virus inocu-
lation, and Sabin administered oranges to his control mon-
keys, whereas Jungeblut does not describe the basal diet;
these are some examples of potential factors explaining the
inconsistency in their findings. With marmosets, Murphy
et al. (1974) found that vitamin C increased resistance
against experimental parainfluenza infection. Several stud-
ies with guinea pigs found that vitamin C protected against
M. tuberculosis and M. bovis, and against various other
micro-organisms (Appendix 2).
Rabbits, cats and mice synthesize vitamin C and thus
cannot be used to study the effects of vitamin C deficiency,
but the effects of supplementation can be studied in these
species (Appendix 2). Three studies with rabbits found pro-
tection against pneumococcus using vitamin C, and cats ad-
ministered vitamin C recovered faster from rhinotracheitis.
Several studies with mice found benefits from vitamin C
supplementation.
Davelaar and Bos (1992) found substantial protection in
chickens against infectious bronchitis virus (IBV). This is
an interesting report because IBV belongs to the family of
coronaviruses which includes the recently identified SARS
(severe acute respiratory syndrome) coronavirus (Hemilä
2003b). Vitamin C also protected chickens against Salmo-
nella and E. coli infections (Appendix 2). Finally, a few
studies found that vitamin C supplementation improved the
resistance of fish to various infections.
Appendix 2 lists 148 separate animal studies with vita-
min C, 86 of which found a statistically highly significant
benefit, P ≤ 0.01, on at least one infectious disease outcome,
while 58 studies reported benefit at a level of P ≤ 0.001
(Table 2). Of 100 studies with mammals, 58 found highly
significant benefit, P ≤ 0.01, from vitamin C on some infec-
tious disease outcome.
Although many of the studies in Appendix 2 are old, it
seems unlikely that administering a fixed dose of vitamin C
and evaluating mortality were meaningfully different in the
older days compared with modern methods. Furthermore,
897 of the papers were published in the 1970s or later, and
56 of these newer papers reported a statistically highly sig-
nificant effect, P ≤ 0.01, on at least one infectious disease
outcome (Appendix 2). Furthermore, among the non-sig-
nificant recent studies, Bourke et al. (1980) reported over
100% longer median survival time in vitamin C supple-
mented mice infected with malaria, but the number of ani-
mals was not reported, making any statistical interpretation
impossible. In mice infected with pneumococcus, Esposito
(1986) found no effect on mortality; nevertheless, vitamin
C significantly enhanced the clearance of pneumococci from
the lungs. Thus, there is no apparent pattern that the newer
studies would have yielded less positive results than the
older. In most of the studies in Appendix 2, statistical analy-
Table 2. Meta-analysis of the studies on animal infections: effects of vitamins C and E
________________________________________________________________________________________________
Vitamin C studies Number of studies
(for the studies, ____________________________________________________________
see Appendix 2)
Benefit in any infectious disease outcome with
______________________________________
Total in the
Category category P[1-t] ≤ 0.01 P[1-t] ≤ 0.001
______________ _________ ___________ ____________
All studies 148 86 58
Published ≥1970 97 56 39
Mammals 100 58 40
Monkeys or guinea pigs 49 25 15
___________________________________________________________________________________
Vitamin E studies Number of studies
(for the studies, ____________________________________________________________
see Appendix 4)
Benefit in any infectious disease outcome with
______________________________________
Total in the
Category category P[1-t] ≤ 0.01 P[1-t] ≤ 0.001
____________ __________ ___________ ____________
All studies 70 37 20
Published ≥1970 69 37 20
Mammals 44 28 13
________________________________________________________________________________________________
A ‘study’ is defined here operationally as the group of findings with a stated number of animals in Appendices 2 and 4.
Appendices 2 and 4 are based on extensive literature searches. Studies in which the number of events is very small are excluded, since they are
uninformative. A few studies used different levels of vitamins C or E, the lowest being compared with the highest in most cases in the appendices,
but in some cases different vitamin groups are combined and, when pertinent, different levels of intake are shown separately against the lowest
level.
In some studies, different amounts of bacteria or different time-points, etc. were used and in these cases the selection of results shown in
Appendices 2 and 4 involved subjective considerations, but the goal was to present the findings as objectively as possible given the complexity of
some publications. A few reports stated in their text that vitamin C or E had no effect on a relevant outcome but no explicit data was
mentioned preventing inclusion of those studies in the Appendices.
9ses of the results are missing or inappropriate in the origi-
nal papers, and in this respect the statistical analyses in Ap-
pendix 2 are essentially all novel.
Matsumoto et al. (1992) examined the effect of
2-octadecylascorbic acid in parallel with ascorbic acid, but
only the results with the latter are presented in Appendix 2.
Nevertheless, assuming that the effect of vitamin C on in-
fections is based on the antioxidant effect, the results with
the derivative are also of interest. When 2-octadecylascorbic
acid was administered subcutaneously in E. coli infected
rats, only 2 of 8 rats produced renal scarring of the two
highest scores (2 or 3), in contrast to all 8 control rats (mid-
P = 0.002). Similarly with pyelonephritis caused in rats by
Serratia marcensces, subcutaneous administration of the
derivative resulted in none of 8 rats producing renal scar-
ring of the two highest scores (2 or 3), in contrast to 7 of the
8 control rats (mid-P = 0.000,4).
Nonaka et al. (1990) studied the effect of 2-octa-
decylascorbic acid on mouse endotoxemia. None of the mice
administered the vitamin C derivative died (0/20) whereas
45% (9/20) of the control mice died (mid-P = 0.000,3).
Appendix 3 lists studies in which vitamin C group was
administered either fruit or vegetables as the source of vita-
min C. Albert Sabin (1939) found that rhesus monkeys fed
vitamin C deficient diet had a high mortality due to infec-
tions, in particular pneumonia. In a number of studies using
guinea pigs, fruit or vegetables protected against various
infections better than a deficient diet. Although vitamin C
is an important substance in fruit and vegetables, it is also
possible that the differences are caused by substances other
than vitamin C (see Paper IV). In this respect, no specific
conclusion can be drawn from Appendix 3 as to the impor-
tance of vitamin C per se, although these studies are con-
sistent with the notion of benefits from higher levels of vi-
tamin C intake.
In addition to the animal studies yielding quantitative data
on the effect of vitamin C on infections (Appendices 2 and
3), a few studies reported qualitative findings on its role on
infections. Russell et al. (1944) found that caseous foci caused
by tuberculosis were considerably larger in vitamin C defi-
cient guinea pigs than in animals administered lettuce as a
source of vitamin C. Tuberculous lesions in the spleen were
also substantially larger and less well demarcated in vitamin
C deficient guinea pigs than in normal animals. Höjer (1924)
infected guinea pigs with tuberculosis bacilli and, compared
with normally nourished animals, he found that in animals
that had scurvy, tuberculous foci in muscles, lymph-glands
and the spleen were not surrounded or penetrated by any con-
nective tissue, and the necrotic parts passed into non-tuber-
cular tissue without such demarcation. Meyer and Meyer
(1944) reported that abscesses caused by staphylococcal in-
fection remained soft and undemarcated in vitamin C defi-
cient guinea pigs, whereas they were hard and button-like in
animals administered pure vitamin C. In an uncontrolled study,
Hans Zinsser et al. (1931) found that the infection caused by
Rickettsiae was very severe in vitamin C deficient guinea
pigs, so that particularly high concentrations of Rickettsiae
were found in pleural and peritoneal exudates. Witt et al.
(1988) reported that an unexpected outbreak of pneumococ-
cal infections in guinea pigs was associated with a diet unin-
tentionally low in vitamin C. Nungester et al. (1951) did not
find any difference in the clearance of streptococci from the
lungs of rats and guinea pigs, or in the occurrence of pneu-
monia by vitamin C level administered.
Rawal et al. (1974) reported that survival of mice in-
fected with Pseudomonas aeruginosa was increased by vi-
tamin C supplementation in a dose-dependent fashion.
Senatuite and Biziulevicius (1986) reported that in rats in-
fected with Trichinella spiralis the average number of mus-
cle larvae after 3 weeks was 40% lower in the vitamin C
administered group. Chaiyotwittayakun et al. (2002) induced
mastitis in cows using intramammary infusion of endotoxin,
and vitamin C reduced the fall in milk production caused
by endotoxin. Goldschmidt (1991) reported that in rhesus
monkeys vitamin C administration dropped oral Actinomy-
ces viscosus counts by six orders of magnitude.
Two case-series were reported describing the therapeu-
tic benefit of vitamin C on dogs afflicted by the canine dis-
temper virus. Belfield (1967) described a series of 10 dogs
that appeared to benefit from 1 – 2 g/day of vitamin C in-
jected i.v. over 3 consecutive days. Leveque (1969) had some
ten years of veterinary practice and with the pessimistic ob-
servation that only 5-10% of dogs recovered from canine
distemper with signs of central nervous system (CNS) dis-
turbance, he became interested in Belfield’s case series. In
a series of 16 dogs showing CNS disturbance that were
treated with vitamin C, the proportion of dogs that recov-
ered was 44% (95% CI: 20% to 70%; based on
7/16)(Leveque 1969).
Although the great majority of studies found benefits with
higher vitamin C intake on various infections, a study on
cryptosporidiosis in mice found more oocysts and a higher
infection score in the vitamin C supplemented group (Leitch
& He 1999).
Mortality and severity of infection in animals are hard
outcomes, rather than surrogates such as various laboratory
measures of the immune system. In this respect the animal
studies with actual infections are more interesting from the
human perspective than studies on laboratory measures of
the human immune system. It is noteworthy that dramatic
effects have been reported in numerous animal species rang-
ing from rhesus monkey to fish, and with a great diversity
of infecting organisms. Still, it is not clear to what degree
the animal studies can be extrapolated to human subjects. It
would seem unlikely that human beings qualitatively differ
from the other animal species with respect to the general
role of vitamin C on infections. Therefore, the fundamental
question in human beings is not whether vitamin C affects
susceptibility to and severity of infections, but rather the
relevant questions seem to be focused on estimation: e.g.,
what the population groups that might get some benefit from
higher vitamin C intakes are, what the dose-dependency
relation between intake and the effects on infections is, and
how great the proper levels of intake might be.
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Vitamin E and infections
Effects on the immune system
Vitamin E is a lipophilic antioxidant which may affect the
immune system by protecting against reactive oxygen spe-
cies much the same way as vitamin C.
The extensive literature on vitamin E and the immune
system has been reviewed by several authors (Nockels 1979;
Tengerdy 1989; Meydani et al. 1995; Moriguchi & Muraga
2000; Serafini 2000). A recent review of this topic contained
about 100 references (Moriguchi & Muraga 2000).
Some studies have indicated a complex dose-response
relationship between the amount of vitamin E and its im-
munological effects. In mice, lymphocyte proliferation
caused by concanavalin A and phytohemagglutinin in-
creased with medium dose vitamin E supplementation, but
was suppressed by high dose supplementation, indicating
that large doses may cause harmful effects on the immune
system (Yasunaga et al. 1982; Bendich et al. 1986).
The effects of vitamin E supplementation on the immune
system have been variable in human studies. Although some
found apparent benefit on the immune system from vitamin
E supplementation (Meydani et al. 1997; Serafini 2000),
some other studies found none (Goodwin & Garry 1983,
1988; Payette et al. 1990; Waart et al. 1997) and, moreover,
a few studies found reduced bactericidal activity of
phagocytes in subjects administered large doses of vitamin
E (Baehner et al. 1977; Prasad 1980; Kaul et al. 2000).
Infections in animals
A number of animal studies found that vitamin E supple-
mentation affects resistance to various infections (Appen-
dix 4). As regards human respiratory infections analyzed in
this thesis, the protection of mice against S. pneumoniae
(Heinzerling et al. 1974a), influenza virus (Hayek et al.
1997; Han et al. 2000), and coxsackie virus B3 infection
(Beck et al. 1994, 2003), and lambs against Chlamydia
(Stephens et al. 1979) with vitamin E supplementation are
of most prominent interest.
Two animal studies compared different doses of vitamin
E, finding that medium dose vitamin E increased resistance,
but the groups with large vitamin E doses had higher mor-
tality than those with medium doses (Heinzerling et al.
1974a; Peck & Alexander 1991b). Consequently, these two
studies suggest dose dependency, so that excessive doses of
vitamin E may become harmful, as was also observed in
two immunological studies (Yasunaga et al. 1982; Bendich
et al. 1986).
Appendix 4 lists 70 separate animal studies with vitamin
E, 37 of which found a statistically highly significant ben-
efit, P ≤ 0.01, on at least one infectious disease outcome,
while 20 studies reported benefit even at a level of P ≤ 0.001
(Appendix 4). Of 44 studies with mammals, 28 found highly
significant benefit, P ≤ 0.01, from vitamin E on some infec-
tious disease outcome.
The studies discussed above used pure vitamin E. In ad-
dition, wheat germ oil, which is a rich source of vitamin E,
affected the development of fatal paralysis in young mice
infected with vesicular stomatitis virus (Sabin & Duffy 1949;
Appendix 5); this study was the first to indicate that vita-
min E intake may affect infections. Vitamin E was also stud-
ied in combination with other vitamins and minerals, but it
is not clear what the role of vitamin E is in these combina-
tions (Appendix 5).
In addition to the controlled studies listed in Appendices
4 and 5, the deficiency of vitamin E rendered rats and ham-
sters susceptible to M. leprae, to which these animals are
normally resistant, but there was no parallel control group
(Mason & Bergel 1955). In a study with rats, vitamin E did
not protect against liver damage caused by E. coli endo-
toxin (Rücker et al. 1997). In rat models of chronic portal
hypertension and common bile-duct ligation, the combina-
tion of vitamin E and C led to reduction in the bacterial
colonization of the liver and spleen (Schimpl et al. 1997).
In rats, vitamin E administration reduced the degenerative
changes in kidney glomeruli caused by E. coli endotoxin
(Coskun et al. 2005).
The animal studies in Appendix 4 mostly found positive
effects on animal infections with vitamin E supplementa-
tion, but a few studies found that a high intake of vitamin E
is harmful in animal models of malaria, so that animals with
low intakes survived longer (Godfrey 1957; Eaton et al.
1976; Eckman et al. 1976; Friedman 1979; Taylor et al.
1997). In hamsters infected with Leishmania donovani vi-
tamin E increased the parasite counts (Garg et al. 2004).
The combination of vitamins E, C and A, and selenium led
to increased number of Trichinella spiralis worms in intes-
tines and muscles of rats (El-Sheikh et al. 1999). Wahli et
al. (1998) found that vitamin E increased the incidence of
VHS (viral hemorrhagic septicemia) virus in rainbow trout
administered low vitamin C levels, but not in those admin-
istered high vitamin C levels (Appendix 4).
Interaction between vitamins C and E
Vitamin C and vitamin E are both antioxidants and protect
against reactive oxygen species. These substances are of
parallel interest as water-soluble vitamin C regenerates li-
pid-soluble vitamin E in vitro (Packer et al. 1979; Sharma
& Buettner 1993; Wijesunara & Berger 1994).
There is much evidence indicating that vitamins C and E
may also have a physiologically relevant interaction. In
guinea pigs, vitamin C deficiency led to reduced levels of
vitamin E in the liver, kidney, spleen, and lungs (Kanazawa
et al. 1981; Hruba et al. 1982; Bendich et al. 1984). In in-
herently scorbutic rats, vitamin C deficiency led to reduced
vitamin E levels in the liver, kidney, and heart (Tanaka et
al. 1997). In guinea pigs administered oxidized frying oil,
large doses of vitamin C increased the level of vitamin E in
liver, kidney, heart, lung, and spleen (Liu & Lee 1997). In
normal rats, vitamin C supplementation increased plasma
vitamin E level (Chen et al. 1980). Nevertheless, in one
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study, vitamin C deficiency did not affect the plasma vita-
min E level in guinea pigs (Hruba et al. 1982), and in an-
other, excessive doses of vitamin C reduced plasma vita-
min E levels (Chen & Chang 1979).
In studies with human subjects, vitamin C supplementa-
tion increased plasma lipid standardized α-tocopherol (Ham-
ilton et al. 2000). Vitamin C supplementation also led to a
higher level of vitamin E in plasma in participants who were
administered 800 mg/day of vitamin E than in participants
administered vitamin E alone (Baker et al. 1996).
In normal rats and guinea pigs, vitamin E supplementa-
tion increased the plasma vitamin C level (Chen et al. 1980;
Bendich et al. 1984). In inherently scorbutic rats, a defi-
ciency of vitamin E led to lower levels of vitamin C in the
plasma, liver, kidney, and heart (Tanaka et al. 1997). In rats,
vitamin E deficiency did not affect the plasma vitamin C
level, but the muscle vitamin C level was significantly in-
creased (Gohil et al. 1986).
In a study with human subjects, vitamin E supplementa-
tion increased the plasma level of vitamin C (Hamilton et
al. 2000).  In smokers, but not in nonsmokers, vitamin E
disappearance in plasma was inversely related to vitamin C
levels (Bruno et al. 2005)
A recent study found that a combined deficiency of vita-
mins C and E in guinea pigs produced a clinical picture dif-
ferent from scurvy. Many of these doubly deficient animals
had paralysis of their limbs, and there was evidence of
oxidative damage in the central nervous system (Hill et al.
2003). In endotoxin-treated guinea pigs, simultaneous sup-
plementation of vitamins C and E led to higher levels of vita-
min E in the liver than vitamin E supplementation alone
(Cadenas et al. 1998). Wahli et al. (1998) found an interac-
tion between vitamins C and E in their effects on the suscep-
tibility to infection of rainbow trout (pp 118, 129).
Accordingly, there is experimental data indicating that
vitamin C and vitamin E have a physiological interaction,
but its significance is poorly understood both in experimental
animals and human beings.
Infections in humans
Vitamin C and the common cold
Before the 1970s a few physicians had concluded from their
own observations that vitamin C administration would be
beneficial against the common cold (e.g., Ruskin 1938;
Markwell 1947; Bessel-Lorck 1959; Regnier 1968). The au-
thors of the influential Sheffield trial examining the effects
of vitamin C deprivation of human subjects concluded that
common cold episodes "lasted longer in the deprived group"
(Bartley, Krebs & O’Brien 1953 p 43). Some other early
controlled trials also indicated that vitamin C intake may
affect the common cold, but the results of various trials were
not quite consistent and the early positive findings did not
affect mainstream medicine.
The notion that vitamin C might be of benefit against
colds achieved wide popularity in the 1970s when Linus
Pauling wrote a best-selling book entitled Vitamin C and
the Common Cold in which he claimed that supplementa-
tion would prevent and alleviate common cold episodes
(Pauling 1970a, 1971c,d, 1976a; Marinacci 1995 pp 249-
51). In 1971, Pauling’s book received the Phi Beta Kappa
award for the best scientific book of the year in the USA
(PBK 2005). Pauling’s book made million of Americans
interested in vitamin C supplements and, in the academic
world, it led to the initiation of dozens of new trials intended
to find out whether Pauling was right or wrong (Fig. 2). To
understand why Pauling’s book could have such an enor-
mous impact on the vitamin C field, his personal background
must be briefly reviewed.
Pauling is widely considered the greatest chemist of the
previous century (Greenberg 1984; Lipscomb 1994; Pauling
1994; Rich 1994; Dunitz 1996, 1997; McConnell 1996; Ma-
son 1997; NLM 2005a; OSU 2005a,b,c,d; Nakamura &
Csikszentmihalyi 2001; UC 2005). "In 1931, at only thirty
years old, the Oregon-raised Linus Pauling knew he was
the world’s best chemist. Ten years later the rest of the
world’s chemists agreed" (Watson 1999, 2001). "Pauling
helped to transform chemistry from a largely
phenomenological subject to one based firmly on structural
and quantum mechanical principles" (Perutz 1994). "The
extrapolation from physics to chemistry and the articula-
tion of chemistry as an independent subject was the handi-
work of a single individual. Linus Pauling ranks … as one
of the great thinkers and visionaries of the millennium…
Chemistry grew and prospered simply by proving time and
again that Pauling was correct in just about all his conjec-
tures, for he projected with unerring accuracy into future
with only 0.01% of today’s structural information" (Desiraju
2000).
Pauling was also one of the founders of molecular biol-
ogy (Gray 1949; Judson 1979; Pauling 1986b, 1993; Kay
1989; Crick 1992; Perutz 1994; Rich 1995; Mason 1997;
Morgan 1998; Edison 2001; Eisenberg 2003; UC 2005;
Gruber & Lupas 2003). Before any protein structures had
been solved, Pauling conceived, for example, that "A mo-
lecular explanation of biological specificity results from a
detailed complementariness in structure of two molecules
… The significance of the hydrogen bond for physiology is
greater than that of any other structural feature," and "En-
zymes are molecules that are complementary to the acti-
vated complexes of the reactions that they catalyze." Pauling
discovered the basic structural features of proteins, α-helix
and β-sheet, and invented the concept of the "molecular evo-
lutionary clock." In one of his major papers, Pauling et al.
(1949) showed that hemoglobin from patients suffering from
sickle cell anemia had a different electric charge from that
from healthy individuals, and this report laid the ground-
work for establishing the field of molecular medicine (Azar
1996; Strasser 1999, 2002; Eaton 2003). Pauling received
the Nobel Prize in Chemistry in 1954 (Pauling 1954; NF
2005e).
At the end of the Second World War, Pauling served on a
presidential committee formed to plot the path of science in
the post-war period. The resulting Vannevar Bush Report
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led to the expansion of the National Institutes of Health
(NIH), allowing for extramural research funding, and the
creation of the National Science Foundation (Paradowski
1996). In 1946 Pauling joined the Emergency Committee
of Atomic Scientists, chaired by Albert Einstein, whose most
important task was to make people in all countries aware of
the transformation of the world brought about by the devel-
opment of the atomic bomb. During 1958, Pauling sent a
copy of the petition opposing nuclear weapons testing, with
endorsement by 11,021 scientists from 49 countries includ-
ing 40 members of the US National Academy of Sciences,
216 members of the Soviet Academy of Sciences and 36
Nobel Laureates, to Dag Hammarskjöld, the Secretary-Gen-
eral of the United Nations. Public opinion worldwide led to
test-ban negotiations in late 1958. On the same day (10th
Oct 1963) that the limited test ban treaty signed by the USA,
UK, and the USSR went into effect, it was announced that
Linus Pauling would be awarded the Nobel Peace Prize for
1962 (Pauling 1963; Kreisler 1983; Mason 1997; Jolly 2002;
NF 2005f). Because Pauling was the best-known American
scientist publicly arguing for disarmament, he began to come
under attack from right-wing political groups. Because of
the pressures of McCarthyism on government officials,
Pauling encountered difficulties in obtaining a passport. For
example, he was without a passport when his Nobel Prize
in Chemistry was announced in 1954, but the Undersecre-
tary of State overruled the Passport Division, enabling him
to travel to Sweden to receive his award (Allison 1960;
Paradowski 1996; Mason 1997; Nye 1999).
With such a particularly strong background in science
and high-level competence in politics, it is obvious that
Pauling’s 1970 book Vitamin C and the Common Cold
reached extensive readerships in both lay and academic cir-
cles and had great impact. Because of Pauling’s book, the
demand for vitamin C substantially increased. In the USA,
the production of vitamin C increased from 8.9 million
pounds in 1969 to 11.7 in 1971, corresponding to an in-
crease of 39% in two years and an annual growth rate of
18% (CMR 1972a), in contrast to the annual growth rate of
about 6% in the 1960s (CMR 1972c). About 5.6 million
pounds of vitamin C were also imported to the US between
January and November 1971, up about 160% from the
amount imported during the same period in 1970 (CMR
1972b). In the USA, Pauling personified the issue of vita-
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Fig. 2. Placebo-controlled studies in which ≥1 g/day of vitamin C was administered to the participants regularly over the trial period. Regular
supplementation refers here to initiating supplementation with healthy people and continuing over the occurring common cold episodes. The
number of studies published over two consecutive years is combined and plotted for the first of the two years. For the list of references to these
trials, see Hemilä (1992a, 1994a). This figure is reproduced from Hemilä (1997b) International Journal for Vitamin and Nutrition Research
67:329-335 with permission.
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min C (Apple 1996). The US Food and Drug Administra-
tion (FDA) was alarmed by this increasing interest in the
consumption of large doses of vitamins, and proposed that
over-the-counter sales be restricted to relatively low-potency
products, with ‘megadoses’ requiring a physician’s prescrip-
tion. The health food industry felt threatened and it encour-
aged customers to protest. Members of the US Congress
received more mail on this issue than any other, except for
the Vietnam War, and the FDA had to give up their attempt.
Why, it was asked, did FDA threaten the sales of vitamins,
and do nothing comparable about tobacco and alcohol,
whose ill effects in excess were not debatable (Apple 1996).
In addition to his book intended for lay people, Pauling
(1971a) carried out a meta-analysis of 4 placebo-controlled
trials, which was one of the very first meta-analyses in medi-
cine. The results of 3 of the 4 trials are shown in Table 3.
The fourth trial by Wilson et al. (1973a,b,c) was available
to Pauling only as an abstract (Wilson & Loh 1969) and the
final report was complicated with 48 significance tests, with
several outcomes in various subgroups, so that it does not
provide unambiguous data (Kinlen & Peto 1973). In his
meta-analysis, Pauling combined the P-values of the 4 tri-
als by Fisher’s method, concluding that it was highly un-
likely that all the reported effects on common cold morbid-
ity from vitamin C supplementation could be explained by
chance alone. Pauling (1971a) also pointed out that, out of
these 4 trials, the greatest benefit was found by Ritzel (1961;
Brubacher 1989), who used the largest dose, 1 g/day. Pauling
thus concluded that gram doses of vitamin C daily would
prevent colds in the general population. Pauling (1971b)
also carried out a second meta-analysis in which he focused
on the two best early trials (Cowan et al. 1942; Ritzel 1961;
Table 3).
Pauling analyzed previously published trials but did not
carry out any experimental work on the common cold him-
self. His book and other activities, however, led to the ini-
tiation of several new trials. Before the 1970s, there was
only one trial which used ≥1 g/day of vitamin C regularly
over the trial (Ritzel 1961), but within a decade of Pauling’s
book about 20 new trials using such high doses regularly
over the trial had appeared (Fig. 2). However, the interest in
vitamin C and colds disappeared in the middle of the 1970s.
This waning interest was caused by the publication of two
negative reviews in wide-circulation journals (Chalmers
1975; Dykes & Meier 1975), and by a particularly influen-
tial trial, carried out at the National Institutes of Health (NIH)
and published in JAMA, which concluded that the apparent
benefits of vitamin C were simply explained by the placebo
effect (Karlowski et al. 1975). Thus all these three impor-
tant negative papers were published the same year. Further-
more, the Karlowski trial (1975) and the Dykes and Meier
review (1975) were published in the same issue of JAMA,
and Thomas Chalmers was both the principal investigator
of the Karlowski, Chalmers, et al. trial (1975; Chalmers
1996) and the author of the other review published in the
same year (Chalmers 1975). The importance of these three
papers is reflected, for example, by the comment in the TIME
magazine: "Three reports now cast a further shadow on
Pauling’s theory … that large doses of vitamin C would pre-
vent or cure the common cold" (Anonymous 1975 [see
Pauling 1975] ). Only a few trials on vitamin C and the com-
mon cold were initiated after the middle of the 1970s, after
the publication of these three influential papers (Fig. 2).
Since this large set of new trials was carried out, there
has been general consensus that vitamin C has no effects on
colds, and the three papers published in 1975 are the most
usual references for such negative statements. For exam-
ple, based on these three papers, vitamin C was stated to be
useless for colds in major textbooks on infectious diseases
(Gwaltney 1979, 1985, 1990, 1995; Liu 1989; Dick et al.
1992, 1998; Cherry 1987, 1992, 1998), in Cecil Textbook of
Medicine (Kapikian 1985; Hendley 1996, 2000), various
textbooks on nutrition (Halsted 1993; Thurnham et al. 2000;
Hamilton & Whitney 1982, 1994; Whitney & Rolfes 1993;
Shils et al. 1994), and the US nutritional recommendations
(FNB 1980, 1989a).
The conclusion that vitamin C is useless for colds has
also reached the clinicians. For example, a survey of gen-
eral practitioners in the Netherlands revealed that 47% of
respondents considered that homeopathy is efficacious in
the treatment of the common cold, whereas only 20% of the
respondents considered that vitamin C was (Knipschild et
al. 1990). On a scale from 0 to 10, with the high scores
corresponding to stronger belief in efficacy, homeopathy
for colds received a mean score of 4.7, whereas vitamin C
for colds received a mean of only 2.5.
In the UK, 52% of 86 general practitioner trainees consid-
ered that homeopathy was useful, whereas only 7% consid-
ered large doses of vitamins useful, although no specific in-
dications for usage were presented for either therapy (Reilly
1983). In the USA, 21% of 348 pediatricians considered that
homeopathy may be effective, and 21% considered that high-
dose antioxidant vitamins may be so, but again no indica-
tions for usage were presented (Sikand & Laken 1998). Ac-
cordingly, the use of vitamin C to treat the common cold comes
unambiguously under the Eisenberg et al. notion (1993; Dalen
1998) that "medical interventions not taught widely at [US]
medical schools or generally available at [US] hospitals" are
unconventional or alternative medicine (Barrett & Herbert
1994; Turow 1997; Goodwin & Goodwin 1984; Goodwin &
Tangum 1998; Hemilä 2000a,b).
Vitamin C and infections other than
the common cold
The effect of vitamin C on the common cold was not stud-
ied for any particular biological reason, but because of the
publicity aroused by Linus Pauling on the topic (Fig. 2).
The common cold is a ubiquitous ailment with high inci-
dence and is therefore easy to research. Nevertheless, a large
number of animal studies have indicated that vitamin C in-
take may affect a wide variety of infections caused by vi-
ruses, bacteria, and protozoa (Table 2).
In the early twentieth century, several authors suggested
that low intake of vitamin C may decrease resistance to in-
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Table 3. Results of three major early vitamin C and
common cold trials
__________________________________________________
   Treatment
____________
Trial Vit C Placebo Difference P 1
_________ _____ _______ _________ ___
Ritzel (1961)
Schoolchildren
Skiing camp
in Swiss Alps
1 g/d vit C
1 week
Participants 139 140
The common cold 2
All cases 17 31 -45% 0.015
Duration of colds:
Mean (d) 1.8 2.6 -31% <0.05
Days per group 31 80 -61%
Constitutional
Symptoms during
the common cold 3
Cases  8 21 -62% 0.006
Days per group  9 48 -81%
__________________________________________________
Cowan et al. (1942)
Schoolchildren
USA
0.2 g/d vit C
4 months
Participants 208 155
Cold episodes
Mean per person 1.9 2.2 -14% 0.003
SD 4 1.01 1.00
SE 0.07 0.08
Days lost from school
Mean per person 1.1 1.6 -31% 0.000,3
SD 4 1.1 1.6
__________________________________________________
Franz et al. (1956)
Schoolchildren
USA
0.2 g/d vit C
4 months
Participants 5 44 45
Common cold
episodes 14 15
Colds cured or
improved in 5 d 13 8 +74% 0.012
__________________________________________________
1 One-tailed mid-P-value was calculated by the
current author. The P-value for the duration of
colds was calculated by Ritzel.
2 The number of episodes not being published, it
is inferred from the total number of days per
group and the average duration (Pauling 1971a,
1976b; pp 43-5).
3 General malaise, headache, muscle ache, ab-
dominal pain, vomiting, diarrhoea.
4 Cowan et al. (1942): the SD values for the
number of ‘cold episodes per person’ were calcu-
lated from the reported SE values. Cowan et al.
did not report the SD or SE for ‘days lost from
school per person.’ In most trials, the SD for
common cold duration has been about 70% of the
mean duration of colds (Douglas, Hemilä, et al.
2004). Here the P-value for ‘days lost from
school per person’ is calculated on the assump-
tion that both SD values are equal to the mean.
5 The Franz et al. trial (1956) had a 2x2 factorial
design and the bioflavonoid and no-bioflavo-
noid groups are combined here. This data is
from their tables 1 to 4. Their summary table 5
erroneously records 4 ‘improved or cured,’ for
the bioflavonoid group whereas their table 4
gives 5 (= 1 + 4).
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fections other than the common cold (Hess 1917, 1920, 1932;
Clausen 1934, 1935; Robertson 1934; Perla & Marmorston
1937). Thomas Barlow, who defined the disease infantile
scurvy, pointed out that in infantile scurvy "If the cachexia
is very profound the supervention of bronchitis, pleuro-pneu-
monia, severe diarrhoea, or an intercurrent exanthem may
bring about a fatal issue" (1894). Casimir Funk, who coined
the term ‘vitamin[e]’ (1912), stated that an epidemic of pneu-
monia in the Sudan disappeared when an antiscorbutic, vi-
tamin C containing, treatment was given to the numerous
cases of scurvy which appeared at about the same time (cited
in Robertson 1934).
Hess (1920 p 88) summarized a large series of autopsy
findings on scorbutic patients: "Pneumonia, lobular or lo-
bar, is one of the most frequent complications [of scurvy]
and causes of death. Active tuberculosis is a not uncommon
secondary manifestation" and the histopathological findings:
"Secondary pneumonias, usually broncho-pneumonic in
type, are of common occurrence, and in many [scurvy] epi-
demics constitute the prevailing cause of death. Tuberculo-
sis lesions are also frequently present, and are stated to as-
sume fresh activity as a result of the nutritional disorder
(p 99). In the chapter on the prognosis of scurvy, Hess com-
mented: "An important factor in the prognosis of scurvy …
is the marked susceptibility to infection. Even latent or su-
bacute scurvy causes peculiar susceptibility to diphtheria
(especially the nasal type), or coryza, bronchitis, and pneu-
monia. A perusal of the literature shows that this suscepti-
bility was noted by the older authors in relation to adults"
(p 227).
Three exhaustive searches of the old literature on trials
about vitamin C and infections have been published, but
the data of the original publications were not quantitatively
analyzed in any of the reviews (Stone 1972; Briggs 1984;
Levy 2002). The findings of the published controlled trials
were recently analyzed (Hemilä 1997a). The few trials re-
lated to the incidence of tuberculosis and pneumonia are
briefly analyzed in the experimental section of this thesis
because these topics are covered by a few controlled trials
and because these topics are the subject of the analytic epi-
demiological work of this thesis. Therapeutic studies with
vitamin C are briefly commented on here.
There have been suggestions by German and US physi-
cians that vitamin C might have therapeutic benefits for
pneumonia patients (McCormick 1951; Klenner 1971; see
also Hemilä & Douglas 1999; Hemilä & Louhiala 2005).
Gander and Niederberger (1936) concluded from a series
of 15 cases that "The general condition is always favorably
influenced [by vitamin C] to a noticeable extent, as is the
convalescence, which proceeds better and more quickly than
in cases of pneumonia which are not treated with vitamin
C". Referring to seven German papers, Glazebrook and
Thomson (1942) commented that "there is evidence that
[vitamin C] is of value in pneumonia, particularly in has-
tening convalescence, and the claims made do not appear to
have been contradicted." Benefit of intravenous vitamin C
was reported in a series of over 40 cases (Klenner 1948,
1951), and in 3 cases of viral pneumonia (Dalton 1962).
Large-dose oral vitamin C was also claimed beneficial for
patients with viral pneumonia (Cathcart 1981; Luberoff
1978). In one of his last texts, Albert Szent-Györgyi (1978)
mentioned a personal experience: "Last year I collected a
rather unfortunate personal experience. I broke down with
pneumonia which I could not shake off for months, until I
discovered that the quantities of ascorbic acid which I took
(one gram daily) had become insufficient at my age (84
years). When I went up from one gram to eight, my troubles
were over."
However, only one randomized trial has examined the
effect of vitamin C treatment on lower respiratory tract in-
fections. This was carried out in the UK with elderly pa-
tients suffering from pneumonia (n = 17) and acute bron-
chitis (n = 40) (Hunt et al. 1994). Therapeutic vitamin C
caused a statistically significant reduction in the score of
respiratory symptoms in patients who were most severely
ill when admitted to hospital, and a decrease bordering on
statistical significance in all patients (Table 4). Furthermore,
there was a substantially lower mortality among the vita-
min C group compared with the placebo group. The effect
of vitamin C operated over and above the normal medica-
tion, mainly antibiotics and cough medicines, to which all
patients of this double-blind trial were exposed.
Several controlled trials reported that vitamin C caused
therapeutic benefit to patients with tuberculosis (Hemilä
1997a). All of these trials are old and technically more or
less deficient. In some reports there is no data allowing the
calculation of the P-value corresponding to the reported dif-
ferences. Still, several of the therapeutic tuberculosis trials
reported statistically significant differences in favor of the
vitamin C groups, but it is likely that the differences are
caused at least in part by the placebo effect and/or biases
between the study groups.
The limited and fragmentary data on the potential thera-
peutic effects of vitamin C on other infections have been
summarized elsewhere (e.g., Stone 1972; Briggs 1984; Levy
2002; Hemilä 1997a, 1998), and only two particularly in-
teresting trials are mentioned here (Table 5).
Since a study with rats found that vitamin C protected
against tetanus toxin even after the tetanus symptoms ap-
peared (Dey 1966; p 112), the study by Jahan et al. (1984)
in Bangladesh reporting that vitamin C reduced mortality
caused by tetanus infection is particularly interesting (Ta-
ble 5). The allocation method is not described and a pla-
cebo was not used. However, it does not appear reasonable
to assume that such a difference between study groups would
arise from the placebo effect, which overall is negligible
(Hrobjartsson & Gøtzsche 2001, 2004). The patients of the
trial received conventional therapy upon which the effect
of vitamin C supplementation was tested.
Another dramatic benefit in a vitamin C supplemented
group was found by Terezhalmy et al. (1978) who investi-
gated the effect of vitamin C combined with an equal amount
of bioflavonoids on herpes labialis (Table 5). Pain and time
before healing were shorter in the vitamin C+bioflavonoid
group, and the formation of vesicles was significantly re-
duced. Furthermore, Terezhalmy et al. (1978) reported that
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Vitamin E
In the case of vitamin E, the focus on surrogates is a sub-
stantially greater problem than with vitamin C. There are
several dozen immunological studies about the effects of
vitamin E, and proposals that supplementation might be
useful for people are mainly based on extrapolations from
the immunological studies. Although a large number of ani-
mal studies found some benefit from vitamin E on various
infections (Appendix 4), the number of animal studies with
vitamin E yielding highly significant benefits is substan-
tially lower than for vitamin C (Table 2). Moreover, only a
few trials with human subjects have been carried out to ex-
amine the effects of vitamin E supplementation.
Most of the vitamin E trials with human subjects have
been small and of short duration, which increases the risk of
false negative conclusions. In doses of 200 and 400 mg/day,
vitamin E did not affect the incidence of respiratory and uri-
nary tract infections among patients in a chronic care facility
(Harman & Miller 1986). In two rather small trials, the risk
of respiratory and urinary tract infection was not affected by
the combination of 15 mg/day of vitamin E with 6 mg/day of
β-carotene and 120 mg/day of vitamin C in subjects aged
≥65 years (Girodon et al. 1997, 1999). In addition, 30 mg/
day of vitamin E taken with other vitamins had no impact on
unspecified infections among non-institutionalized subjects
aged 60 years or more (Chavance et al. 1993). A small trial
of people aged ≥65 years reported 30% fewer unspecified
infections among participants administered 60-800 mg/day
of vitamin E, but the difference was not statistically signifi-
cant (Meydani et al. 1997). A trial with 652 subjects aged
≥60 years found no effect on the incidence of respiratory in-
fections with 200 mg/day of vitamin E, but the illness dura-
tion was unexpectedly increased by vitamin E (Graat et al.
2002). A recent vitamin E trial involving 617 elderly partici-
pants observed a slightly lower common cold incidence in
the group administered 200 mg/day of vitamin E (RR = 0.83;
95% CI: 0.68-1.01) (Meydani et al. 2004).
Combination of vitamins C and E had no effect on the
incidence of nosocomial pneumonia in critically ill surgical
patients (RR = 0.79; 95% CI: 0.53-1.20), but days of me-
chanical ventilation (-0.9; -0.6 to -1.2) and days of stay in
the intensive care unit (-1.2; -0.8 to -1.5) were significantly
reduced in the antioxidant group (Nathens et al. 2002). In
adults aged ≥45 years, vitamin and mineral supplement con-
taining 60 mg/day vitamin E reduced the incidence of all
infections by 41% (P < 0.001), but the role of vitamin E per
se remains unclear (Barringer et al. 2003). A recent trial
examining the effect of a multivitamin-multimineral sup-
plement containing 10 mg/day of vitamin E and 60 mg/day
of vitamin C found no effect on infections in elderly people
(Avenell et al. 2005 [see Hemilä 2005g] ).
A few small trials found that vitamin E supplementation
reduced the severity of hepatitis B and C infections (Herbay
et al. 1997; Ramrakhiani & Neuschwander 1997; Andreone
et al. 2001), except one (Nguyen et al. 1998).
The majority of the vitamin E trials have thus been nega-
tive. Moreover, an often-cited trial which examined the ef-
1 One-tailed P-value. The mid-P-value was calculated for mortality.
The difference in the change in clinical score was calculated using
the t-test; according to the original authors, the ‘clinical score’ was
approximately normally distributed. A score value of 10 corresponds
to death.
Table 4. Therapeutic effect of 0.2 g/day of vitamin C
on elderly hospitalized patients with lower
respiratory tract infections (Hunt et al. 1994)
_______________________________________________
Treatment
Patients and ___________
Outcomes
Vit C Placebo P 1
_____________ _____ _______ ___
No. of patients 28 29
Decrease in ‘total respiratory
clinical score’ in 4 weeks
(scale 3 to 10)
     Mean 3.43 2.31 0.026
     SD 1.77 2.44
Deaths 1 5 0.059
          __________
Subgroup of patients
most severely ill
when admitted
to hospital
(initial score 8 or 9)
No. of patients 12 15
Decrease in ‘total respiratory
clinical score’ in 4 weeks
     Mean 4.25 1.87 0.015
     SD 2.14 3.00
_______________________________________________
when vitamin C supplementation was initiated within 24
hours of the onset of the symptoms, 6 out of 26 patients
(23%) developed herpes vesicles, whereas with delayed ini-
tiation of supplementation 8 out of 12 patients (67%) did
so. It is unlikely that such a difference is caused by chance
(mid-P[2-t] = 0.003), indicating that the rapidity of initia-
tion of vitamin C supplementation may be important in
achieving a positive effect. Terezhalmy’s trial was double-
blind and placebo-controlled, but the method of allocation
of participants to the study groups was not described. Be-
cause vitamin C was administered with an equal amount of
bioflavonoids, this comparison is not specific to vitamin C;
however, there is no compelling data indicating that
bioflavonoids could affect infections.
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1 One-tailed P-value. The mid-P-value was calculated for dichotomous data and the t-test was used for continuous data.
Table 5. Therapeutic effect of vitamin C on non-respiratory infections
____________________________________________________________________________________
Tetanus  Treatment
(Jahan et al. 1984) _____________
Vit C Control Reduction
1 g/d vit C in mortality P 1
_____________ _____ ______ __________ ____
All patients 58 59
All deaths 10 42 75% 0.000,000,002
Age subgroups
1 – 12 years
Patients 31 31
Deaths 0 23 100% 0.000,000,000,1
13– 30 years
Patients 27 28
Deaths 10 19 45% 0.013
____________________________________________________________________________________
Herpes labialis  Treatment
(Terezhalmy et al. 1978) __________________
Vit C Placebo Reduction
in outcome
_____________ _____ _______ _________
0.6 g/d vit C
Patients 19 10
Duration of pain (d)
Mean 1.7 3.5 51% 0.000,000,2
SD 0.6 0.8
Time before healing (d)
Mean 4.2 9.7 56% 0.000,000,2
SD 1.7 2.8
1.0 g/d vit C
Patients 19 10
Duration of pain (d)
Mean 1.3 3.5 63% 0.000,000,003
SD 0.6 0.8
Time before healing (d)
Mean 4.4 9.7 54% 0.000,4
SD 3.9 2.8
0.6-1.0 g/d vit C
Patients 38 10
Vesicle development
No. of patients 14 10 63% 0.000,2
____________________________________________________________________________________
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fects of a supplement containing vitamin E (44 mg/day)
along with other micronutrients on infections in elderly sub-
jects by Ranjit K Chandra (1992) was recently shown to
contain fabricated data (Shenkin et al. 2002; Carpenter et
al. 2003; Roberts & Sternberg 2003; White 2004; Meguid
2005; Payne 2005). Chandra was the recipient of the year
1990 McCollum Award of the American Society for Clini-
cal Nutrition (ASCN 2005); see footnote to Table 1.
Furthermore, sometimes papers on vitamin E and infec-
tions are grossly biased. In the recent vitamin E paper,
Meydani et al. (2004) cited the above-mentioned paper with
fabricated data (Chandra 1992), without noting its problems.
Meydani et al. also cited a retrospective study of elderly
subjects who were asked about their recollection of preced-
ing infections which were correlated with plasma vitamin
E levels (Chavance et al. 1985, 1989), although this type of
experimental design has a high risk of recall bias, and plasma
vitamin E has no meaningful correlation with vitamin E
intake (FNB 2000 p 210). In contrast to these poor-quality
studies, Meydani et al. failed to cite a randomized placebo
controlled double-blind trial that found no overall effect of
vitamin E on the incidence of colds in 21,796 participants
(III; Hemilä & Kaprio 2004), which is a very large trial
compared with the 617 participants in the Meydani  trial
(2004). Meydani et al. also failed to cite the controlled trial
by Chavance et al. (1993) that was motivated by their above-
mentioned retrospective study, but which produced nega-
tive results. Meydani et al. (2004) thus cited poor-quality
studies when the results were consistent with their own pre-
conceptions, but failed to cite better quality trials if the re-
sults were inconsistent with those preconceptions.
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AIMS OF THE PRESENT THESIS
The primary purpose of this thesis was to determine whether
vitamin C has effects on respiratory infections. This thesis
was initiated with two different lines of approach: (1) meta-
analyses of published controlled trials on vitamin C and res-
piratory infections, and (2) analysis of the baseline dietary
vitamin C intake of the ATBC Study in relation to respira-
tory infections during the follow-up. The main purpose of
the ATBC Study was to examine the effect of β-carotene
and vitamin E supplementation on the incidence of lung
cancer (ATBC 1994a,b; Virtamo et al. 1987). Since vitamin
C and vitamin E are both antioxidants which have a chemi-
cal and physiological interaction (see pp 10-1), the scope of
this thesis was later expanded to cover (3) the effects of
vitamin E supplementation on respiratory infections.
Although β-carotene was the supplementation of primary
interest in the ATBC Study when the trial was initiated in
1985, it was not of interest in the current thesis, even though
in most cases the β-carotene findings were analyzed in par-
allel with the vitamin E findings in Papers III to V.
Because the analyses of the previously published vita-
min C trials, and the analyses of the ATBC Study are quite
dissimilar activities, they are discussed under separate cat-
egories.
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A) Analyses and meta-analyses of trials
on vitamin C and respiratory infections
Methods
Searches for the trials
Independently of the present author, the earlier literature on
vitamin C-common cold trials was thoroughly searched for
by Briggs (1984) and Kleijnen et al. (1989). Kleijnen et al.
(1989; Kleijnen & Knipschild 1992) identified over 60 con-
trolled trials on vitamin C and the common cold, and pub-
lished the bibliography. Briggs (1984) published an exten-
sive bibliography covering all infections. Although some
authors urge that the literature search should be explicitly
described to show that the search strategy is valid (e.g.,
Kleijnen & Knipschild 1992), in many cases a simple ex-
plicit search phrase may yield grossly misleading results.
For example, a ‘pneumonia’ search of Medline does not
identify any of the three vitamin C trials that reported the
number of pneumonia cases in the study groups (Glazebrook
& Thomson 1942; Kimbarowski & Mokrow 1967; Pitt &
Costrini 1979). The oldest trial is not included in the Medline
database whereas the two more recent ones are, yet pneu-
monia is not mentioned as a keyword in either of them de-
spite being an important secondary outcome in both trials.
Consequently, an explicit search strategy is no evidence that
a search has a meaningful coverage of relevant publications.
The literature searches for trials on vitamin C and infec-
tions by the current author were composed of several
searches using various strategies in different databases
(Medline, Web of Science, Embase, and Chemical Ab-
stracts). In some cases the search phrases were rather loose,
e.g., ‘vitamin C’ alone, whereas some other searches were
limited by additional phrases such as ‘infection’ or ‘im-
mune.’ Papers citing the older seminal papers were sought
in the citation data base (Web of Science). Thus, no single
or simple explicit search strategy was used for this thesis.
The reference-lists of relevant articles, reviews, and books
were also perused. As to the trials on vitamin C and the
common cold, Kleijnen et al. (1989) missed a few old tri-
als, and a few trials on vitamin C and the common cold
have been published since Kleijnen’s bibliography (Table 6).
Statistical methods
The statistical methods used are mostly standard methods
described in textbooks of medical statistics (see Altman 1991;
Feinstein 2002). The mid-P method (Lancaster 1961; Berry
& Armitage 1995), used to analyze the 2x2 tables, is not de-
scribed in the ordinary medical statistics textbooks, but is
described by Rothman (1986 pp 138-9, 161-2, 203-5),
Rothman and Greenland (1998 pp 222-4), and Clayton and
Hills (1993). Since the mid-P value is extensively used in
this thesis, the rationalization for this concept is explained
in Table 7.
One-tailed P-values are mostly used in the analyses of
studies in this text, since the questions in the present thesis
are whether vitamin C or vitamin E supplementation de-
creases the incidence or severity of infections or not, and
these questions are unidirectional. When pertinent, the
2-tailed P-value is given, and in such a case the 2-tails are
explicitly mentioned (P[2-t]).  If the 1-tailed P-value is
higher than about 0.98, there is reason to assume harm in
the treatment group of the particular experiment.
Table 6. Vitamin C common cold trials not included
in the Kleijnen et al. bibliography (1989)
_______________________________________________
Published before 1989
Niemi-1951
Boines-1956
Masek-1974
Carson-1975b
Briggs-1984
Mink-1988
Published in 1989 or later
Shult-1990
Peters-1993
Peters-1996
Moolla-1996
Himmelstein-1998
Gorton-1999
Audera-2001
Van Straten-2002
Sasazuki-2006
_______________________________________________
CURRENT STUDIES AND THEIR FINDINGS
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cluded, the participants were asked in a questionnaire which
capsules they thought they had been administered. In the
case of prophylactic capsules there was strong bias in favor
of correct answers (P < 10-6). In contrast, there was no evi-
dence of bias in the case of therapeutic capsules (P[2-t] =
0.3). After finding that several participants had correctly
identified their treatment, Karlowski et al. carried out a sub-
group analysis in which they divided participants into those
who remained blinded and to those who were unblinded
after the trial was concluded. In this subgroup analysis,
Karlowski was able to show that all the benefit of vitamin
C was seen in the ‘unblinded’ group, whereas there was no
effect from vitamin C on the participants who remained
‘blinded’ (Table 8). The authors thus concluded that vita-
min C supplementation has no physiological effect, and the
apparent benefit was simply caused by ‘the placebo effect.’
Thus, the Karlowski trial seemed to provide direct evidence
of the placebo-effect in action. In 1996 Thomas Chalmers
stated that he was "more proud of [the Karlowski trial] than
almost any other that I have published."
Several consecutive editions of two major textbooks on
infectious diseases referred to the Karlowski trial in no un-
certain terms: "Many participants correctly surmised from
the taste of the contents of the capsules used whether they
were receiving vitamin C or a placebo" (Gwaltney 1979,
1985, 1990, 1995), and "It is most probable that the reported
benefits are a result of statistical artifacts and placebo ef-
fect due to poor study design rather than specific
pharmacologic drug effects" (Cherry 1987, 1992, 1998).
The Karlowski trial was also alluded to in two recent
editions of the Cecil Textbook of Medicine: "Because the
Table 7. Rationalization of the mid-P-value
_______________________________________________
Let us assume that we observe results
forming the following 2x2 table:
_______
1 1
1 1
_______
In the Fisher exact test, we calculate the probability of all
tables that have the same fixed margins (3 tables in this
case):
_______ Probability of the table:
2 0
0 2 P[up] = 1/6
_______
1 1
1 1 P[obs] = 4/6
_______
0 2
2 0 P[low] = 1/6
_______________________________________________
The lower 1-tailed ‘Fisher P’ adds the probabilities of the observed
table (P[obs]) and the probabilities of the tables of the lower tail.
Thus here,
Fisher P[1-t] = 4/6 + 1/6 = 5/6 = 0.833.
The lower 1-tailed ‘mid-P’ adds half of the probability of
the observed table (½ x P[obs]) and the probabilities of the tables of
the lower tail.
Thus here,
mid-P[1-t] = 2/6 + 1/6 = 3/6 = 0.5.
With the ‘observed table’ having 1 observation in each cell, there is
no evidence of any difference from the null effect, and we should
expect the corresponding P[1-t] to be exactly 0.5. In this respect the
mid-P corresponds to scaling the P-value so that P[1-t] = 0.5 corre-
sponds to the null effect. Thus the mid-P modification is consistent
with the t-test, which also yields P[1-t] = 0.5 if there is no difference
between the groups, so that their means are equal.
The 1-tailed mid-P-values never add up to a 2-tailed mid-P-value
above 1. In contrast, the 1-tailed Fisher P-values may add up to
the 2-tailed Fisher P-value above 1 as in the case above
(Fisher P[2-t] = 2 x 0.833 = 1.67); however, P values above 1 are
inconsistent with the concept of probability.
The most influential trial on vitamin C
and the common cold: Karlowski et al. (1975)
In the middle of the 1970s, Karlowski, Chalmers, et al. (1975)
published a vitamin C common cold trial which received wide-
spread attention for several reasons. First, the trial was car-
ried out at the NIH. Since the participants in the trial were
NIH employees, the social background of this particular trial
was highly significant. Secondly, the principal investigator
of the trial was Thomas Chalmers, who was an eminent clini-
cal trialist (see p 36). Third, the trial was published in JAMA,
a respected journal with a particularly wide circulation. Fi-
nally, the same issue of JAMA contained a review of vitamin
C and the common cold, which concluded that it has no ef-
fects on colds (Dykes & Meier 1975; see pp 42-5).
Technically, the Karlowski trial is not among the best.
Karlowski’s placebo capsules contained lactose which is
sweet, whereas ascorbic acid was used in the vitamin C cap-
sules, so that some of the participants may have identified
their treatment by taste. In fact, the authors concluded from
their trial that the results were explained by the placebo ef-
fect: "The effects demonstrated might be explained equally
well by a break in the double blind" (Karlowski et al. 1975).
The Karlowski trial lasted for 9 months and included
4 treatment arms (Table 8). Each participant received 2 kinds
of capsule: prophylactic (each day) and therapeutic (5 days
during a cold). Ascorbic acid (3 g/day) was used in the ac-
tive capsules and lactose in the placebo capsules, a differ-
ent combination being administered to each of the 4 study
arms. The mean duration of cold episodes in each study
arm is shown in Table 8. After the Karlowski trial was con-
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Table 8. Results and subgroup analysis of the Karlowski et al. trial (1975)
________________________________________________________________________________________________
               Subgroup analysis
_______________________________________
Study
Group Vitamin C dose All subjects ‘Blinded subjects’ ‘Unblinded subjects’
_____ __________________ ______________ ______________ ________________
Prophylaxis Therapy Duration No. of Duration No. of Duration No. of
(g/d) (g/d) of colds colds of colds colds of colds colds
(d) (d) (d)
#0 0 0 7.1 65 6.3 30 8.6 16
#1 0 3 6.5 56 6.7 18 4.7 15
#2 3 0 6.7 52 6.4 14 7.0  8
#3 3 3 5.9 76 6.5 30 4.8 13
________________________________________________________________________________________________
subjective symptoms of a cold disappear in 7 days without
intervention, a variety of actually ineffective treatments have
been reported to be effective due to inadequate blinding of
placebo recipients. One example of this phenomenon was a
study of large dose of vitamin C to prevent colds, in which
many placebo recipients dropped out of the study because
they could tell by tasting the medication that they were not
receiving the vitamin C" (Hendley 1996, 2000). Although
the Karlowski trial had stronger evidence of divergence in
dropping out than the 5 largest vitamin C common cold tri-
als, the difference between the vitamin C and placebo groups
was nevertheless not statistically significant in the Karlowski
trial (Table 9), and in this respect the comment is mislead-
ing.
A US Food and Nutrition Board monograph referred to
the Karlowski trial when stating that vitamin C has no worth-
while effects on colds (FNB 1989b). Another recent mono-
graph by the Food and Nutrition Board also briefly discusses
the role of vitamin C on the common cold, stating that in
the Karlowski trial "the break in the double-blind study may
have been due to the curiosity of the scientist participants"
(FNB 2002).
Karlowski’s trial has been cited in major reviews of com-
mon cold therapy (Coulehan 1979; Sperber & Hayden 1988;
Spiers 2002), in BMJ  (Editorial 1976), and in a recent re-
view on echinacea and the common cold when proposing
that the effects of echinacea in placebo-controlled trials are
caused by the placebo effect (Caruso & Gwaltney 2005 [see
Hemilä 2005a] ).
Because the notion of ‘breaking blindness’ is technically
a highly relevant issue in the field of controlled clinical tri-
als, the Karlowski trial has been cited by several clinical
trialists. In a paper discussing frauds and errors in medical
research, clinical trialist DeMets (1997) wrote of the
Karlowski trial: "Since patients in the study were employ-
ees of the NIH, they had either direct or indirect access to
laboratories, and were easily able to break the double blind
… Patients were asked if they had, in fact, used their own
resources in the laboratories to break the blind." This is,
however, erroneous, since Karlowski et al. (1975) did not
report evidence that their participants actually examined the
contents of their capsules. The participants were simply
asked to "guess which substance they had been taking." The
same comments on the Karlowski trial were reiterated in a
more recent paper by DeMets (1999).
A popular textbook Fundamentals of Clinical Trials used
the Karlowski trial as an example of unsatisfactory blind-
ing causing false conclusions (Friedman et al. 1998 p 83):
"A trial of the possible benefits of ascorbic acid in the com-
mon cold started out as a double-blind study. However, it
soon became apparent that many of the participants, most
of whom were medical staff, discovered whether they were
on ascorbic acid or placebo. Since evaluation of severity
and duration of colds depended on the participants’ report-
ing of their symptoms, this unblinding was important.
Among those participants who claimed not to know the iden-
tity of the treatment, ascorbic acid showed no benefit over
placebo. In contrast, among participants who knew or sus-
pected what they were on, ascorbic acid did better than pla-
cebo. Therefore preconceived notions about the benefit of a
treatment, coupled with a subjective response variable, may
have yielded biased reporting. Only the alertness of the in-
vestigators prevented them from arriving at probably false
conclusions."
The Karlowski trial was also cited in a recent paper in
JAMA discussing the blinding of trials (Devereaux et al.
2001), and in recent papers by specialists in controlled tri-
als commenting on the question of breaking of blindness in
blinded trials (Bang et al. 2004 [see Hemilä 2005b]; Chow
& Shao 2004 [see Hemilä 2006a]; Forder et al. 2005 [see
Hemilä 2005d]; Rees et al. 2005; Walter et al. 2005).
The Karlowski trial was cited as an example of placebo
effect in action by the CONSORT group, an international
group of clinical trialists, statisticians, epidemiologists, and
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biomedical editors, who suggested improvements in report-
ing clinical trials (Begg et al. 1996). Consecutive editions of
the Cochrane Reviewers’ Handbook also cite the Karlowski
trial, stating that "There is evidence that participants who are
aware of their assignment status report more symptoms, lead-
ing to biased results" (Mulrow & Oxman 1994 s 6.4; Clarke
& Oxman 2002 ss 6.4 and 6.6; Alderson et al. 2004 ss 6.4
and 6.6; Higgins & Green 2005 ss 6.4 and 6.6). The Karlowski
trial was also referred to in a popular textbook of epidemiol-
ogy as an example of important controlled trials (Rothman
1986 p 54; Rothman & Greenland 1996 p 70).
The ‘placebo-explanation’ of the Karlowski-results was
forcefully emphasized in a concurrent and influential re-
view by Thomas Chalmers, the principal investigator of the
Karlowski trial (Chalmers 1975, 1996; see pp 36-8).
Furthermore, the Karlowski trial was also cited in a text
discussing vitamin C and the common cold by Stephen
Barrett (1995, 2005; see p 64), a prominent and influential
crusader against health quackery.
There are several vitamin C common cold trials that are
considerably larger, and that do not suffer from the short-
coming that vitamin C could be distinguished from the pla-
cebo by taste, 5 larger trials confirming that their vitamin C
and placebo tablets were indistinguishable (Table 10). How-
ever, these larger and better trials are much less frequently
cited than the Karlowski trial. For example, none of them
are cited in the major textbooks of infectious diseases
(Gwaltney 1979, 1985, 1990, 1995, 2000, 2005; Cherry
1987, 1992, 1998), even though these 5 trials together re-
corded 27 times as many common cold episodes as the
Karlowski trial (Table 10).
Table 10 shows that, excluding the citations in Hemilä’s
papers, the Karlowski trial (1975) has been cited 13 times
per 100 recorded common cold episodes (33/249), whereas
the 5 largest trials together have been cited 0.2 times per
100 recorded cold episodes (14/7,167). Thus, per recorded
episode, the Karlowski trial has had 65 times as great an
impact as the 5 largest trials combined, even though the
latter trials used valid placebos, unlike Karlowski. In this
respect, the great impact of the Karlowski trial seems to be
a good example of the Mathew effect in science (Merton
1968), in that famous scientists in famous institutions are
cited because of their social context, irrespective of the qual-
ity of their work. Citation bias has also been documented in
several other topics (Gøtzsche 1987; Ravnskov 1992;
Kjaergard & Gluud 2002).
Table 9. Drop-outs in the major vitamin C common cold trials
________________________________________________________________________________________________
Vitamin C group Placebo group
______________ ____________
Difference
No. of participants No. of participants in drop-out
________________ _______________ proportion
Trial 1 Initiated Concluded Initiated Concluded P[2-t]
_________ _______ _________ _______ _________ _____
Karlowski-1975 153 101 158 89 0.063
(regular capsules)
_____________
Anderson-1972 2 500 407 500 411 0.7
Anderson-1974 3 1,320 860 880 578 0.8
Pitt-1979 429 331 432 343 0.4
Ludvigsson-1977b 4 321 304 321 311 0.2
Elwood-1976 5 449 339 474 349 0.5
________________________________________________________________________________________________
1 These trials are the 6 largest in terms of the total number of episodes that administered ≥1 g/day vitamin C regularly during the trial
(see Table 10; Paper II; Douglas, Hemilä et al. 2004).
2 Randomization was in pairs. The participants at start totalled 1,000, but the distribution into groups is not stated;
here it is assumed that the groups were initially of equal size.
3 In the Anderson et al. trial (1974), the placebo group refers to arms #4 and #6 (see Table 16), and the vitamin C group refers to
arms #1, #2, and #3, which were administered ≥1 g/day vitamin C regularly during the trial.
4 In all, 642 initiated the trial; "every class was divided at random into two groups." A total of 615 completed the trial, so that 27 children had
dropped out. Side-effects were the reason for 1 child to drop out from each group, but the distribution of the remaining drop-outs (27 – 2 = 25)
is not reported. Here it is assumed that the size of the groups was initially the same.
5 Dropping out because of ‘moving away’ was 5, and records of 2 participants were lost, but the distribution of these 7 participants between the
treatment groups is not reported; it is assumed here that 3 of these were in the vitamin C group, and 4 in the placebo group. Dropping out
because of ‘inadequate co-operation’ was 107 in the vitamin C group and 121 in the placebo group.
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Table 10. Citations of the major vitamin C common cold trials
________________________________________________________________________________________________
Citations from 1991 to 2002 1
_________________________
Total no. of Excluding
cold episodes Total citations Constituent
Trial 2 in the trial citations by Hemilä of the placebo
_____________ ___________ _______ _________ ___________
Karlowski-1975 249 43 33 Lactose
_____________ _____ ___ ___ ___________
Anderson-1972 1,170 12 4 Citric acid 3
Anderson-1974 4 2,182 9 4 Lactose and
   citric acid 3
Pitt-1979 1,219 12 3 Citric acid 3
Ludvigsson-1977b 1,279 11 2 not stated 3
Elwood-1976 1,317 9 1 not stated 3
___ ___
Total episodes Total citations
excluding excluding
Karlowski-1975 7,167 Karlowski-1975 14
________________________________________________________________________________________________
1 ISI Web of Science search.
2 These trials are the 6 largest administering ≥1 g/day vitamin C regularly during the trial (see Paper II; Douglas, Hemilä, et al. 2004).
All were randomized, double-blind, and placebo-controlled.
3 The authors state that placebo and vitamin C tablets looked and tasted the same.
4 The number of episodes is based on the total of arms #1, #2, and #3, which were administered ≥1 g/day vitamin C regularly during the trial,
and arms #4 and #6, which were administered placebo (see Table 16).
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Paper I: Re-analysis of the Karlowski et al.
trial (1975)
Problems with Karlowski’s ‘placebo explanation’
The authors of the Karlowski trial concluded that the ob-
served benefit in vitamin C groups was explained by the
placebo effect (Table 8). Since the ‘placebo explanation’ is
such a spectacular conclusion to a double-blind placebo-
controlled trial, and since this is by far the most influential
vitamin C common cold trial (Table 10), it was considered
worthwhile to determine whether Karlowski’s ‘placebo ex-
planation’ is actually consistent with the reported differ-
ences between the study groups.
Karlowski et al. (1975) asked participants after the trial
to guess the type of capsule they were given, and Karlowski
used a ‘correct answer’ as a surrogate for actually ‘know-
ing,’ without considering that many answers were correct
purely by guesswork (Table 11). There was strong statisti-
cal evidence that participants gave a correct answer to the
question on the prophylactic capsules more often than ex-
pected, but there was no evidence that participants identi-
fied the therapeutic capsules more often than by guessing
(Table 11). However, prophylactic capsules had consider-
ably less effect (-0.48 days; see Paper I) on the duration of
colds than the therapeutic capsules (-0.73 days; P = 0.05;
see Paper I). The greater benefit from the therapeutic cap-
sules is inconsistent with the ‘placebo explanation,’ because
there is no statistical evidence that therapeutic capsules were
identified by the participants, and at most only 11 (8%) par-
ticipants identified the therapeutic capsules (Table 11).
Furthermore, Karlowski et al. did not describe how they
divided participants into the two subgroups of ‘blinded’ and
‘unblinded.’ The sum of these two subgroups does not match
with data for all participants, although the authors presented
the subgroups as if they were complementary. Table 8 shows
that the total number of common cold episodes in the pla-
cebo group (#0) was 65. The ‘blinded’ placebo subgroup
contained 30 episodes, and the ‘unblinded’ placebo sub-
group contained 16 episodes, with a total of 46. Thus, there
were 19 common cold episodes (= 65 - 46) in the placebo
group affecting participants who were neither ‘blinded’ nor
‘unblinded.’ In total, there were 105 common cold episodes
(42% of all) missing from Karlowski’s subgroup analysis
(Table 8). The maximum effect of vitamin C on common
cold duration can be calculated for the ‘missing group’
(-1.4 days/episode; difference between 6 g/day and 0 g/day
groups; see Paper I); thus it is even greater than the effect in
the entire study population (-1.2 days/episode [=7.1 – 5.9];
Table 8). Karlowski et al. did not mention the exclusion of
the 105 episodes from their subgroup analysis, nor did they
offer their rationalization for the greater than average ben-
efit in those participants who were neither ‘blinded’ nor
‘unblinded.’
A number of further problems with the ‘placebo expla-
nation’ are discussed in Paper I. Consequently, the ‘placebo
effect’ explanation is inconsistent with the data reported by
Karlowski et al. (1975).
An alternative explanation of the bias in ‘know-
ing’: Inference from subjective observations
There has been a persistent popular belief, long predating
Pauling’s book (1970a), that vitamin C is beneficial against
the common cold. Consequently, it is possible that several
participants inferred the vitamin C treatment from the sub-
jective feeling that their cold symptoms were milder than
they expected. Similarly, the impression that the symptoms
were prolonged may have led a participant to infer that the
placebo was being given, not vitamin C.
Vitamin C has substantially reduced the duration or se-
verity of colds in several placebo-controlled trials (up to
20-50%; Fig. 3), so that it would be no surprise if vitamin C
could be correctly distinguished from placebo by some peo-
ple on the basis of subjective observation. Moreover, one
double-blind placebo-controlled trial was initiated to ex-
amine the therapeutic effects of 6 g/day of vitamin C on
common cold symptoms, but the trial was discontinued be-
cause the participants receiving the vitamin could be iden-
tified by their clinical progress (Asfora 1977). With such
positive reports it is quite possible that correct identifica-
tion of capsules in the Karlowski trial was partly caused by
the physiological effects of vitamin C.
In fact, the ‘knowledge inferred from subjective obser-
vation’ explanation is directly supported by the data from a
parallel publication of the Karlowski trial (Lewis et al. 1975).
Among participants who had not tasted their prophylactic
placebo capsules, those who had colds during the trial tended
to suspect that they were being given placebo (15 of 18),
whereas those who did not have colds tended to suspect
they were being given vitamin C (6 of 8) (mid-P[2-t] =
0.004). A similar inference can apparently be drawn from
the duration or severity of colds, but this was not consid-
ered by the authors. The alternative explanation is briefly
mentioned but not properly analyzed in the JAMA paper
(Karlowski et al. 1975) or in the parallel study report (Lewis
et al. 1975), and the ‘placebo explanation’ is strongly favored
in both papers. However, the alternative explanation is not
mentioned at all in Chalmers’ review (1975).
The re-analysis of the Karlowski trial (I) was criticized
by Thomas Chalmers (1996), but the criticism seems not to
be valid (I; Hemilä 1996c), except for Chalmers’ statement
that they used capsules in their trial, and not tablets as erro-
neously stated in Paper I. Unfortunately Chalmers died while
Paper I and the accompanying commentaries were being
published (Feinstein 1996).
Inference of treatment by subjective observation
in the Pitt and Costrini trial (1979)
The possibility that certain of Karlowski’s participants may
have correctly inferred their treatment from subjective ob-
servation is supported by the findings of Pitt and Costrini
(1979) in a randomized double-blind placebo-controlled trial
with Marine recruits in the USA. In this trial, "The placebo
tablets were formulated from citric acid and were indistin-
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Table 11. Subjective deduction of the treatment in the double-blind trials by Karlowski et al. (1975)
and Pitt & Costrini (1979)
________________________________________________________________________________________________
Karlowski et al. (1975) Pitt & Costrini (1979)
______________________________ __________________
The published figures Prophylactic Therapeutic
__________ __________
No. of participants 190 132 674
________________
  Vitamin C group 101 70 331
  Placebo group 89 62 343
_____________ ____ ____ ____
Did not guess 88 79 358 (53%) 1
Guessed 102 53 316
_____________ ____ ____ ____
Participants
giving an answer:
Correct answer
Vitamin C group 40 20 89 (27%) 1
Placebo group 39 12 89 (26%) 1
Guessed incorrectly
Vitamin C group 12 11 66 (20%) 1
Placebo group 11 10 72 (21%) 1
        ______
Both groups
Correct answer 79 32 178
Guessed incorrectly 23 21 138
___________________ ___ ___ ___
Assuming pure guessing,
χ2-test for the distribution of
correct and wrong answers
P[2-t] <0.000,1 0.3 0.013
___________________ _______ ___ _____
Inference from the published figures
‘Correct answers’ 79 32 178
are composed of:
Pure guess (assumed the same
as the wrong guesses) 23 21 138
Really knew 56 11 40
Of correct answers 71% (56/79) 34% (11/32) 22% (40/178)
Of all participants 29% (56/190) 8.3% (11/132) 5.9% (40/674)
________________________________________________________________________________________________
1 Pitt & Costrini (1979) published the percentages indicated and the corresponding numbers of participants was calculated from these.
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guishable in appearance and taste from the vitamin C tab-
lets." After the trial, participants were asked which pill they
thought they were taking, and the percentage of participants
giving various answers was reported; the number of par-
ticipants corresponding to the percentage is calculated in
Table 11. There is a statistically significant difference in
the number of participants who gave the correct answer
(n = 178) compared with those giving an incorrect answer
(n = 138). Correct identification may be caused by the posi-
tive or negative effects of vitamin C, but the authors found
no difference in adverse events between the study groups.
Instead they reported a statistically significant, but clini-
cally minor effect on common cold severity (P = 0.012),
and an 85% lower incidence of pneumonia in the vitamin C
group (see pp 50-1). Pitt and Costrini’s data suggests that
some 6% of all participants (40/674) inferred their treat-
ment by subjective observation (Table 11).
A) Effect on incidence
Benefit
Placebo
0 2 4 6 8 10
-60 %
-40 %
-20 %
0 %
20 %
B) Effect on duration
or severity
No. of trials No. of trials
-60 %
-40 %
-20 %
0 %
20 %
0 2 4 6 8 10
Fig. 3. Vitamin C supplementation does not affect the incidence of the common cold (A), but does decrease its duration and alleviate
its symptoms (B). The vertical scale shows the relative effect of vitamin C compared with the placebo. The horizontal bar indicates the number of
trials reporting the effect falling within the vertical limits of the bar. Black bars indicate trials with ≥400 participants. All trials used 1-4 g/day of
vitamin C, all were placebo-controlled, and all except one were double-blind. For details and original references, see Hemilä (1994a)
Scandinavian Journal of Infectious Diseases 26:1-6 from which the figure is reproduced with permission.
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Meta-analysis: methodological
considerations
Meta-analyses on vitamin C and the common cold:
from Linus Pauling and Thomas Chalmers
to the Cochrane Collaboration
In the 1970s, three meta-analyses on vitamin C and the com-
mon cold were published (Pauling 1971a,b; Chalmers 1975).
In fact, these three papers were among the first few meta-
analyses carried out in medicine. However, the conclusions
of these three meta-analyses diverged substantially.
Linus Pauling (1971a; see pp 13, 35-6) combined the
P-values derived from 4 placebo-controlled trials by the
Fisher method, concluding that there was strong evidence
that vitamin C decreased the ‘incidence of colds’ (P =
0.0014), and the ‘integrated morbidity’ due to colds (P =
0.000,022). In a second meta-analysis, Pauling (1971b) fo-
cused on ‘days of illness per person’ in the best two trials
(Cowan et al. 1942; Ritzel 1961; Table 3). Combining the
P-values by the Fisher method led him to conclude that "The
null hypothesis of equal effectiveness of ascorbic acid and
placebo is rejected at the level P less than 0.001."
Thomas Chalmers (1975; see pp 36-8) carried out a meta-
analysis of 8 placebo-controlled trials, calculating the
unweighted average of the treatment effect. According to
his calculation, colds in vitamin C groups were 0.11 ± 0.24
(SE) days shorter, and the incidence of colds in vitamin C
groups was 0.09 ± 0.06 (SE) episodes less per year, neither
of which is a statistically or clinically significant difference.
This meta-analysis of vitamin C and the common cold was
Thomas Chalmers’ second, his first being published in the
1960s (Grace et al. 1966).
In the late 1980s, a fourth meta-analysis on vitamin C
and the common cold was published, but neither combined
P-values nor pooled estimates were calculated (Kleijnen et
al. 1989; see pp 38-41). In the 1990s, a series of meta-analy-
ses which focused on various different questions related to
the possible effects of vitamin C on the common cold was
published (Hemilä 1990a,b, 1992a, 1994a, 1995a, 1996a,b,
1997a,b, 1999a). Since all 21 trials with regular ≥1 g/day
doses had found that vitamin C was better than placebo when
measuring the severity or duration of colds, the sign-test
was used to calculate the probability that all 21 trials would
find vitamin C to be better than placebo (P = 2exp(-21) =
0.000,000,5; Fig. 3; Hemilä 1994a). A Cochrane Review
on vitamin C and the common cold also appeared in the late
1990s (Douglas et al. 1998; see pp 40-2).
Because meta-analysis has been extensively used as a
method of analyzing the potential effect of vitamin C on the
common cold, the opportunities provided by this method as
well as some of its limitations are considered here, in par-
ticular since Paper II of the current thesis covers 3 meta-
analyses of vitamin C and the common cold incidence with
different objectives.
The purpose of meta-analysis
In general, ‘meta-analysis’ denotes systematic and thorough
investigation of scientific literature on a specific topic, and
combining the results of ‘close enough’ studies by statisti-
cal formulae, but there is substantial difference of opinion
as to how people see the coverage of the term ‘meta-analy-
sis.’ The term was coined by Gene Glass to describe the
process of synthesizing results from separate but similar
studies (Mann 1990).
Interestingly, the origin of the meta-analytic approach was
connected to vitamin C (Hampton 2002; Milne & Chalmers
2004), since in his treatise on vitamin C deficiency, James
Lind carried out a systematic search of all the older literature
and wrote that "As it is no easy matter to root out old preju-
dices, or to overturn opinions which have acquired an estab-
lishment by time, custom and great authorities; it became
therefore requisite for this purpose, to exhibit a full and im-
partial view of what has hitherto been published on the scurvy;
and that in a chronological order, by which the sources of
those mistakes may be detected. Indeed, before this subject
could be set in a clear and proper light, it was necessary to
remove a great deal of rubbish" (1753 p 7; see Appendix 1).
Typically, meta-analysis is used (1) to increase statistical
power for primary end points and for subgroups, or (2) to
improve estimates of the size of the effect, or/and to (3) re-
solve uncertainty when reports disagree (Sacks et al. 1987).
The purpose of increasing statistical power emerges from the
problem that a large proportion of controlled trials are so small
that they cannot provide meaningful evidence for the effec-
tiveness or otherwise of therapy, simply because the confi-
dence intervals (CI) are very wide. This problem of low sta-
tistical power was illustrated by Freiman, Chalmers, et al.
(1978) who analyzed 71 ‘negative’ trials (P > 0.05 for the
difference of interest), showing that 50 of them could have
missed a 50% benefit because the trials were simply too small.
Thus, meta-analysis can be used to enhance the use of data
from small studies with ambiguous results by combining the
results of several to test whether there is any overall evidence
of effect, and to estimate its magnitude. This is the most com-
mon use of meta-analysis.
When the optimism on the fruitful opportunities provided
by meta-analysis was high, Chalmers’ group believed that
"A quantitative synthesis of the data in similar randomized
controlled trials can potentially be more useful to the
practicing physician than a traditional narrative review arti-
cle, but such a synthesis must be properly performed to war-
rant serious attention" (Sacks et al. 1987). Thomas Chalmers
also commented that "Meta-analysis is the wave of the fu-
ture. The days of the expert supposedly putting the state of
the field into a review article are numbered" (Mann 1990).
Some examples of problems with meta-analysis
The most severe problems of meta-analysis are related to
the experimental similarity of the studies that are combined
and their validity. ‘Combining apples and oranges’ has been
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commonly used as a metaphor to describe this problem, but
often the meta-analytic mixtures are so heterogeneous that
‘combining rotten fruits’ might sometimes be a more ap-
propriate way to describe the problem (Feinstein 1995).
Improper consideration of the experimental features of
trials is illustrated by an early, often-cited meta-analysis that
combined the findings of 6 small randomized trials exam-
ining the value of anticoagulants in acute myocardial inf-
arction (Chalmers et al. 1977); this was Thomas Chalmers’
third meta-analysis. Of the 6 randomized trials included,
2 contained no criteria for the diagnosis of myocardial inf-
arction, and in 3 others the published definitions were so
inexact that the patient populations could not be reproducibly
identified (Goldman & Feinstein 1979). The treatments also
varied from heparin alone to heparin with warfarin or war-
farin derivatives and even warfarin with optional heparin,
but the modes of action of heparin and warfarin are differ-
ent and it should not be assumed that these treatments are
pharmacologically equivalent enough to be combined in a
meta-analysis (Goldman & Feinstein 1979).
In another example of the lack of properly considering
the experimental aspects of controlled trials included in
meta-analyses, Bailar (1995; MacArthur et al. 1995) dis-
cussed one meta-analysis by the Chalmers group of 6 trials
dealing with the effects of diethylstilbestrol on the outcome
of pregnancy (Goldstein et al. 1989). One of the 6 trials did
not deal with diethylstilbestrol at all, and 3 others were
methodologically flawed enough to destroy any credibility
in their reported findings. Two studies appeared to have had
adequate methodological strength, but one dealt with a se-
ries of pregnant women from the general populations, while
the other was limited to pregnant women who had diabetes.
It seems questionable, at best, to pool results from these
last two studies without some thoughtful discussion (Bailar
1995). Furthermore, although Goldstein et al. had excluded
one trial based on the probable non-alternate assignment of
treatment as well as inconsistencies in the text, Bailar iden-
tified the same problems in 3 of 5 trials that Goldstein et al.
did include. Considering the various shortcomings, Bailar
concluded that the ‘typical odds ratio’ calculated by
Goldstein et al. (1989) was meaningless.
In a further meta-analysis by the Chalmers group, 9 tri-
als with 744 participants were combined to form a pooled
estimate of antibiotic prophylaxis for recurrent acute otitis
media (Williams et al. 1993). "Of those [nine] studies,
2 were on special populations, Alaskan Eskimos and asth-
matics involving 388 children. They are nonrepresentative
groups of the general population because of differences in
severity and pathogenesis. Williams et al. also included
3 small crossover trials which used sulfisoxazole (a drug
not recommended for extended use). Excluding those stud-
ies, there were only 4 RCTs with a combined population of
235 patients [in contrast to Williams’ 744 patients]. In that
group, the rate difference was only 0.067 [episodes per
month; in contrast to Williams’ estimate of 0.11]" (Cantekin
1994, 1998).
In addition to the problems in the Goldstein et al. meta-
analysis (1989), Bailar (1995) also pointed out serious short-
comings in 4 other meta-analyses. Klein (2000) pointed out
severe flaws in 4 meta-analyses comparing psychotherapy
with pharmacotherapy. Indeed, there are numerous exam-
ples of unreliable meta-analyses.
The concept of meta-analysis seems to imply objectiv-
ity, but the selection criteria can vary substantially when
different research groups carry out meta-analysis of the
‘same’ topic. In a ‘meta-meta-analysis’ Katerndahl and
Lawler (1999) analyzed 23 meta-analyses that had exam-
ined the value of cholesterol reduction in coronary heart
disease, finding substantial variation in the meta-analyses
and their conclusions. Similarly, Prins and Buller (1996)
discussed the divergent findings in 4 meta-analyses on the
preferred dosage of aminoglycosides and concluded that
"The physician can only follow the conclusion of the meta-
analysis most closely in accordance with his or her own
beliefs." The divergent and incompatible conclusions of the
first three meta-analyses on vitamin C and the common cold
were mentioned above (p 28).
Although many meta-analyses of controlled trials are
problematic, the problems are even greater in meta-analy-
ses of non-experimental studies, since there may be con-
sistent biases in the studies included. A meta-analysis on
the association between chlorination of drinking water and
cancer risk by the Chalmers group (Morris et al. 1992) in-
cluded such severely biased studies that, independently,
Bailar (1995) and Shapiro (1997) pointed out various prob-
lems. Also, Cantor (1994) commented that "A recent meta-
analysis [by Morris et al.] … has probably confused the
situation. This exercise may have been premature since most
of the input data came from studies with (1) inadequate con-
trol of confounding and other sources of bias, and (2) highly
limited estimates of historical exposure to drinking water
contaminants."
A meta-analysis of the association between alcohol con-
sumption and breast cancer by the Chalmers group
(Longnecker et al. 1988) included studies that had such se-
vere methodological defects, that the meta-analysis was con-
sidered seriously misleading by Shapiro (1994, 1997; see
also Rosenberg 1989), who published both the initial asso-
ciation which led to the series of studies, and finally the
large study finding a null result. Because of the large vari-
ety of potential biases in non-experimental studies, Shapiro
(1997) considered that "The meta-analysis of non-
randomized observational studies resembles the attempt of
a quadriplegic person to climb Mount Everest unaided."
The main limitations and challenges of meta-analysis are
related to the experimental issues. The statistical methods
available for combining P-values or data on individual stud-
ies are well established (e.g., Greenland 1987, 1998; Laird
& Mosteller 1990; Fleiss 1993; Higgins & Green 2005 ss
8.6 to 8.8), but there are examples of demonstrably invalid
methods of analysis even in some of the influential meta-
analyses. In one meta-analysis, the average case fatality
percentage was calculated for 6 trials, without using any
weight, even though the number of participants in the 6 tri-
als varied from 53 to 1,427; i.e., close to 30 fold (Chalmers
et al. 1977). In fact, since the large trials found a consider-
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ably smaller benefit than the small trials, combining the
actual data instead of percentages led to a substantially
smaller difference (by 30%) between the pooled study
groups (Goldman & Feinstein 1979). The Chalmers (1977)
meta-analysis was cited in a recent systematic review com-
paring randomized and non-randomized trials (Kunz &
Oxman 1998), without noting its severe methodological
problems, yet Oxman was an editor of the previous edition
of the Cochrane Reviewers’ Handbook, which commented
that "interpretation of results is dependent upon the validity
of the included studies" (Clarke & Oxman 2002 s 6).
Lack of basic arithmetic is also seen in a meta-analysis
of vitamin C and the common cold in which treatment ef-
fects on ‘duration in days’ were averaged without consider-
ing either the differences in the size of the trials or the large
variations in the cold duration in the control groups
(Chalmers 1975; see pp 36-8). Sometimes meta-analysts are
not familiar with the standard methods either; for example,
in his vitamin C common cold meta-analysis, Chalmers
(1975) claimed that in the earlier meta-analysis on vitamin
C and the common cold, Pauling (1971a) had "averaged ‘p’
values from the different studies." However, in his statisti-
cal analysis Pauling used the well-established Fisher method
of calculating the combined P-value from several independ-
ent P-values (1938; Sokal & Rohlf 1981; Laird & Mosteller
1990), which cannot be described as naive ‘averaging.’
Furthermore, Chalmers himself used the same Fisher method
two years after his criticism (Chalmers et al. 1977).
Because of many published meta-analyses were not prop-
erly performed, several experts have been rather skeptical
as to its usefulness (Meinert 1989; Spitzer 1991; Feinstein
1995; Feinstein & Horwitz 1997; Eysenck 1994; Bailar 1995,
1997a,b, 1999; Shapiro 1994, 1997). Bailar (1995) com-
mented that "Meta-analysis has been seized with enthusi-
asm by many scientists not trained in statistics and cognate
sciences, and it is clear in conversations that many of them
have utterly unrealistic views about its scope and power."
Shapiro (1997) noted that "I think there is something pro-
foundly amiss in the uncritical way in which the epidemi-
ologists, and indeed the medical profession as a whole, have
allowed themselves to be seduced by the numerological
abradacabra of meta-analysis." Meinert (1989) commented
that "There are no easy, inexpensive answers to complex
questions and attempts to substitute small trials and meta-
analysis for large trials is illusionary and detrimental to both
medicine and clinical trials." In an editorial in a major jour-
nal, Bailar (1997a) further commented that "In my own re-
view of selected meta-analyses, problems were so frequent
and so serious … that it was difficult to trust the overall
‘best estimates’ … I still prefer conventional narrative re-
views of the literature, a type of summary familiar to read-
ers of the countless review articles on important medical
issues." Although such strong comments can be understood
against the background of the severe errors in some of the
products by meta-analysts, ‘meta-analysis’ as a method will
not disappear. As a statistical tool it has inherent strengths
and weaknesses which should be understood by those car-
rying out such analyses, and by readers of the conclusions
of meta-analyses. Furthermore, meta-analyses have provided
a large number of conclusions that have been consistent with
later findings.
The political and social consequences of meta-analysis
have also aroused concern. In particular, the Evidence-Based
Medicine (EBM) movement puts great weight on the semi-
official meta-analyses of the Cochrane Collaboration
(EBMWG 1992; Chalmers et al. 1992; Editorial 1992; Sackett
1994; Bero & Rennie 1995; Hill 2000; Cochrane 2005a).
Feinstein and Horwitz (1997) concluded a thorough critique
with the comment that "The threat of official, corporate, or
private abuse will always remain, whenever any collection
of information has been prominently heralded as the ‘best
available evidence.’ A new form of dogmatic authoritarian-
ism may then be revived in modern medicine, but the pro-
nouncements will come from Cochranian Oxford rather than
Galenic Rome." Shapiro (1994) was worried that "Govern-
ment departments will continue to make public health deci-
sions, often misguided ones, based on the results of meta-
analyses." Bailar (1995) commented that "A traditional nar-
rative review can do much more than estimate parameters,
and the additions are critical to the progress of science. Meta-
analysis … is a poor tool for developing new concepts, new
hypotheses, and new methods of study… meta-analysis has
never been promoted as an alternative to thoughtful but un-
structured reading, but it may nevertheless carry the seeds of
a diminished respect for and a diminished role for simple
browsing through the primary literature."
Quality of studies included
The internal validity of the studies included in a meta-analy-
sis is a relevant concern. For example, substantial baseline
differences in the treatment groups were found in therapeu-
tic trials that used ‘non-random’ assignment of participants
to the treatment groups, and ‘unblinded randomization’ led
to substantial baseline differences, whereas ‘blinded
randomization’ led to relatively similar baseline variable
levels (Chalmers et al. 1983). Because of such severe prob-
lems with non-randomized studies, the advocates of EBM
have suggested that "If you find that the study was not
randomized, we’d suggest that you stop reading it and go
on to the next article" (Sackett et al. 1997 p 94).
If such an opinion became common it would completely
transform current medicine, since probably not even exten-
sive literature searches would reveal randomized trials sup-
porting the widespread beliefs that smoking, high-level al-
cohol usage, and overweight increase the risk of poor health.
It is also inappropriate to require that therapeutic conclu-
sions should be based simply on randomized trials. For ex-
ample, Sir Austin Bradford Hill, who designed the first
modern randomized controlled trial (Doll 1992, 1998;
Yoshioka 1998; Hampton 2002; Armitage 2003), com-
mented that "Any belief that the controlled trial is the only
way [to study therapeutic efficacy] would mean not that the
pendulum had swung too far but that it had come right off
its hook" (Hill 1966).
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In any case, because of the problems related to the study
quality, Chalmers et al. (1981) proposed a quality scale to
assess the validity of trials. About two dozen further ‘qual-
ity scales’ have since been devised. The scoring systems,
however, have various shortcomings (Higgins & Green 2005
ss 6.7 to 6.11). Scoring is based on whether something was
reported rather than whether it was done appropriately in
the study. For example, if the original investigators explic-
itly stated criteria for the diagnosis of ‘congestive heart fail-
ure’ the trial is given ‘quality points’ because of the explicit
definition. However, if ‘congestive heart failure’ is defined
as ‘use of digitalis’ the evidence is of poor scientific quality
and is clinically silly, but still gets the ‘quality score points’
because of the explicit definition (Feinstein 1995). A recent
survey requesting the technical features directly from the
investigators found that in many cases randomization and
allocation concealment were appropriate although they were
not properly described in the study reports, so that Hill et
al. (2002) concluded that it is likely to be inappropriate to
characterize the quality of randomized controlled trials as
‘good’ or ‘poor’ on the basis of the published report.
Furthermore, many scores also contain items that are not
directly related to validity, such as whether a power calcu-
lation was done (related to precision and not validity) or
whether the inclusion and exclusion criteria were clearly
described (related to applicability and not validity) (Higgins
& Green 2005 s 6.7). In a recent comparison, the summary
quality scores were not significantly associated with treat-
ment effects, indicating that the relevant methodological
aspects should be assessed individually (Jüni et al. 1999).
In another recent meta-analysis of 276 trials, double blind-
ing and allocation concealment, two quality measures that
are frequently used in meta-analyses, were not associated
with treatment effect (Balk et al. 2002).
It has been argued that quality scoring is based on sub-
jective assignment of points based on features of the stud-
ies, and quality scoring submerges important information
by combining disparate study features into a single score
(Greenland 1998). "It also introduces an unnecessary and
somewhat arbitrary subjective element into the analysis via
the scoring scheme. Quality scoring can and should be re-
placed by direct categorical and regression analyses of the
impact of each quality item. Such item-specific analyses let
the data, rather than the investigator, indicate the impor-
tance of each item in determining the estimated effect."
Shapiro (1997) commented that "Who are these meta-
analysts, sitting on high, to decide for the rest of us what is
and is not good quality, and then to measure it? Quality is
best evaluated qualitatively: as opposed to meta-analysis,
in any adequate qualitative review, we require that the au-
thor should give reasons for judging the quality of any given
study as good or bad in transparent and easily comprehen-
sible language. It is then up to the reader to decide whether
he agrees or disagrees."
It is desirable to use a placebo in controlled trials to in-
crease their internal validity. However, a recent meta-analy-
sis of studies comparing a placebo group to a no-treatment
group found that there was no placebo effect in studies with
binary outcomes and, among studies with continuous out-
comes, only those that measured pain showed evidence of
the placebo effect (Hrobjartsson & Gøtzsche 2001, 2004).
Consequently, lack of a placebo should not lead to the me-
chanical exclusion of a trial from a meta-analysis, since the
relevance of the placebo depends on the topic.
Because of the various problems of ‘quality scores,’ the
current version of Cochrane Reviewers’ Handbook suggests
that "Reviewers should avoid the use of ‘quality scores’
and undue reliance on detailed quality assessments. It is not
supported by empirical evidence, it can be time-consum-
ing, and it is potentially misleading" (Higgins & Green 2005
s 6.11). Thus, it is not reasonable to employ a rigid me-
chanical algorithm to discard ‘low quality score’ studies
from meta-analysis. The features related to validity should
rather be considered case by case because the relevant fea-
tures depend on the particular scientific question. One type
of ‘quality scale’ was used in the fourth meta-analysis on
vitamin C and the common cold for selecting ‘high quality’
trials for deeper analysis (Kleijnen et al. 1989; see pp 38-
41). Also, one kind of ‘quality scale’ was used in a recent
review on echinacea and the common cold when selecting
two ‘best’ trials on which the conclusions were based (Ca-
ruso & Gwaltney 2005 [see Hemilä 2005a]).
Although randomization is a feasible method of allocat-
ing participants in most controlled trials, it seems that the
problems caused by the lack of randomization have been
grossly exaggerated. For example, Thomas Chalmers’ much-
cited classical study (1983) suggesting that ‘blinded ran-
dom allocation’ leads to smaller treatment effects than ‘non-
random assignment’ was itself severely biased. The group
of ‘blinded randomization’ trials contained 9 trials about
beta-blockers and 0 trials about coronary care units. In con-
trast, the group of ‘non-random assignment’ trials contained
1 trial about beta-blockers and 11 trials about coronary care
units. With such extremely biased distribution of study top-
ics between ‘random’ and ‘non-random’ allocation groups,
it is not reasonable to assume that the method of allocation
is the only reason for the difference between the findings in
the two groups, even though Chalmers et al. (1983) did so.
For example, they presented the ‘results of trials in terms of
case-fatality rates’ by the method of allocation without strati-
fying by the topic of the trials; there are probably substan-
tial base-line differences between the participants in beta-
blocker trials and coronary care unit trials. Some other ta-
bles in Chalmers et al. (1983) are also misleading as pointed
out earlier (Gillman & Runyan 1984).
In spite of the severe methodological shortcomings, the
Chalmers et al. paper (1983) has been extensively cited,
e.g., by EBM proponents when claiming that "Studies in
which treatment is allocated by any method other than
randomization tend to show larger (and frequently false-
positive) treatment effects than do randomized trials"
(Guyatt, Sackett, Cook 1993), "Less rigorous studies tend
to overestimate the effectiveness of therapeutic and preven-
tive interventions" (Oxman et al. 1994), and "Because the
potential for bias is much greater in cohort and case-control
studies than in RCTs, recommendations from overviews
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combining observational studies will be much weaker"
(Guyatt, Sackett, et al. 1995). Thus, in this case the EBM
advocates did not read critically the paper they cited, al-
though they emphasize the importance of critical reading
elsewhere (e.g., Sackett et al. 1997 pp 79-156).
The Chalmers 1983 paper was also cited in a recent sys-
tematic review comparing randomized and non-randomized
trials drawing the conclusion "direction of bias: overesti-
mation of effect" (Kunz & Oxman 1998) which makes no
sense considering the extremely biased distribution of study
topics between the ‘blinded randomization’ and ‘non-ran-
dom assignment’ groups mentioned above. Furthermore, the
Chalmers 1983 paper was cited in the Cochrane Review-
ers’ Handbook without paying attention to its lack of valid-
ity (Clarke & Oxman 2002 ss 4.2 and 6.3), although the
Handbook does comment that "Interpretation of results is
dependent upon the validity of the included studies" (Clarke
& Oxman 2002 s 6), and a guideline-paper for readers of
reviews also stated that "Authors will come to correct con-
clusions only if they accurately assess the validity of the
primary studies on which the review is based" (Oxman &
Guyatt 1988).
A recent comparison of randomized controlled trials with
observational studies on 19 different treatments found that
the estimates of treatment effects from the controlled trials
and the observational studies were similar. In only 2 of the
19 analyses did the combined magnitude of the treatment
effect in observational studies lie outside the 95% CI of the
pooled estimate of the controlled trials (Benson & Hartz
2000). Another analysis of 5 clinical topics also found that
the average results of observational studies were remark-
ably similar to those of controlled trials (Concato et al. 2000).
Both of these two analyses were motivated by the over-
emphasis on randomization by EBM advocates. Further-
more, a recent analysis of a large set of studies focusing on
cirrhosis and hepatitis saw no difference between non-
randomized studies and randomized trials in the ‘20-year
survival of conclusions’ derived from these studies (Poynard
et al. 2002).
Cumulative meta-analysis
The various potential limitations of the experimental data
should make a meta-analyst cautious in drawing conclu-
sions, but sometimes the conclusions are extraordinarily
comprehensive considering the kind of small trials on which
they are based.
A particularly bold general proposal related to drawing
conclusions from meta-analyses made by the Chalmers
group was that meta-analyses should be updated with each
new trial so that when, or if, the combined P-value becomes
statistically significant at a chosen level, the treatment should
be considered proven efficacious, and further trials may be
considered even unethical. This approach was called ‘cu-
mulative meta-analysis’ (Antman et al. 1992; Lau et al.
1992), a concept considered to be among the most impor-
tant contributions to medicine by Thomas Chalmers (Ian
Chalmers 1996; Liberati 1996). Using cumulative meta-
analysis, the Chalmers group showed that the effect of ad-
ministering intravenous magnesium in acute myocardial in-
farction reached P[2-t] < 0.05 in 1989, and P[2-t] < 0.001 in
1990 with a cumulative OR of 0.44 (95% CI: 0.27 – 0.71),
and they concluded that the evidence for the benefit of mag-
nesium was persuasive (Antman et al. 1992; Lau et al. 1992).
However, a large trial with 58,050 patients carried out there-
after showed that mortality in the first 5 weeks after myo-
cardial infarction was, paradoxically, slightly higher in the
magnesium group (+6%; 95% CI: 0% to +12%) (ISIS-4
1995; Egger & Smith 1995). The ‘cumulative meta-analy-
sis’ thus led to a completely false conclusion.
Nevertheless, it is of interest that, following the reason-
ing of ‘cumulative meta-analysis’, if Chalmers (1975;
pp 36-8) had restricted his meta-analysis of vitamin C and
the common cold to double-blind placebo-controlled trials
in which ≥2 g/day of vitamin C was regularly administered
to participants, he might have found powerful evidence by
1975 from 5 trials that vitamin C alleviates the symptoms
and/or reduces the duration of colds during supplementa-
tion (P = 0.000,002; Hemilä 1996a). Using the approach of
Chalmers’ ‘cumulative meta-analysis,’ the addition of 3 tri-
als that were carried out after 1975 led to P = 0.000,000,02
by 1996 (Hemilä 1996a). No trials with this selection crite-
rion have been published since 1996.
Publication bias
One concern in meta-analyses of small studies is the possi-
bility of ‘publication bias’ which indicates that studies with
‘negative’ findings tend to remain unpublished more often
than those with ‘positive’ findings (Chalmers et al. 1990). In
such cases, meta-analytical conclusions from the published
trials may be too optimistic. However, in an analysis of 487
research projects approved by the Oxford Research Ethics
Committee, there was evidence of publication bias in the case
of observational and laboratory-based experimental studies
(odds ratio [OR] 3.8 for the comparison of positive vs. nega-
tive results to be published), whereas there was no evidence
of publication bias in the case of randomized clinical trials
(OR 0.8) (Easterbrook et al. 1991). Thus, although publica-
tion bias is probably of concern in certain conditions, and
must be kept in mind in considering the findings of a meta-
analysis, its role should not be exaggerated.
Meta-analysis versus large single trials
In addition to the meta-analysis of intravenous magnesium
in acute myocardial infarction, there are several other ex-
amples of misleading conclusions from meta-analyses.
LeLorier et al. (1997) compared the results of 12 large tri-
als with meta-analyses published earlier on the same topic,
finding that the meta-analyses would have led to the adop-
tion of an inefficient treatment in 32% of cases, and to the
rejection of a useful treatment in 33% of cases.
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When large trials were compared with other large trials on
the same topic, agreement among them was approximately
as low as that reported by LeLorier et al. between meta-analy-
ses and large trials, and thus Furukawa et al. (2000) con-
cluded that taking large randomized trials as the ‘gold stand-
ard’ can be problematic, and there is "no substitute for clear
and hard thinking for a study, be it meta-analysis or a mega-
trial." Horwitz (1987), who analyzed 36 topics on which con-
trolled trials led to discrepant results, also considered that the
‘gold standard’ status of randomized trials is misleading as
the results depend substantially on the settings, such as clini-
cal heterogeneity among patients enrolled in the trials, vary-
ing protocols across the trials, etc. When Poynard et al. (2002)
compared the ‘survival of conclusions’ from meta-analyses
with the conclusions from non-randomized studies and
randomized trials, they found that meta-analysis was conclu-
sively the poorest of the three for producing viable conclu-
sions. It seems possible that meta-analysis is used on average
less on topics on which large studies have shown clearly nega-
tive or positive findings, and in this respect the poor ‘sur-
vival of conclusions’ may reflect the topics that are studied
better than the method per se.
The relevance of the biology of the topic under
consideration
"By means centering, I refer to the tendency to consider
that the essence of science lies in its procedures rather
than in its problems, questions, or goals …
If means-centering philosophies were extreme,
and if they were quite consistent, there would be no way
to distinguish between an important meta-analysis
and an unimportant one.
There could be only technically well-prosecuted
meta-analyses and technically poorly prosecuted
meta-analyses.
Using only methodological criteria, the most trivial
research could demand as much respect as the most
fruitful one."
Modification of Maslow (1954)
‘Meta-analysis’ as a tool is quite easy to understand and
apparently powerful, and this has led some people to carry
out meta-analyses without making themselves familiar with
the actual biology of the topic. Yusuf (1997) was worried
that "Sometimes individuals with only limited knowledge
of the pharmacologic aspects of treatment, the biology of
disease, or clinical circumstances that relate to the specific
question may perform meta-analyses leading to an analysis
with little clinical relevance." Bailar (1995) commented that
"A good meta-analysis requires at least as much as to do a
good original article. To proceed without this level of un-
derstanding is likely to lead to serious difficulty. The ‘job
shop’ that turns its skills to the formulaic meta-analysis of a
sequence of unrelated topics is asking for trouble – and may
often get it. Meta-analysis must not be routinized."
A good example of this procedure as a mechanical
endeavor detached from biology is carrying out meta-analy-
ses on homeopathy, which is not a reasonable scientific topic
for obvious reasons (Vandenbroucke 1997, 1998a;
Vandenbroucke & de Craen 2001). A meta-analysis of ho-
meopathic trials by Kleijnen et al. (1991) did not refer to
any laboratory studies, although a series of papers published
in Nature only a few years before would have provided rel-
evant background in the form of laboratory experiments
(Metzger & Dreskin 1988). In their meta-analysis, Kleijnen
et al. (1991) commented that one homeopathic "trial of very
high quality was … initiated by the French Ministry of So-
cial Affairs and performed by a group consisting of regular
and homeopathic researchers. After the earlier publication
of several trials in which homeopathy was shown to de-
crease the time of recovery of bowel movements after ab-
dominal surgery this hypothesis was retested in a rigorous
trial… No differences at all were found" between the treat-
ment groups (Mayaux et al. 1988). This is substantially simi-
lar to the ‘positive’ findings in the laboratory study on ho-
meopathy, which could not be repeated in four other labo-
ratories (Metzger & Dreskin 1988; Seagrave 1988; Bonini
et al. 1988; Hirst et al. 1993), and not even in the original
laboratory when the editor of Nature came to visit (Maddox
et al. 1988).
Nevertheless, the number of ‘good quality’ homeopathy
trials with ‘positive results’ was so large that Kleijnen et al.
(1991) concluded that "The evidence presented in this re-
view would probably be sufficient for establishing home-
opathy as a regular treatment for certain indications" with-
out specifying what these were. In this case, the thoughtful
narrative review on this topic by Vandenroucke & de Craen
(2001) is substantially more useful than the meta-analytic
list of homeopathic trials with their ‘quality scores’ by
Kleijnen et al. (1991).
In another meta-analysis, Kleijnen et al. (1989; pp 38-
41) focused on vitamin C and the common cold. This meta-
analysis contains no reference to any papers related to the
immune system studies (some 100 listed by Hemilä 1997a)
or to any animal studies (see Table 2 and Appendices 2 and
3) that would provide important background for consider-
ing whether this is a reasonable biological issue rather than
a topic for mechanical ‘job shop’ pooling. Neither did
Chalmers (1975; pp 36-8) refer to any immune system stud-
ies or animal studies in his meta-analysis of vitamin C and
the common cold; however, he did mention the Hume and
Weyers study (1973) reporting that vitamin C in leukocytes
drops sharply on the first day of the common cold (Fig. 1),
and such a dramatic change in vitamin C metabolism does
provide one way to rationalize the question of whether large
doses of vitamin C might have therapeutic effects on colds.
Pauling (1971a,b; pp 35-6) did not supply any direct refer-
ence to biological studies in his meta-analyses, merely re-
ferring to a book which discussed the biological background
(Pauling 1970a).
34
Heterogeneity of studies
Much of the consideration of meta-analysis is focused on
the experimental features of the studies included. Another
important issue is the question of the goals of conducting
meta-analysis. The notions of ’exploratory’ and ‘analyti-
cal’ meta-analysis were proposed to emphasize the great
variation in the possible goals (Anello & Fleiss 1995), the
former referring to combining small trials of variable qual-
ity, and the latter to combining large well-conducted trials
intended to shed more light on the precision of the estimate
and on more powerful exploration of subgroup differences.
Although such dichotomizing of goals may be too extreme,
the notion that meaningful goals of meta-analysis differ
substantially case by case should be understood.
One particular issue related to the goals of meta-analysis
is how to handle large variations in the results of the trials
under consideration. Analysis of heterogeneity can be the
most important function of meta-analysis, often more im-
portant than computing the fictional average effect of a het-
erogeneous mixture. A common problem in meta-analysis
is the failure to investigate the sources of heterogeneity ap-
propriately. Although overzealous inspection of the data in
hand may lead to false conclusions, a sensible investigation
of the sources of heterogeneity may increase both the sci-
entific and clinical relevance of the results of meta-analysis
(Thompson 1994; Greenland 1998). One problem in the sta-
tistical consideration of heterogeneity has been the low
power of standard tests of heterogeneity leading to the false
conclusion that the data is homogeneous, but a more sensi-
tive test has been developed recently (Higgins et al. 2003).
Non-comparability of the vitamin C trials
One particular problem in the meta-analysis of vitamin C
trials arises from the fundamental difference between vita-
min C and ordinary drugs such as antibiotics. It is possible
to select a control group which has no intake of an ordinary
drug, rendering the interpretation of results relatively sim-
ple. It is impossible, however, to select control subjects who
have no vitamin C intake, and no vitamin C in their system.
Accordingly, all vitamin C trials compare two different in-
take levels, the lower level being obtained from the diet,
and usually not estimated at all, which hampers the com-
parison of different trials and the generalization of their re-
sults.
Since the intake of vitamin C in the diet, and the supple-
mentary dosage have both varied substantially between tri-
als (Table 12), the comparison of vitamin C trials is some-
times quite problematic. For example, while there is some
50-fold difference in the vitamin C intake in the diet by the
control group between the Glazebrook and Thomson (1942)
and Peters et al. (1993) trials, both are ‘control groups’ of
vitamin C trials.
The vitamin dosage in the ‘vitamin C group’ has also
varied dramatically (Table 12). At the extreme, Karlowski
et al. (1975) administered up to 6 g/day of vitamin C to
their subjects, whereas Cowan et al. (1942) administered
25 mg/day as their lowest supplementary dose. There is thus
up to a 240-fold difference between the lowest and highest
vitamin C supplementary dose used in these trials, yet in
many cases such studies are simply labeled ‘vitamin C trial’
without paying any attention to the dosage.
Furthermore, the placebo group of Peters et al. trial
(1993) received some 500 mg/day of vitamin C in their diet,
whereas the vitamin C group in Baird et al. trial (1979) re-
ceived only 130 mg/day (diet and supplement together).
Thus, vitamin C intake in the placebo group of the former
trial was 4 times higher than the vitamin C intake in the
vitamin C group of the latter trial.
A further problem in vitamin C doses is the addition of
vitamin C to the placebo group in some studies with the
apparent rationalization of excluding the possibility that any
observed effects of large doses might be explained by inci-
dentally treating marginal deficiency. For example, Carr et
al. (1981) administered 70 mg/day and Miller et al. (1977)
50 mg/day to their placebo subjects. When comparing these
‘placebo-group’ vitamin C doses to the 80 mg/day of vita-
min C administered to the ‘vitamin C group’ of the Baird et
al. trial (1979) or 25-50 mg/day in the Cowan et al. trial
Table 12. Variation in vitamin C intake in diet and
supplementary doses in common cold trials
______________________________________________
Trial Vitamin C Vitamin C
  Country in diet supplement
  Participants (mg/d) (mg/d)
__________ _________ _________
Glazebrook-1942 10-15 50-300
  UK
  Schoolboys
Peters-1993 500 600
  South Africa
  Marathon runners
Baird-1979 50 80
  UK
  Students
Cowan-1942 ? 25-50
  USA
  schoolchildren
Karlowski-1975 ? 3,000-6,000
  USA
  Adults
______________________________________________
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(1942), it is clear that the comparison of ‘vitamin C trials’
can be very complex, and extrapolation of the findings of a
single trial is limited irrespective of the methodological
quality of the particular trial.
The great variation in the vitamin C doses in diet and in
supplements probably explains part of the variation in the
results of the trials. An interesting example of the possible
modification of supplement effect through diet was reported
by Anderson et al. (1972, 1975), who found that vitamin C
was more beneficial for participants who consumed low
amounts of orange juice, which is an important source of
vitamin C (Table 13).
The intake of vitamin C in the diet, and the supplemen-
tary dosages are rarely considered in discussions of vitamin
C trials. For example, they are not considered in the meta-
analyses by Chalmers (1975; pp 36-8) and Kleijnen et al.
(1989; pp 38-41). Dykes and Meier (1975; pp 42-5) listed
the supplementary vitamin C doses used in the trials, but
did not consider the variation in dietary intake.
Major meta-analyses and reviews
on vitamin C and the common cold
Pauling’s meta-analyses (1971a,b)
In his first meta-analysis in the Proceedings of the National
Academy of Sciences, Linus Pauling analyzed the findings of
4 placebo-controlled trials in which at least 0.1 g/day of vita-
min C was administered regularly to the study group (1971a).
In his second meta-analysis in the American Journal of Clini-
cal Nutrition, Pauling focused on the best 2 of the 4 trials
(1971b; Cowan et al. 1942; Ritzel 1961; Table 3).
Among the 4 trials included in Pauling’s meta-analysis
(1971a; see Pauling 1972; p 28), the largest dose was used by
Ritzel (1961), and Pauling based his quantitative estimations
on this trial. Ritzel found that the common cold symptoms in
the vitamin C group were 31% shorter and the number of
colds 45% lower in the vitamin C group. Pauling also calcu-
lated the combination of duration and incidence, ‘integrated
morbidity’ referring to the total sickness days per person dur-
ing the trial, and this was reduced by 61% in the Ritzel trial
(Table 3). Pauling (1971a) then modeled the dose-depend-
ency of vitamin C effect with exponential formulas for which
he took constants from the Ritzel trial. Pauling assumed that
the main problem in his estimation was inaccuracy caused
by ‘experimental error,’ although he did note that "The val-
ues are, of course, expected to depend somewhat on the na-
ture of the population and environment." However, even with
these explicit reservations he was far too optimistic. He could
not imagine how great the variations in the results would be
in the forthcoming trials. Neither did he consider the possi-
bility that the effects observed by Ritzel may have been caused
at least in part by low dietary vitamin C intake, in which case
a smaller dose might have produced a similar benefit, and in
such a case modeling the vitamin C effect as a function of the
supplementary dose would be completely erroneous. Pauling
attributed the difference between the study groups entirely to
the large dose given to the treatment group. Furthermore,
Ritzel carried out his trial with schoolchildren in a skiing
school in the Swiss Alps, children who are not a good repre-
sentative selection of the general population even though tech-
nically the trial was good as it was randomized, double-blind
and placebo-controlled. Thus, when Pauling extrapolated the
results of Ritzel to all people (i.e., to children at school and
adults), he took a bold step and went wrong (Hemilä 1997b).
Pauling (1971a,b) put much weight on the ‘integrated
morbidity’ outcome and summarized the findings of trials
by this outcome in his later texts as well (1976a,b,c, 1986a).
This measure led Pauling to adhere strongly to the idea of
regular supplementation. However, this is not a good com-
bined measure, since the effects on incidence and duration/
severity have quite different patterns (Fig. 3), and it is thus
more to the point to analyze these two outcomes separately.
Thus, Pauling was qualitatively correct in his conclusion
that vitamin C does affect the duration and severity of colds,
and probably the incidence of colds in certain specific con-
ditions, but he was greatly over-optimistic.
Table 13. Subgroup differences in the Anderson et al.
trials (1972, 1975)
_______________________________________________________
 Effect on ‘total days indoors’
_______________________
(1972) (1975)
Subgroups Regular Therapeutic
supplement supplement
_______________________________________________
Daily juice
0-3 oz -48% -33%
≥4 oz -22% -22%
Contact with
young children
Yes -46% -40%
No -17% -13%
Usual colds
≥2 -43%
0-1 -13%
_______________________________________________
Anderson et al. (1972) administered 1 g/day over the whole study
period and 3 g/day extra for 3 days during cold episodes. Anderson et
al. (1975) administered 1.5 g/day on the first day of the cold and
1 g/day for the following 4 days. In the latter trial participants were
also regularly administered 0.5 g once a week (i.e., 0.07 g/day)
on a rationalization that remains obscure.
36
It is worth noting that the Ritzel trial (1961) falls to the
group of 6 trials with participants under heavy acute physi-
cal and/or cold stress that consistently found reduction in
common cold incidence (p 48; graph on the cover; Douglas
& Hemilä 2005). Thus, it was not a misjudgment by Pauling
to put the greatest weight on this trial, but his error was to
extrapolate the findings to the general population. The other
trial on which Pauling put great weight was the Cowan et
al. trial (1942; Table 3) which was carried out with school-
children during the war years and probably the dietary vita-
min C intake was low and in this respect the benefit may be
explained by the correction of marginal deficiency as in the
UK studies with schoolboys and male students (pp 46-7;
Paper II).
As regards the errors in Pauling’s quantitative conclusions,
it should obviously be taken into account that essentially all
of the trials available today were carried out after Pauling
worked on the topic and, even more importantly, were car-
ried out precisely because Pauling popularized the topic (Fig.
2). Without bold conjectures, progress in science is slow or
non-existent, and in this respect the accuracy of Pauling’s
extrapolation from the single placebo-controlled trial using
regular 1 g/day supplementation available to him in the early
1970s is of secondary concern. Furthermore, Pauling’s own
view of science was that an occasional mistake, even when
published, was not as bad as lowering one’s sights to less
challenging research (Lipscomb 1994).
Chalmers’ meta-analysis (1975)
Thomas Chalmers was an eminent pioneer in controlled tri-
als, and one of the early promoters of meta-analysis
(Dickersin 1996; Huth 1996; Liberati 1996; Maclure 1996;
NLM 2005d). Greenhouse (1996) commented that Chalmers
was the most influential non-statistician to affect the ac-
ceptance and direct the course of the randomized, control-
led clinical trial among clinical investigators, at least in the
USA. Chalmers was a founding member of the Society for
Clinical Trials, and president of that society in 1984
(Knatterud 1996). "In leadership roles at the US Veterans
Administration and National Institutes of Health, Chalmers’
intellectual and administrative support of randomized trials
helped lead to their establishment as a prime source of thera-
peutic evidence" (Feinstein 1996). "Tom Chalmers’ name
is synonymous with randomized, controlled trial and meta-
analysis… Many of the medical advances discovered in the
past several decades through the use of randomized, con-
trolled trials can in large measure be attributed to his tire-
less advocacy" (Lau 1996). It was even commented that
Thomas Chalmers "contributed more than anyone else to
the general field of clinical science" (Ian Chalmers 1996).
A volume of the Annals of the New York Academy of
Sciences was dedicated "To Thomas C. Chalmers - A Meta-
Analyst for All Seasons" (Warren & Mosteller 1993), and a
book entitled Systematic Reviews was dedicated to "Tho-
mas C Chalmers in appreciation of his many pioneering con-
tributions to the science of reviewing health research, and
in particular, for the first clear demonstration of the dangers
of relying on traditional reviews of research to guide clini-
cal practice" (Ian Chalmers & Altman 1995). At each an-
nual Cochrane Colloquium "The Thomas C Chalmers MD
Award" is given for the best oral or poster presentation at
the Colloquium (Cochrane 2005b).
Because of this personal background, a meta-analysis on
vitamin C and the common cold by Thomas Chalmers obvi-
ously became highly influential, and found its place in major
medical textbooks as soon as the ink on the paper had dried.
For his meta-analysis in the American Journal of Medi-
cine, Chalmers (1975) selected 8 placebo-controlled trials
and presented their results in a table. Chalmers calculated
that the common cold episodes were on average 0.11 ± 0.24
(SE) days shorter in the vitamin C groups than the placebo
groups. Even if real, a 0.11 day (= 2.6 hours) decrease in
the duration of colds would have no clinical relevance, and
the great variation in the results indicates that the slight dif-
ference is not real. Apparently, because of the presentation
of the published results in a table, and the clear-cut nega-
tive findings, Chalmers’ meta-analysis met ready approval.
Chalmers’ meta-analysis has been frequently cited as evi-
dence that vitamin C has been shown to be worthless for colds.
For example, it was cited in the US nutritional recommenda-
tions (FNB 1980, 1989a), major textbooks of infectious dis-
eases (Gwaltney 1979, 1985, 1990, 1995; Liu 1989; Dick et
al. 1992, 1998), and numerous textbooks on nutrition (Halsted
1993; Thurnham et al. 2000; Hamilton & Whitney 1982, 1994;
Whitney & Rolfes 1993; Shils et al. 1994).
The American Medical Association based its official
statement that "One of the most widely misused vitamins is
ascorbic acid. There is no reliable evidence that large doses
of ascorbic acid prevent colds or shorten their duration"
wholly on Chalmers’ review (AMA 1987 p 1934). Lancet
also referred to Chalmers’ meta-analysis in stating that vi-
tamin C has no worthwhile effect on the common cold (Edi-
torial 1979 [see Pauling 1979] ).
Chalmers’ meta-analysis was cited in several major re-
views of common cold therapy (Hirsch & Swartz 1980;
Anderson et al. 1983; Sperber & Hayden 1988; Steele 1988;
Lorber 1996), and it was also cited by Finnish authorities
on nutrition (Aro 1985a,b, 1990a) in stating that vitamin C
is useless for colds.
Chalmers’ meta-analysis was recently shown to contain
a large number of serious errors (Hemilä & Herman 1995).
In some cases the data was inconsistent with the original
published data, there were errors in calculation, the selec-
tion of trials was not consistent, and in some trials a clini-
cally less meaningful outcome was selected. Table 14 shows
the data for common cold duration that Chalmers presented
in his main table (one trial did not provide data for common
cold duration and is not listed in Table 14: Franz et al. 1956;
see Table 3). The figures which are erroneous or mislead-
ing in Chalmers’ table are underlined in Table 14 (for de-
tails see Hemilä & Herman 1995).
Chalmers did not consider the dose of vitamin C used in
the trials. At the extreme, Karlowski et al. (1975) adminis-
tered up to 6 g/day of vitamin C to their subjects, whereas
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Cowan et al. (1942) administered 25 mg/day as their lowest
supplementary dose (Table 12), meaning an up to 240-fold
difference between the lowest and highest vitamin C doses
used; however, these two trials were presented side-by-side
by Chalmers (1975) in his table without noting this differ-
ence (Table 14). Furthermore, Chalmers justified his meta-
analysis by referring to Pauling’s 1970 book, but Chalmers
included in his table a trial in which only 0.025 - 0.05 g/day
of the vitamin was used (Cowan et al. 1942). This latter
trial obviously does not serve as a meaningful test of
Pauling’s hypothesis that ≥1 g/day might be beneficial
against colds.
In the case of the Anderson et al. trial (1972) Chalmers
did not justify his outcome selection. He showed the effect
of vitamin C on days ‘symptoms present’ per episode which
was reduced by 5% (P = 0.15) in his table, but did not men-
tion the effect on days ‘confined to house’ per common cold
episode which was reduced by 21% (P = 0.007), even though
the latter outcome would seem more relevant for public
health considerations since it is a measure of how much
these infections cause actual functional limitations, whereas
a runny nose is simply a minor nuisance.
Furthermore, there are severe arithmetical problems in
Chalmers’ meta-analysis. In his table, the shortest cold du-
ration in a placebo group is 1.0 days and the longest 6.3
days (Table 14). Chalmers calculated the mean for the ab-
solute difference in duration without paying any attention
to the great variation in the control group duration. For ex-
ample, if a 6-day cold is shortened by 1 day, it is not equiva-
lent to a 1-day cold being shortened by the same amount,
although both differences are equal in absolute units. Fur-
thermore, a 6-day cold can be shortened by 2 days, but a
1-day cold cannot. Thus the outcome scales of such trials
are incompatible in absolute units. Consequently, it seems
much more reasonable to calculate the relative effect of vi-
tamin C, so that a 6-day cold shortened by 2 days and a
1-day cold shortened by 0.33 days both correspond to an
equivalent 33% reduction. Calculating the relative effect
corresponds to normalization of all control groups to an epi-
sode duration of one unit or 100%.
Another shortcoming in Chalmers analysis was not con-
sidering the size of the trials. For example, Anderson et al.
(1972) recorded 1,170 episodes, whereas Karlowski et al.
(1975) recorded only 249 (Table 10). In calculating a pooled
estimate, the former trial should obviously be given much
greater weight than the latter trial. Lack of weighting by
study size leads to an inappropriate significance of small
inaccurate trials in the calculation of the summary estimate.
A further arithmetical problem in Chalmers’ meta-analy-
sis relates to the presentation of papers that contain more
than one trial. In the case of the Cowan et al. paper (1942),
Chalmers correctly presents the two reported trials sepa-
rately (Table 14). However, in the case of the Coulehan et
al. paper (1974), Chalmers combines the two reported tri-
als together, one with 1 g/day and another with 2 g/day of
vitamin C. This combination of Coulehan trials gives more
emphasis in his table to the two trials by Cowan et al. which
administered only 0.2 g/day and 0.025-0.05 g/day. Further-
Table 14. Ascorbic acid and the common cold:
‘Reasonably well-controlled studies’ according to Chalmers (1975)
___________________________________________________________________________________________________
Ascorbic acid Placebo
___________________ ___________________
Mean Mean Difference
No. of duration No. of duration in duration
Trial subjects (days) subjects (days) (days)
___________________________________________________________________________________________________
Anderson-1972 407 3.96 411 4.18  0.22
Anderson-1974 583 3.28 578 3.18 -0.10
Coulehan-1974 321 4.71 320 5.92  1.21
Wilson-1973 158 2.65 144 2.79  0.14
Karlowski-1974 101 6.80  89 6.30  0.50
Cowan-1942 233 1.10 194 1.60  0.50
Cowan-1942 227 1.70 120 1.00 -0.70
          Mean:  0.11 ± 0.24 (SE)
Ritzel-1961 139 1.35 140 1.95  0.60
___________________________________________________________________________________________________
Erroneous and misleading numerical values are indicated by underlining.
Chalmers also listed the incidence of colds, but these are left out to save space.
This table is reproduced from Hemilä & Herman (1995) Journal of the American College of Nutrition 14:116-23 with permission.
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more, when the unweighted mean effect is calculated, the
two small-dose trials of Cowan et al. are accorded a weight-
ing factor of two, while the two large-dose trials of Coulehan
et al. get a weighting factor of only one.
The trials known to Chalmers which had used ≥1 g/day of
vitamin C, i.e., that were testing Pauling’s proposal, were
reanalyzed and the common cold episodes were calculated
as 0.93 ± 0.22 (SE) (unweighted mean; P = 0.005) days shorter
in the vitamin C groups (Hemilä & Herman 1995). Thus, an
estimate of more than 8 times Chalmers’ estimate was ob-
tained by employing correct values and keeping to trials which
used doses as high as Pauling had suggested. Furthermore, a
more useful measure of effect from the same trials is a 21.2%
± 3.0% (SE) reduction of symptom duration. As expected,
the relative effect leads to a more accurate estimate of effect
as indicated by the smaller P-value (P = 0.000,5).
Chalmers review (1975) is no longer cited in the recent
editions of major textbooks on infectious diseases (Liu 1994;
Gwaltney 2000, 2005), but it is still cited in the current US
nutritional recommendations (FNB 2000 p 127). Also, the
Chalmers review (1975) was cited in a recent review on
echinacea and the common cold when proposing that the
effects of echinacea in placebo-controlled trials are caused
by the placebo effect (Caruso & Gwaltney 2005 [see Hemilä
2005a]).
Kleijnen’s meta-analysis (1989)
Kleijnen et al. (1989) carried out a thorough search of the
literature on vitamin C and the common cold and published
a biography of the controlled trials identified. Only a few
old trials are missing from Kleijnen’s bibliography, and a
few have been published since (Table 6). Kleijnen also pub-
lished a table presenting the findings of major trials.
Kleijnen’s meta-analysis (1989) was published in Dutch
with a translation into English in his thesis. This meta-analy-
sis is of particular interest since Kleijnen became the direc-
tor of the Centre for Reviews and Dissemination (CRD,
York, UK) which writes abstracts of meta-analyses for the
Database of Abstracts of Reviews of Effectiveness (DARE).
Prior to joining CRD Kleijnen was the Director of the Dutch
Cochrane Centre. Also, Kleijnen is one of the authors of the
book entitled Systematic Reviews to Support Evidence-Based
Medicine (Khan et al. 2003). Furthermore, Kleijnen’s 1989
meta-analysis of vitamin C and the common cold was used
as an example in a paper on systematic reviews in BMJ
(Knipschild 1994), which was later republished as part of a
book (Ian Chalmers & Altman 1995 pp 9-16). Furthermore,
the Kleijnen et al. paper (1989) is cited in one of these DARE
abstracts (Anonymous 2005). A meta-analysis on vitamin
C and the common cold by an expert on systematic reviews
is highly important. Finally, the selection of 11 ‘high scor-
ing’ trials by Kleijnen et al. (1989) was directly used in the
1998 version of the Cochrane Review on the same topic
(Douglas et al. 1998; see next section).
It has been argued that quality scores are at best useless
and at worst misleading (Greenland 1994); however,
Kleijnen et al. used a scoring system to select trials for fur-
ther analysis. For example, Kleijnen gave 1 point for trials
that had over 200 participants, and 1 point for trials that
lasted over 3 months. When the outcome of interest is a
‘common cold episode,’ the number of episodes is of pri-
mary interest because it is directly related to the precision
of the results. Duration of the trial and the number of par-
ticipants, used in the Kleijnen scoring system, are not di-
rectly relevant in this respect since there are considerable
variations in the incidence of colds in the published trials,
long duration or a large number of participants does not
always lead to a large number of episodes.
At the extreme, Kleijnen’s scoring system led to the in-
clusion of the Coulehan et al. trial (1974), which recorded
only 75 cold episodes, and the exclusion of the Elwood et
al. trial (1976), which recorded 1,317 episodes, the excluded
trial recording 17 times as many episodes as that included.
Furthermore, Kleijnen explicitly commented that "We think
that randomization and blinding are most important." How-
ever, the Coulehan trial (1974) used allocation by alpha-
betic order, not randomization, whereas the excluded Elwood
trial (1976) used randomization. The Elwood trial was a
double-blind placebo-controlled trial and there are no obvi-
ous methodological reasons to exclude it.
Furthermore, Kleijnen wrote that "1 point was given if
the placebo had been described".  Karlowski et al. (1975)
described that "This study was designed during the summer
and rushed into operation to take advantage of the rise in
upper respiratory infections expected to occur in the fall.
There was no time to design, test, and have manufactured a
placebo that would be indistinguishable from ascorbic acid"
(p 1041) … "Some of the volunteers had tasted their cap-
sules and professed to know whether they were taking the
ascorbic acid or the placebo [consisting of lactose which is
sweet and not acidic]" (p 1041).  In contrast, Elwood et al.
(1976) described that their tablets "contained either 1 g ascor-
bic acid in an effervescent base or a matching placebo" in-
dicating that their vitamin C and placebo tablets were indis-
tinguishable. Although we have good reason to assume that
the placebo control was substantially better in the Elwood
trial, Kleijnen included in his further analysis the Karlowski
trial but not the Elwood trial.
Kleijnen et al. (1989) calculated the point scores for each
trial, 11 trials receiving 8 points or more. These 11 trials
were included in the further analysis and their results were
presented in a table in Kleijnen’s paper (listed in Table 15).
The 11 ‘high score’ trials in Kleijnen’s table recorded
overall 9,201 common cold episodes. The largest trial in
Kleijnen’s table was the Anderson et al. trial (1974), which
recorded 3,590 episodes in all. This trial, however, was very
complicated. Anderson had 8 study arms, 2 of which were
administered a placebo. Recollection of previous colds con-
siderably differed between the 2 placebo groups, indicating
that there were problems with allocation of participants to
these study arms (Table 16). In the case of recollection of
‘usual days indoors’ placebo group #6 showed the shortest
colds among all 8 arms and there is strong evidence that
this group is inconsistent with the 6 vitamin C groups in
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Table 15. The major vitamin C common cold trials
according to Kleijnen et al. (1989)
_______________________________________________
Total
No. of
Trial episodes Allocation Blindness 1
__________ _______ _________ _________
Anderson-1972 1,170 random DB
Anderson-1974 3,590 random DB
Coulehan-1974 75 alternately 2 DB
Anderson-1975 3 635 random DB
Karlowski-1975 4 249 random DB
Coulehan-1976 196 random DB
Ludvigsson-1977b 1,279 random DB
Miller-1977 412 random DB
Pitt-1979 1,219 random DB
Carr-1981 292 random DB
Bancalari-1984 84 random DB
____________ ____ _________    ____
Total 9,201 episodes
in all trials of this table
Total 5,611 episodes
if Anderson-1974 is excluded
(see text)
_______________________________________________
1 DB, double-blind trial.
2 "All children were assigned alternately, from an alphabetic listing by
classroom, to one of two study groups… [by] a pharmacist,
not otherwise involved in this investigation."
3 Therapeutic trial; 1.5 g/day of vitamin C was administered on the first
day and 1 g/day for the following 4 days (i.e., a total of 5 days). Once
a week the vitamin C group was administered 0.5 g of vitamin C
(i.e., on average 71 mg/day), for which the rationalization is obscure.
4 Therapeutic (3 g/day for 5 days) and regular supplementation
(3 g/day each day) trial with a 2x2 factorial design (see Table 8).
changed participants between 2 study arms and considered
the labeling error was thus compensated for. There were
also 1,171 dropouts among the original 3,520 participants
(i.e., 33%) which also decreases the validity of this particu-
lar trial. Kleijnen (1989) paid no attention to the various
shortcomings of the Anderson (1974) trial, but calculated
the point scores mechanically. With an 8-arm trial with ex-
plicit evidence of bias between 2 placebo arms, a 33% drop-
out proportion, and errors in labeling it is not clear that one
should simply look at the high ‘Kleijnen scores.’ It seems
that Anderson was too ambitious in his 1974 trial.
If we exclude Anderson’s trial (1974) referring to the
shortcomings discussed above, there are 5,611 common cold
episodes remaining in Kleijnen’s ‘high score’ trials, i.e.,
a reduction by 39% in the number of cold episodes.
Kleijnen excluded 27 placebo-controlled trials from fur-
ther analysis because they got low ‘Kleijnen scores’ in the
arbitrary scoring system (listed in Table 17). Overall these
trials contain 8,579 common cold episodes, thus nearly as
many as the ‘high score trials.’ 11 of the trials excluded are
randomized and double-blind trials recording 3,740 com-
mon cold episodes (Table 17). Kleijnen thus excluded a large
number of randomized and double-blind trials from his fur-
ther analysis, but included the Coulehan trial (1974) that
was non-randomized and the Anderson trial (1974) which
had evidence of various problems. Although the number of
episodes is highly relevant to the precision of the results,
Kleijnen included 2 trials that had less than 100 episodes
(Table 15) but excluded 7 randomized double-blind placebo-
controlled trials that had over 100 episodes (Table 17). The
final sets of included and excluded trials in Kleijnen’s re-
view are good examples of the problems that result from
mechanical ‘quality scoring.’
Furthermore, Kleijnen shows the 11 ‘high scoring’ trials
in a table with subjective comments, but the presentation
suffers from several shortcomings (Table 18). The subjec-
tive comments are also in some cases demonstrably errone-
ous. Kleijnen states that Pitt and Costrini (1979) found ‘no
difference’ in the severity of colds between the study groups.
In fact, they reported an average severity score of 1.87 in
the vitamin C group and 1.97 in the placebo group and tested
the difference: χ2 (15 df) = 27.8 (P = 0.012). Although a 5%
difference in severity is a clinically minor finding, the sta-
tistically significant difference suggests a real biological
effect. It is possible that this effect is greater under dissimi-
lar conditions and in this respect a subjective comment of
‘no difference’ is misleading.
In case of the complicated Anderson et al. trial (1974),
Kleijnen comments that there was ‘no difference’ in com-
mon cold duration or severity. In fact, Anderson remarked
that there seemed to be "a consistent dose-related effect as-
sociated with the 4 and 8 g therapeutic-only regimens
[groups #7 and #8] … group #8 (8 g/day on the first day of
illness) experienced a larger number of one-day ‘false-alarm’
or ‘aborted’ episodes than any other group" (Table 19).
Groups #7 and #8 are well balanced with respect to the rec-
ollection of previous colds (Table 16), and the incidence of
colds during the trial was nearly identical (Table 19). In this
this baseline variable (P[2-t] = 0.000,02; Table 16). The rec-
ollection of ‘usual days off work’ was also peculiarly low
in placebo group #6. Furthermore, the proportion of par-
ticipants who reported ‘contact with children’ differed sig-
nificantly between the 2 placebo groups. When the expected
benefit of vitamin C supplementation is of a magnitude of
10-30%, this kind of baseline bias seriously hampers the
analysis of the results. Furthermore, during the trial, pla-
cebo group #6 had significantly lower ‘total days of symp-
toms’ per participant compared with placebo group #4
(P[2-t] = 0.005; Table 16). In fact, Anderson (1974) pointed
out in their discussion that the 2 placebo groups were diver-
gent, indicating that not all of the groups were well matched.
Moreover, Anderson reported that there was a labeling er-
ror in 2 batches of bottles out of the 176 batches, but they
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Table 16. The allocation problem in the Anderson et al. trial (1974)
_______________________________________________________________________________________________
Recollection at baseline
__________________________________ Outcome during the trial
_______________________
Usual Usual Contact
Study Dose 1 days indoors days off work with Total days of Free of
Arm (g/d) (days/cold) (days/cold) children symptoms sickness
_______________________________________________________________________________________________
#6 Placebo 0/0 1.97 2 1.56 2 46% (202/440) 3 4.16 4 25.6% (75/293) 4
#1 Vitamin 1/4 2.46 2.07 35%
#2 Vitamin 1/0 2.23 1.72 43%
#3 Vitamin 2/0 2.33 1.79 42%
#5 Vitamin 0.25/0 2.46 2.12 38%
#7 Vitamin 0/4 2.46 1.95 37%
#8 Vitamin 0/8 2.46 2.01 41%
#4 Placebo 0/0 2.57 2 2.07 38% (167/440) 3 5.40 4 18.2% (52/285) 4
_______________________________________________________________________________________________
Difference between
two placebo groups -23% -25% +21% -23% +41%
(#6 and #4) (1.97/2.57) (1.56/2.07) (.46/.38) (4.16/5.40) (.256/.182)
_______________________________________________________________________________________________
1 "A/B" dosage indicates that the regular dose over the entire study period was A, and B indicates the therapeutic dose the participant took on only
the first day of the cold episode.
2 Based on the central limit theorem (Altman 1991 p 154) we may assume that the mean values of the 6 vitamin groups follow the normal
distribution. Thus the mean ‘usual days indoors’ is 2.40 ± 0.10 (SD) for the set of 6 vitamin groups, so that in this distribution the placebo group
#6 level (1.97) corresponds to Standard Normal deviate z = 4.3 [=0.43/0.10] and corresponds to P[2-t] = 0.000,02, while the group #4 level
(2.57) corresponds to z = 1.7 and P[2-t] = 0.09.
For the 6 vitamin groups, the mean ‘usual days off work’ is 1.94 ± 0.16 (SD). Assuming this corresponds to the normal distribution,
the group #6 level (1.56) corresponds to z = 2.37 and P[2-t] = 0.018.
3 The number of participants is inferred from the reported percentage. Comparison of placebo groups #6 and #4: mid-P[2-t] = 0.017.
4 For the placebo groups, the ‘total days of symptoms’ during the trial follow-up: 4.16 (SD 4.53; N = 293) and 5.40 (SD 6.00; N = 285) vary
significantly (P[2-t] = 0.005; t-test), between arms #6 and #4. There is also a statistically significant difference in the outcome ‘free of sickness
during the trial’ between the 2 placebo groups (mid-P[2-t] = 0.027).
respect the 6.6% difference in favor of the higher dosage is
interesting as regards the possible therapeutic effects of vi-
tamin C. Thus, it is misleading to state, as Kleijnen does,
that ‘no differences’ were observed in the Anderson trial
(1974).
The Cochrane Collaboration
meta-analysis (1998)
In the late 1990s, a Cochrane Review of the role of vitamin
C for preventing and treating the common cold was pub-
lished (Douglas et al. 1998). This analysis was based on the
combination of trials selected by Kleijnen et al. (1989) and
Hemilä (1992a). Cochrane systematic reviews are particu-
larly important as they are a kind of official review within
the populistic EBM movement, which has various concep-
tual and practical shortcomings (Feinstein & Horwitz 1997;
Charlton 1997; Miles et al. 1997, 2003; Black 1998;
Charlton & Miles, 1998; Hampton 1997, 2002; Tonelli 1998;
Vandenbroucke 1998b; Berk & Janet 1999; Goodman 1999;
Norman 1999, 2003; Rees 2000; Williams & Garner 2002;
Louhiala & Hemilä 2005a,b,c). In some recent reviews on
the common cold, the Cochrane 1998 review was the only
reference to vitamin C trials (Scott & Orzano 2001; West
2002; Heikkinen & Järvinen 2003). The Cochrane Review
was also used in commenting on the role of vitamin C on
the common cold in editorials of BMJ (Bender 2002) and
Epidemiology (Spiers 2002). It was also cited in a recent
report on the use of complementary and alternative medi-
cine in the USA (HPDP 2005).
The severe problems in the Kleijnen et al. selection of
‘high score’ trials (1989) are discussed in the preceding sec-
tion. When describing the Kleijnen set, the Cochrane 1998
review stated that several of the trials were "rejected by
Kleijnen because they were not double-blind randomized
controlled trials" and "Kleijnen adopted double-blind
randomized controlled trials as his standard for inclusion."
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Table 17. Placebo-controlled trials on ‘vitamin C and
the common cold’ excluded from Kleijnen’s meta-
analysis (1989) because of ‘low quality scores’
_______________________________________________
Total no. of
Trial episodes Allocation 1 Blindness 1
__________ _________ _________ ________
Cowan-1942  736 alternately SB
Glazebrook-1942  358 2 SB
Bergquist-1943 (551 subj) alternately SB
Dahlberg-1944  307 alternately DB
Brown-1945  298 alternately SB
Scheunert-1949 (1,066 subj) ? ? 3
Cowan-1950  790 ? DB
Bartley-1953   62 ? DB
Franz-1956   29 alternately DB
Tebrock-1956 1,915 alternately DB
Ritzel-1961   48 random DB
Walker-1967   36 ? SB
Abbott-1968  270 random DB
Liljefors-1972   22 cross-over 4 DB
Charleston-1973  124 ? SB
Elliott-1973 (70 subj) random DB
Schwartz-1973   21 ? DB
Wilson-1973a,b,c (230 subj) random DB
Sabiston-1974   20 random DB
Carson-1974  386 random DB
Clegg-1975  141 ? DB
Elwood-1976 1,317 random DB
Asfora-1977  (133) alternately DB 5
Elwood-1977  264 random DB
Ludvigsson-1977a  236 6 random DB
Tyrrell-1977  603 random DB
Baird-1979  596 random DB
____ _____ _____
Total 7 8,579 episodes
in all trials in this table
Total 7 3,740 episodes
in double-blind randomized
trials in this table
explicit comment only on the blindness of the participant, and no
explicit comment on the blinding of the observer.
2 In the Glazebrook & Thomson trial, for practical reasons the school-
children in a boarding school were not randomly allocated into the
study groups, but certain administrative groups occupying the same
tables in the dining room were served vitamin C supplemented food
while the others remained as controls. The authors argued that a tonsil-
litis epidemic affected all the administrative groups uniformly the year
before, indicating that the dining tables could not be considered as
isolated units. Vitamin C was added to food in the kitchen which
functionally corresponds to a placebo control design since the addition
of vitamin C is not apparent to the consumer of the food in the dining
room.
3 In Scheunert’s trial, the term ‘placebo’ is not used. Study arm #1 was
administered 20 mg/day while arm #2 was administered 50 mg/day
vitamin C. In several trials the ‘placebo groups’ were administered a
small dose of vitamin C; e.g., Carr et al. (1981) administered
70 mg/day, and Miller et al. (1977) administered 50 mg/day. In this
respect, Scheunert’s 20 mg and 50 mg vitamin C arms correspond to
placebo groups compared with the 100 mg/day (#3) and 300 mg/day
(#4) arms.
4 The method of allocation into study groups was not described, but
participants were given vitamin C and placebo using a cross-over
setting.
5 The trial was initiated as a double-blind trial, but was terminated
when it seemed obvious on clinical grounds who were receiving the
‘active’ substance and who were receiving the placebo. The trial was
thereafter continued as an open trial.
6 Ludvigsson et al. (1977a,b) reported two trials in a single paper, but
only the larger one was included in Kleijnen’s set of ‘high score’
trials.
7 The Bergquist (1943), Scheunert (1949), Elliott (1973), Wilson et al.
(1973), and Asfora (1977) trials are not included in the sum because
the number of episodes was not stated.
Table 18. Major shortcomings of Kleijnen’s
meta-analysis (1989)
__________________________________________________
1. Selection of trials is based on an arbitrary and illogical
scoring system
2. No P-values extracted from papers or calculated
by Kleijnen himself
3. No calculation of effect measures (RR or percentage
benefit)
4. No pooling of data from comparable trials
5. No consideration of what might explain differences
between the trial results
6. No consideration of vitamin C intake in diet
7. No consideration of vitamin C supplementary doses
8. No partition of regular supplementation trials from
therapeutic supplementation trials
9. No consideration of biological plausibility (i.e., immune
system effects, animal studies, changes in vitamin C
metabolism during colds, etc.)
__________________________________________________
1 Method of allocation into study groups: ‘random’ refers to the de-
scription by the authors; in most cases the method of randomization
is not described; ‘alternately’ refers to allocating participants
sequentially to different study groups on their arrival or on the basis
of odd and even identity numbers; ‘?’, allocation method not de-
scribed.
Blindness: DB, double blind: the person evaluating the status of
the blinded participant is unaware of the treatment. In many cases
the participants self-evaluated their illness status; SB, single blind:
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In fact, 11 of the trials excluded by Kleijnen were double-
blind randomized controlled trials (Table 17), while the
Coulehan trial (1974) was not randomized. Thus the selec-
tion criteria for the Kleijnen set of trials, based on an arbi-
trary and illogical scoring system, was not properly consid-
ered in the 1998 Cochrane Review.
The purpose of the Hemilä meta-analysis (1992a) was to
test the narrow and specific question of whether Pauling’s
hypothesis (1970a), that regular gram doses of vitamin C
would prevent and alleviate colds, is correct or not. To test
Pauling’s hypothesis, the selection of trials was restricted
to those published after Pauling published his hypothesis,
in which participants were regularly administered ≥1g/day
vitamin C. This restriction by Hemilä (1992a) is meaning-
ful in testing Pauling’s hypothesis, but in a general analysis
of the effects of vitamin C on respiratory infections this
selection has no rationale. For example, it is possible that
vitamin C intake affects respiratory infections in the low
range of intakes and under such conditions doses less than
1 g/day are interesting, even though they do not test Pauling’s
hypothesis. There are also therapeutic trials which should
be taken into consideration instead of being restricted only
to regular dose trials. Finally, there are trials published be-
fore Pauling’s book (1970a), which do not test Pauling’s
hypothesis, but may be relevant in summing up all pub-
lished trials.
A new version of the Cochrane Review was recently pre-
pared (Douglas, Hemilä, et al. 2004; Douglas & Hemilä
2005), and this 2004 Cochrane Review covers all published
placebo-controlled trials using at least 200 mg/day of vita-
min C, not being restricted to the selections by Kleijnen et
al. (1989) and Hemilä (1992a).
The Dykes and Meier review (1975)
In 1975 JAMA published a review of vitamin C and the com-
mon cold by Michael Dykes and Paul Meier in the same
issue as the Karlowski et al. trial (1975). Meier is an emi-
nent statistician, the second author of the widely used
Kaplan-Meier survival analysis method (1958), and he was
elected statistician of the year in the USA in 1985 (ASA
2005). This review in a wide circulation medical journal
has thus been highly influential.
The Dykes and Meier review (1975) has been extensively
cited as evidence that vitamin C is worthless for colds; for
example, in the US nutritional recommendations (FNB 1980,
1989a), Cecil Textbook of Medicine (Kapikian 1985), and
reviews and commentaries of common cold therapy (Edito-
rial 1976; Hirsch & Swartz 1980; Anderson et al. 1983;
Lowenstein & Parrino 1987; Spiers 2002). Dykes and
Meier’s review (1975) was also referred to in the popular
textbook Modern Epidemiology as an example of impor-
tant topics that have been examined by controlled trials
(Rothman 1986 p 54; Rothman & Greenland 1998 p 70).
The Dykes and Meier review (1975) contains several
shortcomings (Hemilä 1996a). The authors state that "Ma-
terial will only be considered that was published in the sci-
entific literature and was, therefore, subjected to both the
careful editorial peer review and the critical scrutiny of the
general scientific community that are inherent in that proc-
ess." It is puzzling that a statistician uses ‘publication in a
journal’ as a surrogate for good quality, instead of critically
reading the papers for himself. For example, Dykes and
Meier (1975 p 1976) uncritically accepted the ‘placebo ef-
fect’ explanation of the Karlowski et al. trial (1975): "When
the analysis is restricted to those subjects who did not know
their treatment, no appreciable differences were found in
any of the reported indices." However, critical reading of
the Karlowski paper would have revealed to Dykes and
Meier that 42% of common cold episodes were missing from
the subgroup analysis without any justification, and there
are many further problems with the ‘placebo effect’ expla-
nation (Paper I; see p 25). Apparently because of their blind
faith in this explanation, Dykes and Meier (1975) did not
present the actual results of the Karlowski et al. (1975) trial.
Table 19. Therapeutic vitamin C in the Anderson et al. trial (1974)
_____________________________________________________________________________________________
Common cold episodes
___________________
Dose of vitamin C Episodes No. of No. of Percentage of colds P
on only the first per 1-day ≥2 day being shorter
day of illness (arm) person colds colds (95% CI)
_____________________________________________________________________________________________
4 g/d (#7) 1.52 164 (39%) 253 0.0% (Reference)
8 g/d (#8) 1.58 222 (46%) 261 6.6% (0.2%, 13.1%) 0.023
_____________________________________________________________________________________________
Data are from table II in Anderson et al. (1974). For the baseline comparability of these two groups, see Table 16.
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Compared with the placebo group, 3 g/day of vitamin C
decreased the duration of colds by 6% to 9%, whereas 6 g/
day decreased it by 17% (P = 0.025), suggesting dose de-
pendency up to 6 g/day (Hemilä 1999a).
Dykes and Meier justified their review by referring to
Pauling’s papers (1971a,b). Furthermore, they stated that
"Pauling gave great weight to the 1961 study of schoolchil-
dren in a skiing camp in Swiss Alps by Ritzel." With such
an explicit background it is odd that they did not present
any of Ritzel’s data (Table 3). Dykes and Meier (1975)
claimed that Ritzel’s "presentation of the data is confused
and unclear in a number of respects." In fact, Ritzel (1961)
listed the duration of colds in his text, and in table form
showed the total days of colds per group, and the number of
cases and total days of ‘constitutional symptoms’ per group,
which are extracted in the present Table 3. Thus, Dykes and
Meier did not mention that there was a 31% decrease in the
mean duration of episodes, a 45% decrease in the incidence
of colds, and a 61% decrease in the total number of days of
colds in the group administered 1 g/day of vitamin C. Nor
did they mention that there was a 62% decrease in the
number of children with ‘constitutional symptoms,’ and an
81% decrease in the total number of days with constitu-
tional symptoms in vitamin C group. Dykes and Meier
merely commented that the difference in common cold in-
cidence in the two groups was only marginally significant
(P[2-t] = 0.04), which seems to be intentional camouflag-
ing of the actual results. It is quite possible that some read-
ers of JAMA might have considered that a 61% reduction in
total number of sickness days, or an 81% reduction in days
with constitutional symptoms might be worth serious con-
siderations when the results arise from a randomized dou-
ble-blind placebo-controlled trial with children, even though
a one-week trial in a skiing camp does not allow any direct
extrapolation to ordinary schoolchildren. Thus, concealing
the actual results prevented a critically minded reader from
drawing his or her own conclusions.
Dykes and Meier (1975) presented the results of the
Anderson et al. trial (1972), but did not calculate any esti-
mates of effect, such as percentage difference in favor of
the vitamin C group, which hampers the reader in consider-
ing the practical significance of the findings. Dykes and
Meier wrote of the Anderson 1972 trial: "The estimated ef-
fect is considerably less than that predicted by Pauling for
the dose level." Anderson had reported a 30% decrease (P =
0.000,5) in the ‘total number of days confined to house’ per
participant. Dykes and Meier’s comment seems irrelevant
as many readers might consider that with an inexpensive
nutrient which costs pennies per gram and is safe in large
doses, even such moderate benefits might be worthy of ex-
ploitation irrespective of how they compare with Pauling’s
predictions. Moreover, on biological grounds one would
expect the benefit of supplementation to be greater for sub-
jects with a low dietary vitamin C intake, and in this respect
Anderson’s subgroup finding that supplementation was sub-
stantially more beneficial for those participants that had low
intake of fruit juices is highly interesting (Table 13). Thus
Dykes and Meier were not consistent in their review when
they uncritically accepted Karlowski’s subgroup analysis
which was based on the exclusion of 42% of cold episodes
without any rationalization, and rejecting Anderson’s sub-
group analysis, which is biologically well rationalized.
Dykes and Meier comment on the Anderson et al. trial
(1974) that "A question is raised whether one of two con-
trol groups may have been biased, but the data given are not
sufficient to evaluate this point." This is quite a puzzling
comment by a statistician, since the discrepancy between
the 2 placebo groups in the Anderson 1974 trial can be seen
in several simple calculations (Table 16), and accordingly
the data are sufficient to evaluate this point, in contrast to
Dykes and Meier’s statement.
Dykes and Meier (1975) explicitly commented on the
Coulehan et al. trial (1974) with Navajo schoolchildren that
"Because the data required for an appropriate analysis are
not presented, the statistical significance of the differences
reported cannot be considered to have been established." In
fact, Coulehan et al. (1974) reported in their table 4 that
44% (143/321) of school children administered vitamin C
were ‘never ill on active surveillance,’ while only 29%
(93/320) of those administered placebo were ‘never ill’
(Table 20). Since it is highly unlikely that such a difference
between the vitamin C and placebo groups would arise
purely by chance (P = 0.000,03; Table 20), in contrast to
Dykes and Meier’s claim in their review, important elements
of Coulehan’s results were presented and can be re-analyzed
by a statistically oriented reader. When such highly signifi-
cant differences between vitamin C and placebo groups are
reported, it is grossly misleading to state in a review that
significant differences "cannot be considered to have been
established."
Furthermore, Dykes and Meier are not consistent in their
text. They accuse Coulehan et al. (1974) of failure to present
relevant data (partly true), whereas they themselves fail to
present the data Coulehan did report (e.g., Table 20) in their
own review. Coulehan et al. (1974) also found that the du-
ration of colds was 12% and 29% shorter in children ad-
ministered 1 and 2 g/day of vitamin C respectively, sug-
gesting dose dependency up to 2 g/day, but this data was
also missing from the Dykes and Meier review. Finally,
Dykes and Meier failed to present any results of the Ritzel
(1961) and Karlowski et al. (1975) trials, thereby prevent-
ing readers from drawing any independent conclusions about
them.
Pauling (1976b) considered that "some significant studies
in this field were not mentioned by Dykes and Meier, and
some important aspects of the studies discussed by them were
also not mentioned by them." Pauling thus wrote a manu-
script in which he presented the results of the relevant stud-
ies, his own interpretations, and some criticism of Dykes and
Meier’s argument. For example, commenting on the Ritzel
trial, Dykes and Meier (1975 p 1075) stated that "Pauling
infers the number of subjects [with colds] by dividing ‘ill-
ness days’ by ‘mean illness days’ and concludes that there is
a significant difference in proportions of subjects experienc-
ing colds. If his interpretation is correct, the difference is in-
deed significant." To which Pauling replied that "It is hard
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Table 20. Prophylactic benefit of vitamin C in large trials
________________________________________________________________________________________________
Free of illness during the trial
         / Persons in group Proportion
________________________ of participants
getting benefit
Trial Vitamin C Placebo (95% CI) P 1
________________________________________________________________________________________________
Coulehan-1974 2
641 Navajo schoolchildren
Duration 3 months
Alternative allocation, DB
Children never ill
on active surveillance
by a medically trained clerk
or the school nurse
All children 2 143/321 (44%) 93/320 (29%) 16% (8%, 23%) 0.000,03
Low grades
1 g/d vit C
Boys 31/81 (38%) 18/87 (21%) 18% (4%, 31%) 0.007
Girls 30/109 (28%) 12/105 (11%) 16% (5%, 26%) 0.002
High grades
2 g/d vit C
Boys 40/62 (64%) 34/61 (56%) 9% (-8%, 26%) 0.2
Girls 42/69 (61%) 29/67 (43%) 18% (1%, 34%) 0.021
Anderson-1972
818 adults in Canada
with colds usually in winter
Duration 3 months
Randomized, DB
1 g/d vit C
Free of any illness
during the trial 105/407 (26%) 76/411 (18%) 7.3% (1.6%, 13%) 0.006
No ‘days confined to house’ 232/407 (57%) 195/411 (47%) 9.5% (2.7%, 17%) 0.003
No ‘days off work’ 275/407 (67%) 243/411 (59%) 8.4% (1.8%, 15%) 0.006
________________________________________________________________________________________________
1 One-tailed mid-P-value. The CI was calculated using the CIA (confidence interval analysis, BMJ) program.
2 In the Coulehan trial, the number of children ‘free of illness’ in the placebo group does not match in the original paper: 18 + 12 + 34 + 29 = 93,
and not the 92 published by Coulehan; in this table N = 93 is used as the sum of children ‘free of illness’ in the placebo group since it matches
with the subgroup data. DB, double-blind.
The outcome in Coulehan’s table 4 is erroneously called as ‘No. of days without sickness observed per total in group’ whereas the actual data is
‘Number of children without sickness observed per total in group’ (Coulehan 1995).
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for me to understand why Dykes and Meier should suggest
that my interpretation might be incorrect. It involves a very
simple calculation. Ritzel states (in his table 1 [see current
Table 3]), that the total number of days of illness for the ascor-
bic-acid subjects was 31. He also states (page 66) that the
average number of days per episode of illness was 1.8. The
ratio 31/1.8 is 17.2; that is, there were 17 episodes of illness
in this group. A similar calculation gives 31 colds for the
placebo subjects (80 total days of illness, 2.6 average number
of days per episode). It is safe to assume that no subjects had
two colds in the same week. With this assumption, the null
hypothesis of equal probability of colds for the two groups is
rejected at the level P (one-tailed) < 0.015. Dykes and Meier
mention that I give great weight to the Ritzel study. I do give
great weight to it, and I find it strange that they should reject
it on the basis of trivial complaints, such as their apparent
failure to understand the simple calculation described above"
(Pauling 1976b).
Pauling submitted his manuscript to JAMA, but his pa-
per was rejected even after Pauling twice made revisions to
meet the suggestions of the referees, and the manuscript
was finally published in a minor journal (1976b,c; see also:
1976a pp 133-5; 1986a pp 231-2). The rejection of Pauling’s
review was quite a strange policy by JAMA, since the read-
ers were thereby prevented from seeing the other side of an
important scientific controversy.
Truswell’s mini-review (1986)
A. Steward Truswell is an eminent nutritionist who was a
co-editor of a major textbook of nutrition (Davidson et al.
1975, 1979), and the author of a popular book ABC of
Nutrition, which is currently printed as the fourth edition
(Truswell 2003). Truswell (1986) reviewed the vitamin C
trials in a letter to the New England Journal of Medicine.
The main text of the letter was only half a column long, but
a journal with great prestige and a wide circulation makes
the statements in Truswell’s mini-review influential and wor-
thy of a critical look. This mini-review was cited in
Truswell’s own book on nutrition (2003 p 64) as the only
reference to the topic of vitamin C and the common cold,
and in a Finnish book chapter stating that vitamin C has no
effect on colds (Aro 1994 [see Hemilä 1995a]).
Truswell did not present any figures or P-values of the
original reports, merely providing subjective comments
about the trials. Neither did he make any effort to rational-
ize the great variations in the reported results. For example,
on pharmacological grounds it is highly plausible that the
effect depends on the dose. Truswell, however, listed the
Karlowski et al. trial (1975) in which vitamin C dose was
up to 6 g/day and the Dahlberg et al. trial (1944) in which
the dose was only 0.05 g/day side-by-side without men-
tioning that there was a 120-fold discrepancy in vitamin C
dosage. Obviously, such trials are not equivalent.
At the end of his mini-review, Truswell stated that "In
another five combined trials there appeared to be slight amel-
ioration of symptoms, which was not statistically signifi-
cant." In fact, the 5 papers cited by Truswell contained 6
trials and not 5 (Table 21; Hemilä 1996a). Furthermore, all
6 trials reported a statistically significant benefit in at least
one of the outcomes (Table 21). Thus Truswell’s statement
is gravely misleading, even though the 5 papers did contain
some other outcomes in which the benefit was not signifi-
cant statistically. Some further problems in Truswell’s mini-
review are discussed elsewhere (Hemilä 1996a).
Table 21. ‘Five’ trials in which the amelioration of common cold symptoms by vitamin C
was not statistically significant according to Truswell (1986)
_________________________________________________________________________________________
No. of Vitamin C The effect
subjects   dose of vitamin C
Trial  (g/d)    (%) P[2-t] Outcome
________________________________________________________________________________________
Karlowski-1975 103   6 -17  0.047 Duration of symptoms
Pitt-1979 674   2  -5  0.023 Severity of symptoms
Ludvigsson-1977a 1 158   1 -39  0.003 Duration of symptoms
Ludvigsson-1977b 1 615   1 -14  0.016 Absence from school
Carr-1981 190   1 -19 <0.05 Duration of symptoms
Wilson-1973 2 128   0.2 -45  0.035 Intensity of symptoms
________________________________________________________________________________________
All 6 trials were placebo-controlled and the effect of vitamin C refers to the difference between the vitamin C and placebo groups. The exact P
values were calculated where appropriate data was available. This table is reproduced from Hemilä (1996) Nutrition 12:804-9 with permission.
1 Ludvigsson et al. (1977) reported the results of 2 separate trials in the same paper.
2 ‘Whole colds’ among girls administered 0.2 g/day of vitamin C; for details, see the reference.
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Paper II: Meta-analyses of trials on
vitamin C and common cold incidence
Based on previously published trials, Pauling (1970a,
1971a,b) concluded that regular high dose vitamin C sup-
plementation considerably decreases the incidence of the
common cold. To test Pauling’s hypothesis, a meta-analy-
sis was carried out to analyze placebo-controlled trials in
which large vitamin C doses (≥1 g/day) were regularly ad-
ministered to participants. A second selection criterion re-
quired that ≥200 common cold episodes be recorded in the
trials. Small trials with negative results may remain unpub-
lished, leading to publication bias, whereas large-scale tri-
als are probably published irrespective of the results. 7 tri-
als satisfying the selection criteria were identified, but the
Anderson et al. trial (1974) was excluded because of the
significant divergence in the placebo arms (Table 16). The
largest 5 of the 6 trials are listed in Table 10. Since all
6 trials were published after 1970 they explicitly tested
Pauling’s hypothesis. Since the 6 trials were carried out in
5 different Western countries, using schoolchildren, adults
and military recruits as participants, they cover a wide range
of populations in the Western countries.
None of these 6 major trials found a significant differ-
ence between vitamin C and placebo groups in the inci-
dence of colds. Pooling the results of the 6 trials did not
reveal any difference between the vitamin and placebo
groups with a narrow confidence interval (pooled RR = 0.99;
95% CI: 0.93-1.04). Thus these 6 large-scale trials suggest
firm rejection of Pauling’s general hypothesis that regular
high dose vitamin C supplementation markedly decreases
the incidence of common cold episodes across all popula-
tion groups in Western countries.
Nevertheless, even though these trials found no overall
benefit from vitamin C, Anderson et al. (1972) found a sta-
tistically significant decrease in the incidence of ‘throat
colds’ (-21%, P < 0.01) and Elwood et al. (1976) in the
incidence of ‘chest colds’ (-18%, P = 0.015), neither find-
ing any effect on the incidence of ‘simple colds’, however
(nose running or sneezing). Thus, concluding from these
two large-scale trials, it is still possible that vitamin C sup-
plementation has some limited effects on incidence, depend-
ing on the type of cold.
Quite a few technically satisfactory small trials found
that vitamin C group had a significantly lower incidence of
colds than the placebo group and explorative meta-analy-
ses of the common cold trials were therefore carried out on
the hypothesis that vitamin C supplementation may affect
common cold susceptibility in specific groups of people.
 Assuming that any potential effects of vitamin C sup-
plementation may be most conspicuous in subjects with a
particularly low dietary vitamin C intake, it is possible that
supplementation would have effects in populations with low
intakes. Unfortunately, since few trials have estimated the
vitamin C intake of the participants, a surrogate for low
vitamin C intake was used, namely, trials that were carried
out in the UK. Several studies over a long period of time
reported low vitamin C intake in the UK of 30-60 mg/day
(II). By comparison, the median vitamin C intake in the
USA is about 100 mg/day (FNB 2000 pp 416-9).
In 4 trials with UK females, vitamin C supplementation
had no marked effect on common cold incidence (pooled
RR = 0.95; 95% CI: 0.86-1.04). However, in 4 trials with
UK males, a statistically highly significant but quantitatively
modest reduction in common cold incidence was found in
vitamin C groups (pooled RR = 0.70; 95% CI: 0.60-0.81;
P = 0.000,001). These 4 trials with UK males indicate that
vitamin C may have physiological effects on susceptibility
to the common cold under specific conditions, but the ef-
fect seems quantitatively meaningful only in limited groups
of people and is not large.
Furthermore, 4 trials with UK males reported the number
of people with ≥2 colds during the study period and a signifi-
cant reduction in the number of men with recurrent colds
was found in the vitamin C groups (pooled RR = 0.54;
95% CI: 0.40-0.74; P = 0.000,05). Table 22 shows the pro-
portion of participants benefiting from vitamin C supplemen-
tation when the outcome is ≥2 colds during the trial. Table 22
also includes the results of the recent UK trial by van Straten
and Joslin (2002), which reported 37 common cold episodes
in the vitamin C group (N = 84), 50 in the placebo group (N
= 84) and, for the difference in incidence, the authors calcu-
lated the "Student’s t-distribution .375" corresponding to
"P<.05." In fact, t(166 df) = 0.375 corresponds to P[2-t] =
0.71 which is not smaller than 0.05. Furthermore, the t-test is
inappropriate for analyzing incidence data. Analysis of this
incidence data with the normal approximation of Poisson dis-
tribution (see Paper II) yields RR = 0.74, 95% CI: 0.48-1.13;
P[2-t] = 0.17. Nevertheless, despite the errors in statistical
analysis, van Straten and Joslin (2002) reported a highly sig-
nificant reduction in the number of participants who had
2 colds during the trial (Table 22). The van Straten and Joslin
(2002) trial consisted mainly of women and they did not
present the results separately for sexes.
Methodologically, the trials in Table 22 diverge substan-
tially. Charleston and Clegg (1972), Elwood et al. (1976),
and van Straten and Joslin (2002) administered 1 g/day vi-
tamin C. Clegg and Macdonald (1975) administered 1 g/
day ascorbic acid to one group and 1 g/day D-isoascorbic
acid (erythorbic acid) to another, and the two groups are
combined in Table 22 based on the fact that the D-isomer is
an equivalent antioxidant, although it does not cure scurvy
as efficiently as the L-isomer. Baird et al. (1979) adminis-
tered only 80 mg/day of vitamin C. All the trials adminis-
tered vitamin C over the whole study period, except Tyrrell
et al. (1977), which administered vitamin C therapeutically
at 4 g/day for only 2.5 days during the first common cold
episode, so that therapeutic treatment seemed to reduce the
occurrence of later episodes.
Paper II was commented on (Bates 1997; Schorah 1997),
but none of the criticism seems to be valid (II; Hemilä
1997d).
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Table 22. Prophylactic effect of vitamin C on recurrent colds in the UK trials
_______________________________________________________________________________________________
   Persons with ≥2 colds
Trial Duration      / All persons in the group Proportion of P 1
(weeks) ____________________________ participants
getting benefit
Vitamin C Placebo (95% CI)
________________________________________________________________________________________________
Males
Charleston-1972 15 2/24 (8%) 17/30 (57%) 48% (27%, 69%) 0.000,1
Baird-1979 10 21/133 (16%) 23/61 (38%) 22% (8%, 35%) 0.000,6
Tyrrell-1977 16 23/351 (7%) 43/392 (11%) 4.4% (0.4%, 9%) 0.018
Clegg-1975 14 18/89 (20%) 9/47 (19%) -1% (-15%, 13%) 0.5
Females
Clegg-1975 14 8/52 (15%) 10/23 (43%) 28% (6%, 51%) 0.007
Charleston-1972 15 10/23 (43%) 9/13 (69%) 25% (-7%, 58%) 0.08
Tyrrell-1977 16 26/373 (7%) 29/385 (8%) 1% (-3%, 4%) 0.4
Elwood-1976 14 196/339 (58%) 201/349 (58%) 0% (-7%, 7%) 0.5
Baird-1979 10 19/105 (18%) 7/51 (14%) -4% (-16%, 8%) 0.7
Both genders
van Straten-2002 9 2/84 (2%) 16/84 (19%) 17% (8%, 26%) 0.000,2
27 men, 141 women
________________________________________________________________________________________________
1 One-tailed mid-P. The CI was calculated using the CIA (confidence interval analysis, BMJ) program.
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Other findings from the controlled trials
on vitamin C
Common cold severity and duration
High dose vitamin C supplementation administered regu-
larly throughout the trial period has consistently reduced
common cold severity and duration (Hemilä 1990a,b, 1992a,
1994a, 1995a, 1996a, 1997a,b, 1999a,b, 2003a). The prac-
tical importance of this effect is, however, unsettled. Cer-
tain subgroup differences have been identified when com-
paring different trials and subgroups within individual tri-
als (Hemilä 1997a, 1999a; Table 13).
In the published trials, there is a trend for trials with chil-
dren to reveal greater benefit than adult trials (Hemilä
1999a). In 18 trials with adults administered ≥0.2 g/day of
vitamin C regularly over the trial, the duration of colds was
reduced by 8.0% (95% CI: 3.0% to 13.1%) in the vitamin C
groups, whereas in 12 trials with children administered ≥0.2
g/day of vitamin C regularly over the trial, the duration of
colds was reduced by 13.6% (5.6% to 21.6%) (Douglas,
Hemilä, et al. 2004; Douglas & Hemilä 2005).
There is also a trend for trials with ≥2 g/day of vitamin C
to yield a greater benefit than those with 1 g/day supple-
mentation (Hemilä 1999a), and dose-dependency was also
seen in two trials (Coulehan et al. 1974, Karlowski et al.
1975; see Hemilä 1999a). Assuming dose-dependency, the
effect of the same dose should be greater in children than
adults, because children weigh on average substantially less.
Comparison of adult trials with exactly 1 g/day of vitamin
C with child trials with exactly 2 g/day of vitamin C reveals
a big difference in the point estimates of the benefit (Table
23). The two trials with children are small and the confi-
dence interval of the pooled estimate wide, but this com-
parison would seem to warrant further study of children in
particular.
The great majority of published trials have examined the
effect of regular vitamin C supplementation. However, if
the main effect of vitamin C is the alleviation of cold symp-
toms, it would appear more reasonable to administer vita-
min C therapeutically, starting immediately after the first
symptoms. However, only a few therapeutic trials have been
carried out and they have substantial variations in their set-
tings which hampers their interpretation (Hemilä 1999a).
Elwood et al. (1977) and Tyrrell et al. (1977) administered
3-4 g/day of vitamin C for only 3 days (total 10 g in both)
when the participants contracted colds, and Audera et al.
(2001) administered 1 or 3 g/day of vitamin C for 3 days
(total 3 or 9 g). These 3 trials found no benefit on common
cold duration with vitamin C, but Tyrrell et al. did find an
unexpected reduction in the number of men with recurrent
colds (Table 22). On the basis of the consistent benefit in
regular supplementation trials (e.g., Fig. 3; Table 23), we
may hypothesize that the duration of supplementation might
be an important variable modifying the effect of vitamin C
supplementation. A 5-day therapeutic trial by Anderson et
al. (1975) found a reduction in ‘days spent indoors per sub-
ject’ because of illness by 25% (P = 0.024; vitamin C 1.20
days [SD 1.78], placebo 1.61 days [SD 2.46]) among the
vitamin C participants (1-1.5 g/day). Using 5-day therapeu-
tic supplementation of 3 g/day of vitamin C, Karlowski et
al. (1975) found that colds were 0.73 days (10%) shorter
(P = 0.05; Paper I). These two therapeutic trials with 5-day
supplementation are thus consistent with the possibility that
3 days might be too short a time for vitamin C to produce
unambiguous benefits, and further therapeutic trials should
obviously use longer than 3-day supplementation.
Furthermore, it is possible that the rapidity of initiation
of vitamin C supplementation may affect the effect. Asfora
(1977) gave the same subjects either vitamin C (6 g/day for
5 days) or other medications (aspirin, etc.) during different
common cold episodes, but not in a double-blind fashion.
When treatment started within 24 hours of the onset of symp-
toms, the mean duration of vitamin C treated colds was 3.6
days, whereas the duration was 6.9 days with the other medi-
cations (-48%; t(88 df)=3.5; P = 0.000,4). However, if vita-
min C supplementation was initiated later than 24 hours
from the onset of symptoms, there was no meaningful ben-
efit. A similar effect by time of supplement initiation was
reported by Terezhalmy et al. (1978) when treating herpes
labialis with a combination of vitamin C and bioflavonoids
(see pp 15-6). Evidently, further therapeutic trials should
use rapid initiation of supplementation.
Common cold incidence
Although vitamin C has not shown any consistent effect on
the common cold incidence (II; Fig. 3), there are findings
indicating that it may have preventive effects on the com-
mon cold in particular conditions or among restricted groups
of people.
It seems that people under heavy acute physical stress
may find benefit with prophylactic vitamin C supplementa-
tion (Hemilä & Antila 1993a; Hemilä 1996b). Combining
the results of 3 short-term randomized placebo-controlled
trials with marathon runners (Peters et al. 1993), Canadian
soldiers in short-term winter exercises (Sabiston &
Radomski 1975), and school-children in a skiing camp in
the Swiss Alps (Ritzel 1961) yielded a pooled RR = 0.50
(95% CI 0.35-0.69; P = 0.000,03) lower incidence of colds
in vitamin C groups than the placebo groups (Hemilä 1996b).
Following Thomas Chalmers’ concept of cumulative meta-
analysis (p 32), 3 newer trials with marathon runners (Pe-
ters et al. 1996; Moolla 1996; Himmelstein 1998) were
added to the 1996 meta-analysis of physically stressed sub-
jects. The estimated effect did not change, but the confi-
dence interval became slightly narrower, and the correspond-
ing P-value somewhat smaller: RR = 0.50 (95% CI: 0.38-
0.66; P = 0.000,000,3) (Douglas, Hemilä, et al. 2004; Doug-
las & Hemilä 2005; graph on the cover). Thus 6 studies
with participants under heavy acute physical stress with or
without a cold environment have shown substantial reduc-
tion in common cold incidence but most of the trials were
carried out with marathon runners and the finding should
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therefore be extrapolated with great caution. In any case,
these findings definitely warrant further study with physi-
cally stressed subjects.
Staying free of illness during the study period is also an
important measure of preventive effect. Anderson et al.
(1972) found about 8% increase in the proportion of par-
ticipants who were ‘not ill during the trial’, ‘not confined to
the house’, and ‘not off work’ in the vitamin C group (Ta-
ble 20). Accordingly, about 1 participant in 12 benefited
from vitamin C supplementation in this particular setting
(NNT = 12). It is noteworthy, however, that participants in
this Canadian trial were asked not to enroll to the trial un-
less they normally experienced at least one cold in the win-
tertime, and in this respect the subjects do not represent the
average population.
Coulehan et al. (1974) studied Navajo schoolchildren and
found a 16% higher proportion of children in the vitamin C
group who were ‘never ill on active surveillance’ by a medi-
cally trained clerk or the school nurse (Table 20). This indi-
cates that about 1 of 6 schoolchildren benefited from vita-
min C in this particular setting (NNT = 6).
Although the Anderson et al. (1972) and Coulehan et al.
(1974) trials found statistically significant prophylactic ben-
efit from regular ≥1 g/day vitamin C, it is not apparent how
these two trials should be considered in the wider context.
When a large number of trials are carried out, some find sta-
tistically significant differences purely by chance. However,
only 8 common cold trials have been carried out with ≥400
participants administered ≥1 g/day vitamin C regularly (Fig.
3; Hemilä 1992a) and in this respect the P-values calculated
in Table 20 are not easily explained by the multiple compari-
son problem. Although these two trials support the notion
that limited sub-populations might benefit from regular vita-
min C supplementation, the proportions of 8% and 16% can-
not be directly extrapolated to any other populations. They
would, however, seem to justify further study.
Vitamin C and respiratory infections other than
the common cold
Tuberculosis
Two old studies of young and middle aged African Ameri-
cans in the USA reported a lower incidence of tuberculosis
in subjects with a higher intake of vitamin C (Table 24). In
a controlled trial, Downes (1950) administered other nutri-
ents along with vitamin C, and any effects may be explained
by the other nutrients. In a cohort study, Getz et al. (1951)
correlated tuberculosis incidence with plasma vitamin C
level, but any association with dietary intake could be caused
by other dietary or non-dietary factors associated with vita-
min C intake levels.
Pneumonia
Three controlled trials reported the number of pneumonia
cases among participants on vitamin C supplementation
(Table 25). Each of these 3 trials reported at least an 80%
lower incidence of pneumonia in the vitamin C group, the
difference being statistically significant in each case. The
combined test leads to a very small P-value. The latest of
these trials was a randomized double-blind placebo-con-
trolled trial with Marine recruits in the USA (Pitt & Costrini
Table 24. Vitamin C intake and the incidence of tuberculosis
_______________________________________________________________________________________________
      Cases / Total
_______________
      Vitamin C
Difference
Study High Low    in incidence    P 1
_______________________________________________________________________________________________
Downes-1950 1/644 10/1096  -83% 0.026
Controlled trial
Vitamin C dose 0.02-0.37 g/d
other vitamins also
Getz-1951 0/117 27/896  -100% 0.017
Observational study
Plasma vitamin C limit
34 µmol/l (6 mg/l)
_______________________________________________________________________________________________
1 One-tailed mid-P
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1979), whereas placebo was not used by Kimbarowski and
Mokrow (1967). Glazebrook and Thomson (1942) carried
out a large-scale trial with male students (15-20 years) in a
boarding school in Scotland. No placebo was used; how-
ever, vitamin C was added to the food in the kitchen, so that
the placebo effect does not seem a relevant concern. Fur-
thermore, a recent meta-analysis found that placebo was
powerless in studies measuring binary outcomes
(Hrobjartsson & Gøtzsche 2001, 2004), and it would seem
highly unlikely that a placebo would cause a substantial
effect on such a hard outcome as pneumonia.
Since dietary vitamin C intake was low in the 2 older
trials, the benefit of higher vitamin C intake might be ex-
plained by correction of marginal deficiency. However, in
the Pitt and Costrini trial (1979) the dietary vitamin C in-
take was quite high. It is worth noting that 2 of these trials
used military recruits (Pitt & Costrini 1979; Kimbarowski
& Mokrow 1967), and the third used young males who were
accommodated in crowded lodgings (Glazebrook &
Thomson 1942). In each of the 3 trials, the incidence of
pneumonia was very high (Table 25) when compared, for
example, with the incidence of hospital-treated pneumonia
in the ATBC Study cohort, which was about 5 cases per
1,000 person years (Paper V), so that it seems obvious that
the findings in these 3 trials cannot be extrapolated to the
general population. In any case, the studies in Table 25 jus-
tify examination of the role of vitamin C on people with
high physical stress and/or who live in crowded accommo-
dation (Hemilä 2004).
Table 25. Vitamin C supplementation and the incidence of pneumonia
_______________________________________________________________________________________________
      Pneumonia Pneumonia
      Cases / Total incidence
__________________ in the control
group
Vitamin C Vitamin C Control Difference (1/1000
Trial dose (g/d)   group  group in incidence  P 1 person years)
_______________________________________________________________________________________________
Glazebrook-1942 0.05-0.3 0/335 17/1100   -100% 0.006  30
Pitt-1979 2 1/331  7/343    -85% 0.022 120
Kimbarowski-1967 0.3 2/114 10/112    -80% 0.009 9% of the
   patients
_______________________________________________________________________________________________
Combined test for all three sets of data: mid-P[1-t] = 0.000,02 (Hemilä 1997c).
This table is reproduced from Hemilä (1997c) Pediatric Infectious Disease Journal 16:836-7 with permission,
except that the incidence of pneumonia in the control group was added to this table.
1 One-tailed mid-P
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B) Analyses of the ATBC Study
Participants and Methods
Participants
The rationale of the design and methods of the ATBC Study
examining the effects of α-tocopherol (AT, 50 mg/day) and
β-carotene (BC, 20 mg/day) on the incidence of lung and
other cancers has been described in detail (Virtamo et al.
1987; ATBC 1994a,b). In brief, the trial participants were
recruited from the total male population aged 50-69 years
living in Southwestern Finland, starting in 1985. To be eli-
gible, participants had to smoke ≥5 cigarettes per day at
entry. The eligible participants in the trial (N = 29,133) were
randomized to one of four intervention arms and adminis-
tered a placebo, AT, BC, or AT+BC, using a 2x2 factorial
design. The active intervention continued for 5 to 8 years
(median 6.1 years) until April 30, 1993.
Baseline data and dietary assessment
At baseline prior to randomization the men completed ques-
tionnaires on their general background characteristics, in-
cluding medical and smoking histories, and various social
characteristics. At the first baseline visit, the participants
were given a separate, detailed dietary history questionnaire
for completion at home (Pietinen et al. 1988), and the ques-
tionnaire was returned at the second visit two weeks later.
The questionnaire included a colour picture booklet and
questions about portion sizes for 276 common foods and
mixed dishes and the usual frequency of their consumption
over the previous year. Data from this questionnaire was
used to calculate the dietary intake of vitamin C, vitamin E
and other relevant nutrients (Ovaskainen et al. 1996).
 The validity of the dietary history questionnaire was
assessed by comparing it with food consumption records of
190 participants for 12 separate 2-day periods distributed
evenly over a period of 6 months. To evaluate the degree of
similarity between the results of these two methods, the nu-
trient intake distributions were divided into quintiles
(Pietinen et al. 1988). Classified by the dietary history ques-
tionnaire, 74-76% of participants classified by food con-
sumption records fell into the same vitamin C intake quintile
or into the within-one-quintile category. Among participants
who belonged to the lowest vitamin C quintile using the
dietary history questionnaire, 46-54% fell into the lowest
quintile and 77-79% into the lowest two quintiles, whereas
only 3-6% fell into the highest quintile when categorized
on the basis of the food consumption record.
Outcomes of the ATBC Study analyses
There were 3 follow-up visits annually in the ATBC Study,
at each of which the participants were asked about the
number of common cold episodes since the preceding fol-
low-up visit (III). The occurrence of tuberculosis (IV) and
pneumonia (V) among the ATBC Study participants was
identified in the National Hospital Discharge Register
(Keskimäki & Aro 1991). The outcomes are described in
detail in the original Papers (III-V).
Statistical methods
The statistical methods used in the original Papers (III-V)
are described in detail in the papers and are not reiterated
here. One-tailed P-values are mostly used in the analyses of
studies in this text, since the particular questions in the
present thesis are whether higher vitamin C intake in the
diet or vitamin E supplementation decreases the incidence
or severity of infections or not, and these questions are uni-
directional. Where pertinent, the 2-tailed P-value is shown,
and in such a case the 2-tails are mentioned (P[2-t]). If the
1-tailed P-value is higher than about 0.98, there is reason to
assume harm in the treatment group of the particular study.
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Paper III: The common cold
in the ATBC Study cohort
The meta-analysis of the trials with UK males found a sta-
tistically significant reduction in common cold incidence
with vitamin C supplementation, and it was hypothesized
that this effect is explained by the particularly low dietary
vitamin C intake in the UK (Paper II).
To test the hypothesis that low dietary vitamin C intake
increases the incidence of colds, the relation between com-
mon cold incidence and vitamin C intake was analyzed in
the ATBC Study participants, all of whom were male smok-
ers aged 50 to 69 years at baseline. The analysis of the role
of vitamin C intake was restricted to the placebo arm to
avoid any possible modifications by vitamin E and β-caro-
tene supplementation. The cumulative common cold inci-
dence over 4 years was used as the outcome. On average,
there were 0.8 self-reported colds per person-year during
the 4-year follow-up.
Low vitamin C intake was not associated with an in-
creased incidence of colds; in fact, the incidence was slightly
lower than for participants with high vitamin C intake. Simi-
larly, the incidence of colds was slightly lower among par-
ticipants with low dietary intake of vitamin E, and partici-
pants with low intake of fruit and vegetables.
In the ATBC Study, no overall effect on the common cold
incidence was caused by vitamin E supplementation (RR =
0.99; 95% CI: 0.98-1.01). Nevertheless, in subgroup analy-
sis, vitamin E supplementation was associated with a mar-
ginally significant reduction in common cold incidence in
participants aged ≥65 years (RR = 0.95; 0.90-1.00), but had
no effect on the younger participants (RR = 1.00; 0.98-1.01).
Exploratory analyses among participants aged ≥65 re-
vealed that smoking and residential neighborhood both
modified the effect of vitamin E. Combining these two fac-
tors revealed that vitamin E had no effect in the group of
elderly participants who lived out of cities and/or smoked
≥15 cigarettes per day (RR = 0.99; 0.94-1.05), but among
city-dwellers who smoked 5-14 cigarettes per day (n = 261)
the risk of colds was reduced by vitamin E supplementation
(RR = 0.72; 0.62-0.83; P = 0.000,003).
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Paper IV: Tuberculosis
in the ATBC Study cohort
Two studies reported a lower incidence of tuberculosis in a
group with higher vitamin C intake level (Table 24) and
several studies with guinea pigs found that vitamin C was
beneficial against tuberculosis (Appendices 2 and 3), which
prompted research on whether dietary vitamin C intake is
associated with the incidence of tuberculosis. The occur-
rence of hospital-treated tuberculosis among the ATBC
Study participants was retrieved from the National Hospi-
tal Discharge Register, restricted to participants with base-
line dietary data (167 cases).
In a crude analysis, a statistically highly significant in-
verse association between dietary vitamin C intake and the
incidence of tuberculosis was found (P = 0.003), but after
adjusting for age and smoking, which are often the only
confounders adjusted for in epidemiological studies, the as-
sociation became weaker but remained statistically signifi-
cant (P = 0.01). However, the association became non-sig-
nificant when body mass index, residential neighborhood
and marital status were also added to the statistical model
(P = 0.1). However, the point estimate of tuberculosis risk
still remained 30% lower in the highest vitamin C intake
quartile group compared with the lowest.
The remaining association between vitamin C and tu-
berculosis might be explained by residual confounding, but
another alternative is an actual biological effect, so that the
small number of cases would render the estimate inaccu-
rate and non-significant. Therefore, further analyses were
carried out to explore whether vitamin C intake could be
more explicitly rejected as a cause of the 30% lower risk of
tuberculosis in the high vitamin C intake group.
Fruit, vegetables and berries were the main source of vi-
tamin C in the ATBC Study participants and the sum of
their intake was calculated for further analysis (henceforth
FRUVEBE). Dietary vitamin C intake and FRUVEBE are
highly correlated (r = 0.9). The risk of tuberculosis was de-
creased with increasing FRUVEBE and this association re-
mained statistically significant after adjusting for all avail-
able confounders (P = 0.01).
To determine whether the weak association between vita-
min C and tuberculosis could be explained as a statistical
artifact arising from other substances in fruit, vegetables and
berries, FRUVEBE was modeled by linear regression as a
function of dietary vitamin C, and the residuals of FRUVEBE
were calculated (FRUVEBE-RES). As designed, the
FRUVEBE-RES has no correlation with dietary vitamin C
intake, so that it can be used to determine whether there are
vitamin C independent effects on tuberculosis caused by fruit,
vegetables and berries. FRUVEBE-RES had a significant as-
sociation with tuberculosis risk when adjusted for all avail-
able confounders (P = 0.002), i.e., even stronger than
FRUVEBE, indicating that the effect of FRUVEBE on tu-
berculosis risk is caused by substances other than vitamin C.
Table 26 shows the risk of tuberculosis in vitamin C quar-
tiles stratified by the median of FRUVEBE-RES. Variation
in vitamin C intake has no association with tuberculosis risk
in participants who consumed fruit, vegetables and berries
rich in vitamin C (residual below median) which means a
smaller than average amount of other substances of fruit,
vegetables, and berries. Within the two highest vitamin C
quartiles, tuberculosis risk was less than half in participants
who consumed fruit, vegetables and berries poor in vitamin
C (residual above median), compared with participants who
consumed fruit, vegetables and berries rich in vitamin C
(residual below median). This stratified analysis provides
strong evidence against vitamin C as the substance in fruit,
vegetables, and berries that affects the tuberculosis risk of
the ATBC Study participants.
The vitamin E arm of the ATBC Study had a slightly
higher incidence of tuberculosis (RR = 1.23; 95% CI: 0.80-
1.90) than the placebo arm.
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Table 26. Relative risk of tuberculosis by vitamin C intake and by the residual of fruit, vegetable and berry
consumption, the ATBC Study
______________________________________________________________________________________________
Vitamin C intake quartile
____________________________________________
Vitamin C in diet 1. 2. 3. 4. Test for
 (mg/d) vitamin C
 Range: 5-65 66-89 90-120 121-534 trend 1
 Median: 52 78 103 148 P[1-t]
______________________________________________________________________________________________
HIGH residual group
[vitamin C poor food]
Cases of tuberculosis 27 20 11  8
Adjusted RR 1 1.09 0.90 0.52 0.41 0.002
95% CI 0.64-1.86 0.50-1.60 0.26-1.05 0.18-0.90
Fruit, vegetable, berry
median (g/d) 110 190 260 390
________________
LOW residual group
[vitamin C rich food]
Cases of tuberculosis 27 24 29 21
Adjusted RR 1 1.00 1.00 1.31 1.03 0.7
95% CI ref. 0.58-1.75 0.77-2.22 0.58-1.84
Fruit, vegetable, berry
median (g/d) 60 120 180 280
_________________ _______________________________________________
Comparison between
HIGH and LOW groups
Adjusted RR 1 1.06 0.90 0.39 0.43
95% CI 0.62-1.82 0.49-1.63 0.19-0.79 0.18-0.97
______________________________________________________________________________________________
Participants (N = 26,975) were divided by the median of FRUVEBE-RES (-2.62 g/day) into those with high residual intake (HIGH) and low
residual intake (LOW). The total number of tuberculosis cases in this cohort was 167.
1 The RR and CI were calculated using the proportional hazards regression model adjusting for age, smoking, BMI, marital status, and residential
neighbourhood (see Paper IV). The test for trend was carried out for square root transformed vitamin C intake.
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Paper V: Pneumonia
in the ATBC Study cohort
In three controlled trials, vitamin C supplementation reduced
the incidence of pneumonia (Table 25). Vitamin C and vita-
min E are both antioxidants and appear to have a physi-
ological interaction (see pp 10-1), which prompted investi-
gation of the effect of vitamin E supplementation on the
risk of pneumonia in the ATBC Study cohort. Several ani-
mal studies also found that vitamin E affects the risk of res-
piratory infection (Appendix 4). The first occurrence of hos-
pital-treated pneumonia of the ATBC Study participants was
retrieved from the National Hospital Discharge Register (898
cases).
Vitamin E supplementation had no overall effect on the
incidence of pneumonia (RR = 1.00; 95% CI: 0.88-1.15).
Nevertheless, the age of smoking initiation was a highly
significant modifying factor for vitamin E supplementation.
Vitamin E decreased the risk of pneumonia (RR = 0.65;
0.49-0.87; P = 0.002) among participants who had initiated
smoking at a later age (at ≥21 years; N = 7,469 with 196
cases of pneumonia).
Further exploratory subgroup analyses of supplementary
vitamin E effects were carried out among participants who
initiated smoking at a later age to find out whether other
factors might modify the vitamin E effect within this sub-
group. Vitamin E had a greater effect on participants who
smoked less than a packet of cigarettes per day at baseline
(RR = 0.47; 0.30-0.73; P = 0.000,4) than on participants
smoking more (RR = 0.85; 0.57-1.25). The recent smoking
history just prior to the occurrence of pneumonia was also
analyzed in relation to the effect of vitamin E supplementa-
tion. Among participants who had quit smoking, the occur-
rence of pneumonia was significantly lower in the vitamin
E group than the no-vitamin E group (OR = 0.21; 0.07-
0.60; P = 0.002), whereas among participants who contin-
ued smoking prior to pneumonia, the vitamin E group did
not differ from the no-vitamin E group (OR = 0.80; CI: 0.53-
1.19).
Since vitamin E has been thought to protect against
oxidative stress caused by heavy exercise, we analyzed its
effect among participants who had a heavy or moderately
heavy job, and among participants who were carrying out
heavy or moderate exercise during their leisure. In the ATBC
Study participants, vitamin E supplementation had no ef-
fect on pneumonia incidence among participants with mod-
erate or heavy physical activity on the job (RR = 1.28; 0.78-
2.10). However, among participants with moderate or heavy
exercise during leisure, vitamin E reduced the risk of pneu-
monia by half (Table 27). Since these findings in differ-
ently defined physical activity groups appear discordant,
we determined whether the kind of job might modify the
vitamin E effect among participants carrying out leisure time
exercise. We found a significant interaction between physi-
cal activity on job and during leisure (Table 27). Vitamin E
supplementation affected the risk of pneumonia among those
participants who had a light or very light job, whereas it
had no effect among those who had a heavy or moderately
heavy job. Its effect was also modified by baseline age and
age of smoking initiation. While the number of cases is quite
small and these modifications should be considered cau-
tiously, these potential modifications should be contemplated
if further study is carried out on the role of vitamin E on
physically stressed subjects.
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Table 27. Relative risk of hospital-treated pneumonia by vitamin E supplementation in participants who did
moderate or heavy exercise during leisure, the ATBC Study, 3-year follow-up
________________________________________________________________________________________________
                        Intervention
_________________________________
  Vitamin E     No vitamin E
______________ ______________
No. of No. of Rate No. of Rate RR (95% CI) 1 Test for
subjects cases (1/1,000 cases (1/1,000 interaction
Subgroup person- person- P[2-t]
years) years)
________________________________________________________________________________________________
All in the group 9,570 22 1.5 43 3.0 0.50 (0.30-0.84)
Physical activity on job
Light or very light 5,467   6 0.7 25 3.1 0.24 (0.10-0.59) 0.020
Moderate or heavy 4,103 16 2.6 18 3.0 0.86 (0.43-1.68)
Age at baseline (years)
<60 8,322 21 1.7 31 2.5 0.67 (0.38-1.17) 0.013
≥60 1,248 1 0.5 12 6.6 0.08 (0.01-0.61)
Age of smoking initiation
 (years)
≤20 6,839 19 1.9 25 2.5 0.76 (0.42-1.38) 0.013
≥21 2,729 3 0.7 18 4.5 0.16 (0.04-0.54)
Cigarettes (1/d)
5-19 3,321 6 1.2 17 3.4 0.35 (0.14-0.89) 0.3
≥20 6,247 16 1.7 26 2.8 0.60 (0.32-1.12)
Coffee (ml)
<300 1,071 7 4.4 8 5.0 0.88 (0.31-2.41) 0.2
≥300 7,927 14 1.2 33 2.8 0.42 (0.22-0.78)
Vitamin E in diet (mg/d)
<11.4 (median) 4,500 13 1.9 24 3.6 0.53 (0.27-1.04) 0.8
≥11.4 4,498 8 1.2 17 2.5 0.47 (0.20-1.08)
Vitamin C in diet (mg/d)
<99.2 (median) 4,500 11 1.6 24 3.6 0.45 (0.22-0.91) 0.6
≥99.2 4,498 10 1.5 17 2.5 0.58 (0.26-1.27)
Marital status
Married 8,149 16 1.3 32 2.7 0.49 (0.27-0.90) 0.8
Not married 1,421 6 2.8 11 5.2 0.54 (0.20-1.47)
Residential area
City (>50,000) 3,980 11 1.8 18 3.1 0.60 (0.28-1.27) 0.5
Small neighborhood 5,589 11 1.3 25 3.0 0.43 (0.21-0.88)
________________________________________________________________________________________________
1 Proportional hazards regression model comparing participants who received vitamin E with those who did not. No covariates were included in
the model. Data was missing for coffee consumption, vitamin C and E intake in diet (n = 572), age at smoking initiation (n = 2) and residential
area (n = 1).
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DISCUSSION
The effect of vitamin C on respiratory
infections
The role of vitamin C in infections was studied quite exten-
sively in the early twentieth century and studies with guinea
pigs led to extensive reviews indicating that vitamin C may
affect susceptibility to and severity of infections (Clausen
1934; Robertson 1934; Perla & Marmorston 1937). A
number of clinicians concluded that vitamin C deficiency
seemed to increase susceptibility to infections (e.g., Barlow
1894; Hess 1932; reviewed by Stone 1972; Briggs 1984;
Levy 2002). Although a few studies with human partici-
pants reported favorable results, there were various techni-
cal deficiencies in these studies. Nevertheless, the topic of
vitamin C and infections was not dismissed because of care-
fully conducted trials showing that vitamin C lacked any
effect on infections. Rather, there appear to be two major
reasons for the general disregard of the early studies. Anti-
biotics were introduced in the 1940s and, because of their
highly specific effects on microbes, they were obviously
much more practicable drugs for patients with infections
than vitamin C. A second reason for the rejection of the
topic apparently was the oversimplified notion that the physi-
ological purpose of vitamin C is just to prevent scurvy. Ap-
parently it was not reasonable to assume that a substance
that participates in the synthesis of connective tissue pro-
teins might affect infections. However, the biochemistry of
vitamin C is much more complex than basic textbooks sug-
gest. Although it is not a specific agent against any infec-
tion, it may have moderate effects on general resistance to
infection in human beings as indicated by the large number
of animal studies (Table 2 and Appendices 2 and 3).
In the 1970s, interest in vitamin C and infections, in par-
ticular the common cold, reappeared as an academic topic
largely because of Linus Pauling’s activity (Fig. 2). How-
ever, interest evaporated after the middle of the 1970s mainly
because of the influential reviews by Chalmers (1975) and
Dykes and Meier (1975), and the controlled trial by
Karlowski et al. (1975). The two reviews were however
erroneous, as detailed elsewhere in this text (see pp 36-45),
and the Karlowski et al. (1975) trial was inappropriately
analyzed (Paper I; see p 25).
Problems in planning and analyzing
the common cold trials
Although a large number of trials was published on the vi-
tamin C and common cold relationship, rather less under-
standing was generated compared with the time and effort
invested. Most of the literature related to vitamin C and the
common cold is the product of investigators with only a
transient interest in the topic.
Lack of carefully formulated questions has been a prob-
lem typical of the published trials. In most cases a group of
authors carried out a single trial without a proper look at
those already published. The major exceptions to this prob-
lem are Anderson, who carried out 3 large trials (Anderson
et al. 1972, 1974, 1975), and Clegg, who carried out 2 trials
(Charleston & Clegg 1972; Clegg & Macdonald 1975). Both
of these authors changed their settings on the basis of their
earlier trials. Coulehan et al. (1974, 1976) carried out 2 tri-
als, but the second does not consider the dose-response ten-
dency observed in the first.
In most cases the question in the trials has been oversim-
plified; whether Pauling was wrong or not, or whether vita-
min C has any effects on colds or not. When there already is
a large set of trials with conflicting results, it is difficult to
see that any single new trial could provide meaningful
progress without explicitly formulated questions based on
the older findings. Hypotheses could be generated to ex-
plain the older conflicting results and such hypotheses could
be tested in a new trial, but in most cases no such hypoth-
eses were formulated by the authors before initiating their
own trial. With the existence of a large set of published tri-
als, the meta-analytical approach, extensively used in this
thesis, may be useful.
The problem of planning individual trials is seen in sev-
eral aspects of the published trials. Pauling (1970a) sug-
gested that vitamin C would substantially reduce the inci-
dence of colds. The large-scale trial by Anderson et al.
(1972) showed that vitamin C had no meaningful preven-
tive effects in the general population, but did find a statisti-
cally highly significant reduction in common cold severity.
After such a finding it would appear reasonable to plan new
trials explicitly to test the possible therapeutic effect of vi-
tamin C. Essentially all of the later trials (see Hemilä 1992a,
1994a, 1999a; Douglas, Hemilä, et al. 2004), however, used
regular supplementation without any hypothesis about why
the subjects or experimental conditions in these new trials
might yield a different result on common cold incidence
compared with the Anderson trial (1972). Consequently,
there is a gross shortage of therapeutic trials.
A dose-response relation was observed in schoolchildren
by Coulehan et al. (1974), who reported that 2 g/day of
vitamin C shortened colds by 29%, whereas 1 g/day short-
ened colds by only 12%. Karlowski et al. (1975) found that
6 g/day was about twice as effective as 3 g/day (Table 8).
Although these two trials do not establish dose-dependency,
they should have justified further trials to investigate whether
there actually is dose-dependency in the high dose region.
Essentially all later trials, however, employed only a single
dose, in most cases only 1 g/day (Hemilä 1992a, 1999a).
Thus, here also many authors did not look at the previous
literature to formulate proper questions for their own trials.
Most of the vitamin C trials did not appropriately con-
sider the type of subject that might be meaningful. In this
respect, the Anderson (1972) trial is one of the positive ex-
ceptions, since Anderson selected subjects who had usually
at least one cold during winter. This kind of selection seems
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sound as the role of vitamin C appears to be quite small,
and there is no point in examining the effect of vitamin C
on people that usually have no problems with colds in win-
ter. It seems that most authors were simply enrolling sub-
jects who were easy to reach, rather than subjects for whom
there was a sound biological rationalization.
Thus, problems in planning and analysis of trials have
led to a considerable waste of man-years of work on the
subject of vitamin C and the common cold. Detailed de-
scription of the randomization method, double-blindness and
other technical features are no substitutes for a meaningful
biological question, even though the technical features are
relevant for the validity of the trial. However, some of the
recent trials are of limited use because of severe technical
deficiencies.
In one recent trial, the ‘control group’ data was collected
in 1990 with one group of students, whereas the ‘vitamin
C’ group data was collected in 1991 with a different group,
and, moreover, the protocols of data collection differed be-
tween 1990 and 1991 (Gorton & Jarvis 1999). Given the
variability of cold experience from year to year, the claim
by the authors that the observed differences were attribut-
able to vitamin C must be disputed.
Another recent trial (Himmelstein et al. 1998) started with
52 marathon runners in two groups, but 42% (22 of 52) of
the vitamin C group and 75% (38 of 52) of the placebo group
dropped out during the trial. With such an extreme and sig-
nificantly divergent drop-out rate (mid-P[2-t] = 0.002), and
such a small number of participants in the treatment groups,
it makes no sense to draw any conclusions from the differ-
ences in the incidence or severity of upper respiratory tract
infections between them, although the authors have done
so.
The conclusions of the Karlowski et al.
trial (1975)
The Karlowski et al. (1975) trial is by far the most influen-
tial of the trials on vitamin C and the common cold (Table
10). Karlowski et al. concluded that the apparent benefit of
vitamin C in their double-blind placebo-controlled trial was
explained, paradoxically, by the placebo effect. In this the-
sis it is shown that the ‘placebo effect’ explanation is in-
consistent with Karlowski’s own data (Paper I; see p 25).
The rejection of Karlowski’s ‘placebo explanation’ is im-
portant since it validates the use of Karlowski’s results in
the quantitative estimation of the effects of vitamin C.
Karlowski’s results are important in three particular respects.
First, the comparison of the therapeutic and prophylactic
methods of supplementation in the same trial provides an
estimate of their relative effects. From Karlowski’s results
it appears that with a fixed dose, proper therapeutic supple-
mentation can yield approximately as great a benefit as pro-
phylactic supplementation (I). Most of the published trials
have used regular supplementation, and Karlowski’s results
suggest that the effects of appropriate therapeutic supple-
mentation might be similar.
Second, Karlowski’s results suggest that there is linear
dose-dependency, even with high intakes of up to 6 g/day
(I; Table 8; Hemilä 1999a), and it seems possible that still
higher doses might produce even greater effects. The larg-
est dose (6 g/day) decreased the duration of colds by 17%
and crude linear extrapolation suggests that 18 g/day might
shorten common cold duration by half. Even though such a
crude extrapolation must be regarded cautiously, it is note-
worthy that this dose estimate is of the same magnitude as
the dosage proposed by a few physicians who used vitamin
C in the treatment of the common cold: Bee (1980) pro-
posed 10-15 g/day for treating colds, and Cathcart (1981;
Luberoff 1978) suggested that the optimum dose might be
over 30 g/day. Thus, it appears possible that the vitamin C
doses used in the common cold trials (highest doses 6 g/day
for adults and 2 g/day for children) have not been large
enough to reveal the maximum effects of supplementation.
Third, the observed effect is quite small in Karlowski’s
study when considering the fairly large doses used (up to 6
g/day) compared with the effect in several other trials with
smaller doses (Hemilä 1992a, 1999a). One possible expla-
nation of the relatively small benefit is the character of the
participants used in the Karlowski trial. Anderson et al.
(1972, 1975) found that vitamin C supplementation was
much more beneficial for subjects with a low daily intake
of fruit juice, which is a major source of vitamin C (Table
13). Participants in the Karlowski trial were NIH employ-
ees and it seems probable that such medically-aware peo-
ple have on average a much healthier diet than the general
population and eat more fruit and fruit juices. Thus,
Karlowski’s study with employees of the NIH may under-
estimate the potential benefits of similar vitamin C doses
for subjects with a diet which is more typical of the general
population or for subjects with a poor diet.
Karlowski et al. (1975) considered that the effect, even if
real, has no clinical importance, and concluded that "It does
not seem worthwhile to take two capsules or tablets three times
a day for the rest of one’s life to achieve such a small and
equivocal benefit." In this conclusion, they missed several
important findings in their own trial, which are discussed above.
First, they could have noted that three times a day during a
cold episode is much more feasible and much less expensive
than ‘three times a day for the rest of one’s life,’ and their own
results indicated that the effect of therapeutic supplementation
may be even greater than that of regular supplementation. Sec-
ond, as there was a linear dose-dependency in their own re-
sults, they could have noted that therapeutic doses larger than
6 g/day might have decreased the duration of episodes by over
17%. Third, since they cited the Anderson et al. paper (1972),
reporting that vitamin C supplementation is much more ben-
eficial for subjects with low fruit juice intake, they could have
noted that their own subjects were probably not the kind of
people that would derive the greatest benefit from vitamin C
supplementation. It would seem more relevant to ask what the
subgroups that would benefit most from vitamin C supplemen-
tation are, rather than to ask whether a fixed numerical value
found with NIH employees is great enough to validate regular
vitamin C supplementation for the general population.
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Published trials suggest that it would be worthwhile to
carry out further trials to assess the effects of large thera-
peutic vitamin C doses on the symptoms of the common
cold. Furthermore, the regular supplementation trials have
on average found a considerably greater benefit for chil-
dren than for adults, whereas none of the published thera-
peutic trials used children as subjects (Hemilä 1999a; Doug-
las, Hemilä, et al. 2004). Thus, it would seem worthwhile
to carry out well-planned therapeutic trials to obtain better
quantitative estimates of the optimum doses and maximum
therapeutic effects, and to better understand the potential
differences between various groups of people. Furthermore,
although a tablet is practical and the most common form of
administering vitamin C, it is worth noting that administer-
ing vitamin C powder directly into the nose has also been
suggested (Gotzsche 1989).
Findings from meta-analyses
Pauling (1970a, 1971a,b) concluded from earlier trials that
high-dose vitamin C supplementation would substantially
reduce the incidence of colds in the general Western popu-
lation; however, in this thesis it is shown that the 6 largest
trials suggest a firm rejection of Pauling’s hypothesis (Pa-
per II). Nevertheless, 2 of these large-scale trials found a
statistically significant but small reduction in the incidence
of throat and chest colds (Anderson et al. 1972; Elwood et
al. 1976). Furthermore, a few trials found a reduction in
common cold incidence in subjects under heavy acute physi-
cal stress during the trial period (Hemilä 1996b; Douglas &
Hemilä 2005; graph on the cover). It is also noteworthy that
in 2 trials 8% and 16% of participants remained free of ill-
ness because of vitamin C supplementation (Table 20) and,
in 2 other vitamin C trials, 6% and 29% of participants could
infer their treatment by subjective observations (Table 11).
Thus, it appears possible that regular vitamin C supplemen-
tation has beneficial effects in particular conditions and/or
among particular sub-populations.
People with low dietary intake of vitamin C might show
the most conspicuous effects of supplementation, assuming
that the level of vitamin C intake is important. Low levels
of vitamin C intake were observed in a number of British
surveys, indicating that the average intake was fairly low;
in this thesis the common cold studies carried out in the UK
were analyzed on the assumption that the vitamin C intake
in diet was low in all the UK trials (II).
Pooling the results of the UK trials with males yielded
an estimated 30% decrease in the number of common cold
episodes, and a 46% decrease in the number of males with
recurrent infections with vitamin C supplementation (II).
Nevertheless, these estimates should be interpreted as crude
approximations. If vitamin C intake does have an effect on
the incidence of colds, there is obviously no single estimate
for the effect that is generally applicable. For example, the
effect of supplementation obviously decreases with an in-
crease in the dietary vitamin C intake, and it is also possible
that there are other factors modifying the quantitative ef-
fects of vitamin C intake in a group of subjects. For exam-
ple, a substantial difference between the sexes was found in
the UK studies (II), although a recent trial found a signifi-
cant effect from vitamin C on recurrent colds in a popula-
tion consisting mainly of women (van Straten & Joslin 2002;
Table 22).
Meta-analysis of 3 controlled trials found a substantially
lower incidence of pneumonia in vitamin C supplementa-
tion groups than the control groups (Table 25; Hemilä
1997c). A recent cohort study found no association between
vitamin C intake and community-acquired pneumonia in
middle-aged men in the USA (Merchant et al. 2004). There
are, however, substantial differences in this cohort study
from the 3 trials of Table 25. Merchant et al. investigated
male US health professionals aged 40-75 years, a selection
which meant a population which has a much greater than
average interest in factors that affect health and whose work-
ing conditions are quite sedentary. In Merchant’s cohort,
the median vitamin C intake of the lowest quintile was 153
mg/day, whereas the overall median of the average US popu-
lation is about 100 mg/day (FNB 2000 pp 416-9). In con-
trast, of the 3 trials in Table 25, Glazebrook and Thomson
(1942) estimated that the diet of their participants contained
only 10-15 mg/day of vitamin C, and the Kimbarowski and
Mokrow trial (1967) was carried out with military recruits
in the former Soviet Union whose diet was apparently not
rich in vitamin C. Furthermore, 2 of the trials in Table 25
were composed of military recruits (Kimbarowski &
Mokrow 1967; Pitt & Costrini 1979), while the third inves-
tigated schoolboys in a boarding school (Glazebrook &
Thomson 1942). Thus the living conditions of these partici-
pants were quite different from middle aged US health pro-
fessionals. This divergence in social background is also seen
in the difference in the incidence of pneumonia. Merchant
et al. (2004) recorded 3 pneumonia cases per 1,000 person
years, which is close to that in the ATBC Study cohort with
5 cases per 1,000 person years. In contrast, Glazebrook and
Thomson (1942) and Pitt and Costrini (1979) recorded 30
and 120 pneumonia cases per 1,000 person years in their
control groups respectively, i.e., 10-40 times higher inci-
dence than in Merchant’s cohort. Thus, even though the
Merchant et al. (2004) cohort study suggests that the level
of vitamin C intake does not affect the risk of pneumonia in
sedentary middle aged populations when the intake range
starts from some 150 mg/day, the findings cannot be ex-
trapolated to substantially different population groups.
It is noteworthy that heavy physical stress is a prominent
feature of 2 of the military recruit trials that found some
benefit from vitamin C on pneumonia (Table 25; Hemilä
1997c), a feature apparent in a subgroup of trials that ob-
served a reduction of common cold incidence with vitamin
C supplementation (Hemilä 1996b; Douglas, Hemilä, et al.
2004; Douglas & Hemilä 2005; graph on the cover). Thus,
it would seem worthwhile to research the possible preven-
tive role of vitamin C against pneumonia in more detail; for
example, among military recruits who have a high rate of
pneumonia (Hemilä 2004).
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Findings from the ATBC Study analyses
The relationship between dietary vitamin C intake and the
common cold incidence was analyzed in the ATBC Study
cohort (Paper III), motivated by the positive findings in the
UK trials on the common cold in men, and on the interpre-
tation that the benefit in those trials is explained by low
dietary vitamin C intake. Low vitamin C intake was not
associated with a greater risk of colds, but with a slightly
lower risk. This association in an unanticipated direction
may be explained by residual confounding by life-style vari-
ables as it seems unlikely that such an association might be
explained by the actual biological effects of low vitamin C
intake. Nevertheless, it is noteworthy that the participants
in the 4 UK male trials included in the meta-analysis were
schoolchildren or students (II), whereas all participants in
the ATBC Study were ≥50 years old (III). Thus, it remains
a possibility that low vitamin C intake might affect suscep-
tibility to the common cold only in younger people, or that
there may be other reasons that explain the possible benefit
of vitamin C supplementation among the UK males.
Another recent smaller cohort study also found no asso-
ciation between dietary vitamin C intake and common cold
incidence (Takkouche et al. 2002).
A series of studies with guinea pigs found that pure vita-
min C, and fruit and vegetables as a source of vitamin C,
affected the risk of tuberculosis (Appendices 2 and 3). Two
older studies of young and middle-aged African Americans
reported a lower incidence of tuberculosis among participants
with higher vitamin C intake levels, but the comparison is
not specific to vitamin C (Table 24). In the ATBC Study par-
ticipants, vitamin C intake had a statistically highly signifi-
cant association with the risk of tuberculosis in an unadjusted
analysis, but adding all available confounders rendered the
association non-significant (IV). Furthermore, it was shown
that the association between vitamin C intake and the risk of
tuberculosis was only a statistical artifact caused by the strong
correlation between vitamin C intake and the total fruit, veg-
etable, and berry intake. The importance of vitamin C intake
as a risk factor for tuberculosis was thereby rejected in the
ATBC Study cohort, but since the role of vitamin C may vary
between populations, this negative result should not be di-
rectly extrapolated to populations that substantially differ from
the ATBC Study participants.
The presence of substances other than vitamin C in fruit,
vegetables, and berries that may reduce the risk of tubercu-
losis by some 60% is interesting, but the identity of the
substance(s) is unknown. This finding of the ATBC Study
cohort may indicate that the benefits found in the animal
studies of Appendix 3 may at least partly be caused by sub-
stances other than vitamin C in fruit and vegetables.
Fundamental concepts on the health effects
of vitamin C
As to ascorbic acid, right from the beginning I felt that
the medical profession misled the public. If you don't take
ascorbic acid with your food you get scurvy, so the
medical profession said that if you don't get scurvy you
are all right. I think that this is a very grave error.
Scurvy is not the first sign of the deficiency but a premortal
syndrome, and for full health you need much more, very
much more. I am taking, myself, about 1 g/day. This does
not mean that this is really the optimum dose because we
do not know what full health really means and how much
ascorbic acid you need for it. What I can tell you is that
one can take any amount of ascorbic acid without the least
danger.
Albert Szent-Györgyi
(cited by Pauling 1976a, 1986a)
Scurvy is a definite clinical end point, and preventing
scurvy was the basis of the US RDA nutritional recommen-
dations for vitamin C from the 1940s until the 10th edition
(FNB 1989a, 1994a). Approximately 10 mg/day of vitamin
C prevents overt symptoms of scurvy, and the RDA of the
10th edition was arbitrarily set at 60 mg/day to ‘provide an
adequate margin of safety’ against scurvy (FNB 1989a
p 118). "This level of intake will prevent signs of scurvy for
at least 4 weeks" in the fictional condition that a person
completely stopped getting vitamin C.
Scurvy is an acute severe disease resulting from particu-
larly low vitamin C intake but the lack of a frank deficiency
per se does not necessarily reflect optimal metabolism. Thus,
while the goal of the early RDA was to protect against overt
scurvy, the goal could be to obtain optimal amounts of nu-
trients (Bourne 1949; Pauling 1968, 1970b, 1974; Hughes
1981; Hemilä 1984, 1985, 1986, 1987, 1989, 1990c, 1991;
Levine 1986; Levine et al. 1995; Ginter 1989; Eaton et al.
1996). There were no studies described in the RDA recom-
mendations which would suggest that 60 mg/day is any better
than 10 mg/day as regards any health status outcome in the
long term (FNB 1989a pp 115-24). In the 10th edition of
the RDA, this lack of concern with optimal intakes was ex-
plicitly recognized: "RDAs are not necessarily optimal lev-
els of intake" (FNB 1989a p 8).
In the 10th edition (FNB 1989a p 1) the "RDAs are de-
fined as the levels of intake of essential nutrients that … are
… adequate to meet the nutrient needs of practically all
healthy persons." However, ‘nutrient need’ is a vague con-
cept and was not defined in any more detail in the RDA
recommendations. The concept of ‘nutrient need’ gives the
false impression that exact amounts of vitamins are required
daily, so that larger amounts could not have any active physi-
ological effects, simply providing passive reserves, such that
60 mg/day of vitamin C would only cause ‘reserves’ large
enough to prevent signs of scurvy for 4 weeks. Such rea-
soning clearly demonstrates the lack of consideration of the
principles of biochemical reaction kinetics, as the rates of
biochemical reactions change smoothly with increasing
concentrations. The physiological purpose of vitamin C is
not to be ‘in reserve against scurvy’ but to participate in
chemical reactions in the body, and the rates of these reac-
tions depend on concentrations, which depend on the levels
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of intake. Consequently, an exact level of ‘nutrient need’
sharply distinguishing a frank deficiency from ‘normal
health’ is not a sound concept (Hemilä 1984, 1985, 1991).
Furthermore, mathematical modeling of nutrient dose-
response relationships in animals does not identify any pa-
rameter with ‘nutrient need’, the dose-response relations fol-
lowing the saturation type of functions (Morgan et al. 1975;
Schulz 1987, 1991), as expected on biochemical grounds
(Pauling 1968). In contrast to the ‘nutrient need,’ the con-
cept of ‘optimal intake’ seems to be consistent with bio-
chemical knowledge (Pauling 1968; Hemilä 1984, 1985,
1986, 1987, 1991).
Some early authors on vitamin C and infectious diseases
commented on the question of optimal intake. King (1936)
commented that "The fact that there is a wide zone of vita-
min deficiency between scurvy and optimum health is of
more interest in relation to human health than the problem
of clinical scurvy," and from his own study on the effects of
vitamin C on diphtheria toxin on guinea pigs he concluded
that "It is evident from the data presented that the level of
vitamin C intake for optimum in vivo detoxification of diph-
theria toxin is considerably greater than that necessary to
protect from scurvy or to show a favorable growth rate"
(Sigal & King 1937; p 109). Perla (1937) and Perla and
Marmorston (1937 p 686) asked: "Is one certain of the opti-
mal vitamin requirements? Can the criteria of growth, pro-
gressive increase in weight and absence of clinical evidences
of deficiency be accepted as adequate? Is it not possible
that all these may be present and still, under a given stress,
such as invasion with micro-organisms or injections of poi-
sons, the apparent optimal amounts do not prove to be so?"
With the disappearance of deficiency diseases as a serious
problem in the Western countries, and the increasing interest
in the role of nutrition in affecting chronic diseases (FNB
1994a,b; Lachance & Langseth 1994), "A new paradigm for
determining RDAs was indicated" (King 1996). After the 10th
edition of the RDA, the approach of the nutritional recom-
mendations was extensively revised. In the most recent US
recommendations (FNB 2000) the possibility of affecting
chronic diseases with vitamin C was extensively discussed.
In these latest recommendations, the length of the vitamin C
chapter is 91 pages (FNB 2000 pp 95-185), in contrast to the
10 pages of the 10th edition of RDA (FNB 1989a pp 115-
24). Although the latest recommendations thoroughly dis-
cuss the epidemiological literature relating vitamin C intake
with chronic diseases, the authors conclude that there are no
appropriate studies that would yield data about what might
be proper doses for preventing the chronic diseases. Instead,
the latest vitamin C recommendations consider that "In the
absence of other data, maximal neutrophil concentration with
minimal urinary loss appears to be the best biomarker at the
present time" (FNB 2000 p 140). This end point is, however,
a surrogate and there is no evidence cited that vitamin C level
in neutrophils has any relation to some clinical disease end
point, so that the maximal level in these cells would corre-
spond to optimal intake level in the long term (FNB 2000
pp 95-185). However, there are quite a few examples in which
the effect on a surrogate marker diverged from the effect on a
clinical outcome (Fleming & DeMets 1996; DeGruttola et
al. 1997).
A further important restriction of both the early and the cur-
rent RDAs is that they apply specifically to ‘healthy persons’
(FNB 1989a p 1) and ‘apparently healthy individuals’ (FNB
2000 p 23). Consequently, the RDA levels are not intended to
provide reference levels of intake for people who are sick, for
example, with the common cold or more severe infections.
While the nutritional recommendations have great im-
portance in nutrition politics, they cannot be used as a basis
for claiming that amounts in excess of RDA levels are known
to be useless. The early RDA recommendations used an
acute clinical outcome that is irrelevant when considering
the possible long-term effects of vitamin C intake, and the
new recommendations use a surrogate that has no known
validity as regards its long-term health effects.
Kunkel (1996; Kunkel & Thompson 1988) criticized the
lack of appropriate philosophical considerations behind the
nutritional recommendations: "The reasoning, however, can
become circular and unsound when the considered moral
judgments, moral principles and relevant background are
not independent sources of information. If they are mixed
or, for example, an intuition is mistaken for a scientific con-
clusion, the reasoning can be flawed."
The safety of vitamin C
Often the benefits of vitamin C observed in randomized
double-blind placebo-controlled trials are disregarded, al-
though at the same time authors may exaggerate the poten-
tial harm caused by vitamin C even when it is purely anec-
dotal (e.g., Olson & Hodges 1987; Herbert 1993).
In a casual survey of 20 physician colleagues, Goodwin
and Tangum (1998) found that all of them were aware that
high-dose vitamin C ingestion can cause kidney stones.
Goodwin and Tangum were, however, interested in where
this common ‘knowledge’ comes from and they combed
the medical literature without finding any articles in ref-
ereed journals reporting instances of high-dose vitamin C
causing kidney stones. Review articles cited book chapters
that in turn cited abstracts, letters, and other review articles.
Goodwin and Tangum concluded that nowhere in the trail
of citations was there any fundamental information on
whether or how frequently high-dose vitamin C supplemen-
tation might lead to kidney stones. The authors simply stated
that vitamin C may cause kidney stones, and as proof they
cited other authors who had said the same thing. Thus, this
description reveals a typical urban legend; a story that is
retold, yet no-one confirms that the story is true.
The anecdote of vitamin C and kidney stones is men-
tioned in a major textbook of pharmacology: "…risks of
megadose treatment ... include formation of kidney stones"
(Marcus & Coulston 2001). The statement that vitamin C
may cause kidney stones has been reiterated in the Finnish
literature without any references (Aro 1985a,b, 1994), and
in the Nordic Nutritional Recommendations, also without
any references (NNR 2004 p 310).
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When reviewing the health effects of vitamin C, Olson
and Hodges (1987) and Herbert (1993) claimed that "Large
intakes of vitamin C may reduce insulin production." This
statement was based on a paper published in 1946. Levey
and Suter (1946) reported that vitamin C potentiates the
diabetogenic action of alloxan in rats, whose blood-sugar
level was determined 3 days after injecting alloxan, or al-
loxan with vitamin C. Hyperglycemia was observed in 50%
of the rats treated with alloxan and vitamin C, in contrast to
17% of the rats treated with alloxan alone. Nevertheless,
the authors concluded from their own previous work that
"ascorbic acid alone does not produce hyperglycemia"
(Levey & Suter 1946). Thus, this old experiment with al-
loxan-treated rats was the basis for Olson and Hodges (1987)
and Herbert (1993) to state that large doses of vitamin C
alone may reduce insulin production in human subjects.
Olson and Hodges (1987) and Herbert (1993) stated that
"Large intakes of vitamin C may interrupt pregnancies." This
suggestion was based on a brief Russian paper published in
1964. Twenty women whose menstruation was delayed by
10-15 days were given 6 g/day of vitamin C, and 16 of them
started to menstruate within 3 days (Samborskaya &
Ferdman 1964). Pauling (1976a) wrote a letter to the au-
thors inquiring whether any actual direct test of pregnancy
was carried out, but he received only a copy of the publica-
tion by way of reply. Thus, there was no evidence that the
women were pregnant to begin with. Possibly the women
just had irregular menstruation, yet this report was valid
enough for Olson and Hodges (1987) and Herbert (1993) to
conclude that vitamin C may cause miscarriages.
Olson and Hodges (1987) and Herbert (1993) also ar-
gued that "Large intakes of vitamin C may lower plasma
vitamin B12 levels." This claim was originally made by
Herbert himself (Herbert & Jacob 1974), however, it was
shown afterwards that the apparent breakdown of vitamin
B12 was due to methodological shortcomings (Newmark et
al. 1979; Marcus 1981), and the vitamin B12 level was not
decreased in patients administered as much as 4 g/day of
vitamin C for 11 months or more (Afroz et al. 1975), or in
children administered gram-doses of vitamin C for years
(Ekvall et al. 1981). However, these papers were not cited
by Olson and Hodges (1987) or Herbert (1993).
In extreme cases, suggestions about vitamin C toxicity
have been based on double-speculation. Herbert (1993)
stated that (1) vitamin C might cause elevated iron levels,
and (2) elevated iron levels might cause increased risk of
coronary heart disease. However, (1) in order to quantify
the effect of vitamin C supplementation on iron status, Cook
et al. (1984) administered 2 g/day of vitamin C to 9 sub-
jects for 2 years without finding indications of iron accu-
mulation, and (2) several studies with different types of set-
tings were unable to corroborate the hypothesis that raised
iron levels increase the risk of coronary heart disease
(Bendich & Langseth 1995; Hemilä & Paunio 1997). In
contrast to ordinary people, patients suffering from actual
iron overload may derive harm from vitamin C; however,
its harmful effect on these particular patients and the ra-
tionale of treating such patients with the combination of
vitamin C and desferrioxamine has been known for a long
time (Nienhuis 1981).
Rivers (1987) reviewed 74 publications dealing with the
possible toxicity of vitamin C and concluded that "Large
quantities of ascorbic acid will not result in calcium-oxalate
stones, increased uric acid excretion, impaired vitamin B12
status, iron overload, systemic conditioning, or increased
mutagenic activity in healthy individuals." In another re-
view, Marks (1989) concluded that "A large number of ad-
verse reactions have been alleged to occur with the use of
large doses of ascorbic acid, but almost without exception
further study has demonstrated that the allegations are with-
out foundation ... an overview of all the information shows
that the safe daily level is at least 100 times the RDA." The
RDA level for vitamin C was 60 mg/day at that time.
Hathcock (1997) stated that "Many hypothetical adverse
effects of high intakes of vitamin C have been cited for dec-
ades. Most, with the exception of mild and transient
gastrointestinal effects, seem to have little or no known fac-
tual basis." Several other reviews have also concluded that
vitamin C is safe in doses around 1 g/day (Hanck 1982;
Bendich & Langseth 1995; Diplock 1995; Hathcock et al.
2005). The recent US nutritional recommendations suggest
that the safe range of vitamin C intake goes to 2 g/day for
adults, but the basis for this upper limit of ‘safe doses’ is
the appearance of loose bowels (FNB 2000 pp 155-65),
which, however, is quite a trivial adverse effect and disap-
pears quite quickly with a change to lower intake levels.
There are a few reports of severe harm caused by high-
dose vitamin C administration. Nevertheless, the death of a
68-year old African American man was not attributed to
intravenous injection of 80 grams of vitamin C on 2 con-
secutive days per se, but to his coincident glucose-6-phos-
phate deficiency (Campbell et al. 1975). Such isolated in-
stances have no public health relevance. In a recent
pharmacokinetic study participants were administered up
to 100 grams of vitamin C within a few hours indicating the
safety of such a large dose per se in healthy people
(Padayatty et al. 2004).
There is much evidence indicating that vitamin C me-
tabolism changes during infections and this may affect the
relationship between doses and adverse effects (Fig. 1; see
pp 6-7). It has been reported that people with serious infec-
tions can ingest over 50 g/day of vitamin C without gastric
problems (Luberoff 1978; Cathcart 1981).
Problems with statements by experts
The status of an ‘expert’ implies that an individual is thor-
oughly familiar with the particular field. Unfortunately, in
the vitamin C field, the track record of many experts is poor.
Olson, Hodges, and Herbert (see the preceding section)
were all members of the first committee preparing the 10th
edition of the US RDA nutritional recommendations, which
plays a central role in US governmental policy, and indirectly
affects policy in numerous other counties. James A. Olson
was also an editor of a major textbook on nutrition (Shils,
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Olson, et al. 1994, 1999). The review of vitamin C by Olson
and Hodges (1987), which contained the anecdotal stories of
vitamin C toxicity (see the previous section), was planned as
the vitamin C section of the 10th edition of the RDA recom-
mendations (Olson 1986; Pellett 1988). The US National
Academy of Sciences decided, however, not to publish the
RDA draft by the first committee because of an impasse re-
sulting from scientific differences of opinion between the first
committee and the scientific reviewers appointed by the Na-
tional Academy of Sciences (Press 1985; Marshall 1985).
One reason for the disagreements was the proposal that the
RDA level for vitamin C recommendation be lowered from
60 mg/day to 40 mg/day for men and 30 mg/day for women.
The second RDA committee kept the vitamin C level at 60
mg/day for both men and women (FNB 1989a).
Victor Herbert, who reiterated the anecdotal stories of
vitamin C toxicity (see the previous section) in one of his
papers (Herbert 1993), was also a member of the commit-
tee preparing the 9th edition of the US RDA nutritional rec-
ommendations (FNB 1980). Herbert received the 1972
McCollum Award for outstanding scientific accomplishment
in the field of nutrition (Anonymous 1973; ASCN 2005;
see footnote to Table 1), and was the president of the Ameri-
can Society for Clinical Nutrition in 1980-1981. In 1984
Herbert received the FDA Commissioner’s Special Cita-
tion Award for "outstanding and consistent contributions
against the proliferation of nutrition quackery to the Ameri-
can consumer" (Halsted 2003; Oransky 2003). In his remi-
niscences Pauling described an acrimonious exchange of
letters with Victor Herbert who rejected the results of all
placebo-controlled trials on vitamin C and the common cold
without any reasonable argument. Pauling commented that
"I finally became sufficiently irritated by this fellow that I
decided I ought to do something about it. So I sat down one
summer and in two months wrote a book, Vitamin C and the
Common Cold " (Marinacci 1995 pp 248-51). In this re-
spect Herbert was, paradoxically, indirectly behind the in-
crease in the popular enthusiasm for vitamin C supplemen-
tation that resulted from Pauling’s book. The author of this
current thesis pointed out that Herbert’s conclusions (1993),
that there is no reliable data to show that vitamin C supple-
mentation may provide any benefit and that vitamin C sup-
plements may instead be highly harmful, were based on a
grossly biased selection of references (Hemilä 1994b).
Stephen Barrett (2005) has written several books on nutri-
tional quackery (Barrett 1980; Barrett & Herbert 1994), and
received the FDA Commissioner’s Special Citation in 1984
for "outstanding and consistent contributions against the pro-
liferation of nutrition quackery to the American consumer."
Barrett also received the 2001 Distinguished Service to Health
Education Award from the American Association for Health
Education. However, Barrett’s presentation of facts related
to the findings from studies on vitamin C and the common
cold have been markedly biased. In a comment on Barrett’s
paper (1995) claiming there is no evidence that vitamin C
might affect colds, Hemilä (1995b) pointed out that "Anderson
et al. (1972) found that vitamin C supplementation (1-4 g/
day) decreased the ‘numbers of days confined to house’ per
subject by 48% in subjects with a low dietary intake of fruit
juices [see Table 13]. Barrett’s claim that at best there is only
a slight reduction in symptoms appears grossly misleading
considering the published results." Stephen Barrett replied to
this that "Anderson’s first study found … a 30% difference."
In a subsequent letter Edgar Villchur (1995) pointed out that
"Barrett’s reply in the same issue challenges Hemilä’s report-
ing accuracy, but Hemilä is correct … Barrett, however,
doesn’t say he is citing a different part of the Anderson data,
and thus makes it seem that Hemilä has either misread or
misrepresented Anderson." In a reply to this accusation,
Stephen Barrett conceded that "Villchur is correct that Hemilä
and I referred to different figures."
Thomas Chalmers, Paul Meier, A. Steward Truswell, and
Jos Kleijnen are experts in controlled trials, medical statis-
tics, nutrition, and systematic reviews, yet their reviews on
vitamin C and the common cold contain lots of factual errors
and misleading statements (see pp 36-45). The Chalmers
(1975) and Dykes and Meier (1975) reviews were cited in
major textbooks of infectious diseases and in the US RDA
recommendations, although some of the numerous shortcom-
ings of both reviews should have been apparent to any expert
even superficially familiar with the original study reports.
In the most recent US nutritional recommendations (FNB
2000 pp 126-7), Chalmers’ review (1975) and the Hemilä
and Herman criticism (1995) of Chalmers’ review are cited
in the same paragraph without mentioning that the latter
paper shows that the former review is invalid. Thus, the
experts writing the vitamin C chapter did not read or under-
stand the two papers cited to see that they were incompat-
ible. Although the most recent recommendations extensively
discuss the observational studies related to the possibility
that vitamin C intake might affect chronic diseases, the rec-
ommendations ignore some 40 placebo-controlled trials that
have examined the preventive effect of vitamin C on colds
(FNB 2000 pp 117, 127; Tables 6, 15, 17). Only 4 control-
led trials are cited in the US recommendations (Peters et al.
1993; Coulehan et al. 1976; Miller et al. 1977; Ludvigsson
et al. 1977). Since the Ludvigsson et al. trial (1977) is the
only one of the 6 largest (Table 10) mentioned in the rec-
ommendations, 83% (5/6) of the largest common cold trials
are simply ignored, and some 90% of all the placebo-con-
trolled trials on vitamin C and the common cold are ignored
in the current US nutritional recommendations.
Even in the case of the Ludvigsson paper (1977), the
study findings are disregarded in the recommendations (FNB
2000 p 127). Ludvigsson et al. (1977) found a 14% reduc-
tion (P = 0.008) in the duration of ‘absence from school
because of upper respiratory tract infection’ in the main trial,
and a 39% reduction (P = 0.002) in the duration of ‘upper
respiratory tract infection’ in the smaller trial, but these find-
ings are not mentioned in the recommendations. Two large
trials reporting that vitamin C supplementation significantly
increased the proportion of participants who remained free
of illness during supplementation (Table 20) are not cited
in the recommendations either, or any of the UK trials that
found a significant proportion of participants benefiting
when the outcome is ≥2 colds during the trial (Table 22).
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Neither were any of the 3 trials that found a significant re-
duction in pneumonia incidence by vitamin C supplemen-
tation (Table 25) mentioned in the recommendations. It is
not clear to what extent the poor coverage of literature is
caused by lack of knowledge of the studies, and how much
by an intentional decision to discard studies that do not fit
with a preconception that vitamin C is useless for colds and
other respiratory infections.
In systematic reviews it is essential to cover the pub-
lished studies widely and analyze the results objectively (Ian
Chalmers & Altman 1995; Higgins & Green 2005), but this
was not done in the most recent US nutritional recommen-
dations (FNB 2000). Although the common cold trials do
not allow explicit conclusions to be drawn about what might
be the best doses of vitamin C intake, the published trials
do show that large doses affect common cold severity and
duration in large groups of people, and the incidence of colds
in some people. Objective discussion of the common cold
trials also provides justification to carry out further study,
and to use susceptibility to and severity of infections as
potential outcomes of interest in considering the ‘optimal
intake levels’ instead of focusing only on cancers and car-
diovascular diseases, and using ‘maximal neutrophil con-
centration with minimal urinary loss’ as a surrogate with no
established validity against clinically relevant outcomes.
The problems of expert reliability in nutritional recom-
mendations are also seen in other vitamin C issues. In the
10th edition of RDA, comments on vitamin C and choles-
terol metabolism were based on 2 trials that did not use
placebo-control (FNB 1989a p 120-1), and 3 placebo-con-
trolled studies which found a significant decrease in elevated
cholesterol levels with vitamin C supplementation were dis-
regarded (Hemilä 1992c, 1993).
Similar problems are faced in the UK nutritional recom-
mendations (DH 1991 [see Hemilä 1997d]), where no men-
tion is made of the possible role of vitamin C on the com-
mon cold, although some 40 placebo-controlled trials have
been carried out. Furthermore, one of the trials cited in the
UK recommendations did report that the geometric mean
duration of colds was 6.4 days in vitamin C-deprived sub-
jects and 3.3 days in non-deprived subjects. The authors
concluded that "Such evidence as there is, however, defi-
nitely confirms the hypothesis that the absence of vitamin
C tended to cause colds to last longer" (Bartley, Krebs &
O’Brien 1953 p 43), but the authors of the UK recommen-
dations disregarded this (DH 1991). The brief discussion of
the vitamin C and cholesterol issue referred to a single un-
controlled intervention study, and disregarded 11 published
placebo-controlled trials (DH 1991; Hemilä 1992c, 1997d).
In Finland, an authoritative monograph on antioxidants
based its comments on vitamin C and the common cold on
one observational study and one trial with marathon run-
ners (Aro 1994). Observational studies are substantially less
reliable than controlled trials, whereas there are some 40
published placebo-controlled trials on vitamin C and the
common cold, and findings with marathon runners cannot
be generalized to the normal population (Hemilä 1995a). A
brief Finnish review of the vitamin C and cholesterol rela-
tionship (Aro 1990b) claimed that one cited trial was pla-
cebo-controlled whereas it was not (Hemilä 1990d), and 3
placebo-controlled trials that found a statistically signifi-
cant effect on plasma cholesterol level with vitamin C sup-
plementation were disregarded (Hemilä 1990d, 1992c,
1993). Obviously, such biased presentations were the moti-
vation for the concept of ‘systematic reviews’ (Ian Chalmers
& Altman 1995; Higgins & Green 2005).
In the most recent editions of Mandell et al.’s textbook
of infectious diseases (Gwaltney 2000, 2005), Chalmers’
review (1975) is no longer cited; however, comments on
vitamin C and the common cold are based on 2 small trials
with artificially inoculated colds (Walker et al. 1967;
Schwartz et al. 1973). These 2 trials recorded only 36 and
21 common cold episodes respectively, whereas none of
the 5 large-scale trials recording over 1,000 natural com-
mon cold episodes per trial (Table 14) is cited (Gwaltney
2000, 2005). In a classic paper, Thomas Chalmers pointed
out that negative findings from small trials may correspond
to the type II error in statistics and concluded that "Concern
for the probability of missing an important therapeutic im-
provement because of small sample sizes deserves more
attention in the planning of clinical trials" (Freiman et al.
1979). Thus, drawing conclusions from trials with 36 and
21 common cold episodes may lead to a false negative con-
clusion. Furthermore, it is possible that natural colds differ
from artificially induced colds. The rate of the former is
about 1 per year or 0.02 per week for adults, whereas the
rate of the latter was 0.4 to 1.0 per week (Walker et al. 1967;
Schwartz et al. 1973), indicating that the exposure level to
viruses was orders of magnitude higher in the artificially
inoculated colds, which may affect the role of vitamin C.
Pauling (1971b, 1976a pp 121-38, 1986a pp 225-36) also
provided several examples of how the authorities in nutri-
tion misinterpreted and ignored the findings of published
trials. Evidently, a personal problem for Pauling was that
"Medical experts have a long history of resisting scientific
innovations from what they define as ‘the outside’ " (Bar-
ber 1961).
The poor quality of expert comments on vitamin C and
the common cold is puzzling. Goodwin and Tangum (1998)
provided several examples to support the conclusion that
there has been systematic bias against the concept that vita-
mins might be beneficial in levels higher than the minimum
required to avoid classic deficiency diseases: "Throughout
much of the 20th century, American academic medicine was
resistant to the concept that micronutrient supplementation
might prove beneficial. This resistance is evident in several
ways: (1) by uncritical acceptance of bad news about mi-
cronutrient supplements; reports of toxic effects were rarely
questioned and widely quoted; (2) by the scornful, dismiss-
ive tone of the discussions about micronutrient supplemen-
tation in textbooks of medicine, a tone avoided in most
medical controversies; and (3) by the skeptical reaction
greeting any claim of efficacy of a micronutrient, relative
to other therapies; indeed, most claims were simply ignored."
Bias against vitamin C was also documented by Richards
(1988, 1991; Galloway 1991; Huxtable 1992; Segerstråle
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1992) who compared the attitudes and arguments of physi-
cians to three putative cancer medicines: 5-fluorouracil, in-
terferon, and vitamin C.
The evaluation of the potential effectiveness of a thera-
peutic method usually depends greatly on the possibility of
biologically rationalizing the method. Goodwin and Good-
win (1981, 1984) reviewed several cases in which an effec-
tive method of treatment was erroneously rejected due to a
lack of understanding of the physiological mechanism of
the effect. They designated this problem ‘the tomato effect’,
since the tomato was considered poisonous in the USA in
the 1700s because several other plants in the same family
were poisonous: "The tomato effect in medicine occurs when
an efficacious treatment for a certain disease is ignored be-
cause it does not ‘make sense’ in the light of accepted theo-
ries of disease mechanism and drug action." Thus, the ques-
tion of evaluating a new method of therapy is not just
whether a moderate effect is reproducible in controlled tri-
als, but substantially depends on conceptual issues related
to the biological explanations (Vandenbroucke 1998a;
Vandenbroucke & de Craen 2001). It is possible, for exam-
ple, that the claim in the biochemistry textbooks that vita-
min C participates in the hydroxylation of proline in colla-
gen (Berg et al. 2002) leads to a misleading impression of
the mechanism of vitamin C action, as the effects of vita-
min C on other biochemical reactions (Englard & Seifter
1986; Padh 1990) and on the immune system (Hemilä 1997a,
2003a) are not mentioned at all. Some further possible con-
ceptual reasons for the bias against the effects of vitamin C
on common cold have been discussed elsewhere (Hemilä
1996a, 1997a).
The effect of vitamin E on respiratory
infections
Findings from the ATBC Study analyses
Suggestions that vitamin E supplementation might help pre-
vent infections have mainly been based on immunological
studies. However, immune system markers are only surro-
gates of susceptibility to infection and it is not clear whether
such immune effects have any actual relevance to clinical
infections in human subjects. Nevertheless, several animal
studies indicated that vitamin E may affect infections (Ta-
ble 2; Appendices 4 and 5).
Only a few trials have previously examined the effects
of vitamin E supplementation on clinical infections in hu-
man subjects. Most of the trials found no benefit with vita-
min E, and moreover, one trial found an increase in the du-
ration of respiratory infections with vitamin E supplemen-
tation (Graat et al. 2002).
In this work, we found that vitamin E supplementation
had no overall effect on common cold risk among the mid-
dle-aged male smokers of the ATBC Study (III). Neverthe-
less, in a small subgroup of the ATBC Study participants,
≥65 year old city-dwellers who smoked less, vitamin E sup-
plemented participants had a 28% lower risk of colds than
the non-vitamin E participants. It was not clear whether this
difference resulted from a physiological effect, or emerged
by chance from the series of subgroup analyses. Neverthe-
less, even if real, a 28% effect would correspond to some
4 people taking vitamin E supplement for a year in order to
prevent 1 common cold episode (NNT = 4), which appears
to be quite a low cost-benefit ratio. Still, the statistically
highly significant effect on a universal ailment in the nar-
row subgroup justified more detailed analyses to explore
the modification of vitamin E effect by age, smoking, and
residential neighborhood (Hemilä et al. submitted).
Likewise, vitamin E supplementation had no overall ef-
fect on the risk of pneumonia in the ATBC Study (Paper V).
Nevertheless, various measures of smoking seemed to modify
its effect on pneumonia risk. Among participants who started
to smoke late in life, vitamin E lowered the risk of pneumo-
nia by 35%. Furthermore, within this subgroup of partici-
pants starting to smoke late in life, those who smoked less
than a pack per day at the baseline of the trial seemed to get
greater benefit from vitamin E than those who smoked more
at the baseline. Furthermore, within the subgroup of partici-
pants starting to smoke late in life, the difference in pneumo-
nia risk between vitamin E participants and no-vitamin E
participants was substantially greater among those who had
quit smoking prior to the occurrence of pneumonia than
among participants who continued smoking until its occur-
rence. Thus three different measures of cigarette smoking
appeared to modify the effect of vitamin E supplementation
on pneumonia risk, so that in each case less exposure to ciga-
rette smoking was associated with greater benefit from vita-
min E supplementation. Extrapolation would suggest that the
effect of vitamin E might be greatest among people who have
no life-time exposure to cigarette smoking. Since all ATBC
Study participants were selected as smokers at the baseline,
the effect of vitamin E on the risk of pneumonia in life-long
non-smokers could not be examined in this work.
Although a 35% reduction in the risk of pneumonia is a
substantial effect, it is not clear whether it has practical rel-
evance even if we assume that the finding is valid. At a
pneumonia rate of 5 episodes per 1,000 person-years, a re-
duction of 35% corresponds to 600 people needing vitamin
E supplementation for a year to prevent 1 episode of com-
munity-acquired pneumonia (NNT = 600), which, after all,
is usually cured quite rapidly by antibiotics and rarely leads
to long-term or permanent sequelae.
A recent cohort study found no association between vi-
tamin E intake and community-acquired pneumonia among
middle-aged men in the USA (Merchant et al. 2004).
Because it has been suggested that moderate physical
activity improves the immune system and reduces the risk
of respiratory infections (Nieman 1994, 2000; Woods et al.
1999), we analyzed the relationship between physical ac-
tivity and the incidence of the common cold in the ATBC
Study cohort. No association between physical activity on
the job or during leisure with common cold incidence was
found (Hemilä et al. 2003). Neither was any association
found between physical activity on the job, or during lei-
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sure, and the incidence of pneumonia (Hemilä et al. 2006).
Since heavy physical activity causes oxidative stress in
the body, it was suggested that antioxidants, in particular
vitamin E, might be beneficial for people carrying out heavy
exercise during leisure (Packer 1997; Sen 2001). Vitamin E
did not reduce the common cold risk among ATBC Study
participants with a heavy job, or participants doing strenu-
ous exercise (Hemilä et al. 2003).
Vitamin E supplementation did not affect the pneumonia
risk among ATBC Study participants with heavy or moder-
ately heavy job. However, it did reduce the risk of pneumo-
nia by 50% among participants doing heavy or moderate
exercise during leisure (Table 27; Hemilä et al. 2006). Given
the latter finding, we explored the possible role of adapta-
tion to physical activity with the following rationale. The
body adapts to physical stress arising from regular work-
load, there being substantial experimental evidence indi-
cating that the activities of antioxidant enzymes increase in
response to exercise in both animals and humans (Ji 1999;
Powers et al. 1999; Sen 2001). In contrast, light or very
light jobs leave people unadapted to oxidative stress caused
by sporadic heavy leisure time exercise. Consequently, lei-
sure time exercise could generate severe episodic oxidative
stress in participants having a light or very light job. Con-
sistent with this rationalization, we found that vitamin E
had a great effect on participants carrying out leisure time
exercise who had a light or very light job, whereas it had no
effect on participants doing leisure time exercise who had a
heavy or moderately heavy job. Still, it is noteworthy that
the rate of pneumonia is not increased in the no-vitamin E
participants who had a light or very light job, compared
with no-vitamin E participants who had heavy or moder-
ately heavy job (Table 27). This is inconsistent with the no-
tion that poor adaptation to oxidative stress increases the
risk of pneumonia, so that vitamin E would reduce an el-
evated risk towards the level of adapted participants. Nev-
ertheless, although the pattern of findings is not quite con-
sistent with the oxidative stress adaptation hypothesis, the
subgroup finding arises from large randomized groups. The
effect of vitamin E on the participants carrying out leisure
time exercise was also modified by baseline age, and by
age of smoking initiation (Table 27); however, the number
of pneumonia cases is small and the subgroup differences
should be considered cautiously.
The risk of tuberculosis was slightly higher in the vitamin
E arm compared with the placebo arm of the ATBC Study,
but the difference was non-significant (IV). Nevertheless, this
finding is inconsistent with substantial benefits of vitamin E
supplementation affecting the risk of tuberculosis.
Recommended intake of vitamin E
Overt vitamin E deficiency symptoms have never been de-
scribed in normal individuals consuming diets low in vita-
min E because it is found in such a great variety of foods,
and is stored in the body for such long periods (FNB 2000).
Thus there is no known minimum intake level that prevents
vitamin E deficiency in the same sense as 10 mg/day of
vitamin C prevents scurvy.
The most recent US recommendation of vitamin E in-
take uses ‘hydrogen peroxide-induced hemolysis’ as the
outcome on which the adequacy of vitamin E is assessed,
based on the argument that "In the absence of other scien-
tifically sound data, hydrogen peroxide-induced hemolysis
is the best marker at the present time" (FNB 2000 p 232).
The plasma concentration of 12 µmol/l α-tocopherol was
chosen as the minimal level, since this concentration is as-
sociated with normal in vitro hydrogen peroxide-induced
hemolysis. "Based on NHANES III data, more than 95% of
the population surveyed would have plasma concentrations
greater than 12 µmol/l, thus indicating that the American
public is not vitamin E deficient by this criterion" (FNB
2000 p 233). Since a study with subjects who had been on a
controlled vitamin E diet for over 6 years found 12 µmol/l
to correspond to a dietary vitamin E intake level of 12 mg/
day (pp 232-6), the RDA level was set at 15 mg/day to pro-
vide an arbitrary margin of safety.
However, this kind of argument does not seem reason-
able. ‘Hydrogen peroxide-induced hemolysis’ is a surro-
gate marker and there is no evidence cited that the percent-
age of hemolysis would meaningfully correlate with any
clinically relevant outcome (FNB 2000). The correlation
between dietary vitamin E intake and plasma α-tocopherol
concentration is also very weak or nonexistent in freely liv-
ing people. One study "reported that plasma α-tocopherol
concentrations were not associated with dietary intake,
whereas some others report that associations seen were
largely due to vitamin E supplement intake … [and] …
plasma α-tocopherol concentrations in NHANES III did not
correlate with the 24-hour dietary recall data" (FNB 2000 p
210). Thus, there is no evidence that among freely living
people vitamin E intake might meaningfully correlate with
plasma α-tocopherol level and, moreover, there is no evi-
dence that the percentage of hemolysis might correlate with
any clinically relevant outcome.
In any case, the current vitamin E recommendation for
both men and women was set at 15 mg/day (FNB 2000
p 237). Consequently, in the USA, 90% of men and 99% of
women aged 19-30 years have a vitamin E intake lower
than 15 mg/day (FNB 2000 pp 422-3). However, there is no
evidence cited that this 90-99% of young adults with an
intake lower than the RDA level might suffer any harmful
effect on health because of their ‘low’ intake (FNB 2000).
Thus the level of vitamin E recommendation is arbitrary to
an extreme degree.
In the previous RDA recommendation, the recommended
vitamin E intake was based on the following argument: "The
allowance … is therefore based primarily on customary in-
takes from U.S. food sources. … the subcommittee has es-
tablished an arbitrary but practical allowance for male adults
of 10 mg of alpha-tocopherol equivalents per day. Because
women are generally smaller, their allowance is 8 mg/day"
(FNB 1989a p 103). At these older RDA levels, only 25%
of US men and 50% of women aged 19-30 years would get
less than the recommended level (FNB 2000 pp 422-3).
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The safety of vitamin E
A number of reviewers have concluded that vitamin E is
safe at high doses and most of the suggested harmful ef-
fects are not based on valid evidence (Bendich & Machlin
1988, 1993; Marks 1989; Kappus & Diplock 1992; Diplock
1995; Hathcock et al. 2005 [see Hemilä 2005e]).
In a review discussing the potentially adverse effects of
vitamin E, Diplock (1995) commented that "It is strange to
observe that the most frequently cited observations in the
literature are those that appear to have the least scientific
rigor" concluding that "Regarding controlled, double-
blinded studies of vitamin E toxicity in humans, several re-
ports exist that also confirm that vitamin E has very low
toxicity and no consistent adverse effects have been re-
ported." Bendich and Machlin (1988, 1993) also concluded
that "The majority of side effects was reported in letters to
the editor as individual case reports or uncontrolled stud-
ies. Most of the side effects have not been observed in the
larger, well-controlled studies … vitamin E supplementa-
tion at high doses is not associated with any clinically rel-
evant adverse effects."
The most recent US nutritional recommendations con-
sider that for vitamin E, "The Tolerable Upper Intake Level
(UL)", which means "the highest level of daily nutrient in-
take that is likely to pose no risk of adverse health effects in
almost all individuals" is 1,000 mg/day (FNB 2000 p 249-
59). Furthermore, according to the same monograph, "clini-
cal trials of doses above the UL should not be discouraged"
(FNB 2000 p 249).
Evidently, the lack of adverse effects from such high doses
does not indicate that such doses are beneficial. The current
recommended level of intake is 15 mg/day in the USA as
mentioned above; however, even this low level of recom-
mended intake is based on highly dubious argument as men-
tioned above, and there is no evidence of ill effects even if
the intake level is still lower, such as 8-10 mg/day, which
were the previous RDA levels of vitamin E (FNB 1989a
p 103).
In the ATBC Study, vitamin E supplementation was as-
sociated with a higher risk of subarachnoid hemorrhage
(P[2-t] = 0.07), but a lower risk of cerebral infarction
(P[2-t] = 0.03) (Leppälä et al. 2000a). In a subgroup analy-
sis, the increase in the risk of subarachnoid hemorrhage was
restricted to ATBC Study participants who had high systolic
blood pressure (RR = 2.4; P[2-t] = 0.03; Leppälä et al.
2000b), but there was no effect of vitamin E on the risk of
subarachnoid hemorrhage in male smokers with low blood
pressure. Statistical interaction between vitamin E and
systolic blood pressure was, however, non-significant
(P[2-t] = 0.17). Furthermore, given the multiple compari-
son condition (one of several outcomes and one of three
blood pressure subgroups) the P-value for increased risk
(0.03) is easily explained by chance. Consequently, it is not
clear how far this potential harm in male smokers with high
blood pressure can be extrapolated to other population
groups. In the ATBC Study there was no difference in mor-
tality between the vitamin E and no-vitamin E groups (+2%;
95% CI: -5% to +9%; P[2-t] = 0.6) (ATBC 1994a), indicat-
ing no net harm or benefit from vitamin E supplementation
(50 mg/day) to middle-aged male smokers.
A recent trial with 652 subjects aged ≥60 years found
greater severity of respiratory infections among participants
supplemented with vitamin E (200 mg/day). The presence
of fever during respiratory episodes was more common
(P[2-t] = 0.009) and the total illness duration was longer
(P[2-t] = 0.02) among the vitamin E supplemented partici-
pants (Graat et al. 2002).
In a recent meta-analysis focusing on the potentially
harmful effects of vitamin E supplementation, Miller et al.
(2005) estimated that doses larger than 150 mg/day of vita-
min E might increase mortality. However, their assumption
of a precise threshold level valid for all people may be a
gross oversimplification. It is possible that there is biologi-
cal heterogeneity between population groups, so that peo-
ple’s characteristics would determine whether vitamin E
supplementation causes net benefit or harm (Hemilä
2005f,g). For example, in the ATBC Study cohort, the ef-
fect of vitamin E on the risk of pneumonia was significantly
modified (P[2-t] = 0.000,7) by the age of smoking initia-
tion, so that vitamin E was beneficial to participants who
initiated smoking at later ages (RR = 0.65), but harmful to
those who initiated smoking at earlier ages (RR = 1.14)
(Paper V). In the ATBC Study, the vitamin E dose was 50
mg/day, which is substantially less than the threshold of
150 mg/day estimated by Miller et al. (2005). However,
these subgroup differences observed in the ATBC Study
cohort suggest that some population groups suffer ill ef-
fects at the low dosage of 50 mg/day, but the same dose
seems beneficial to others.
Thus, although there is evidence indicating that doses up
to 1 g/day of vitamin E do not cause adverse effects to the
ordinary population, there is new data suggesting that much
lower doses, 50-200 mg/day of vitamin E, may be harmful
to particular restricted population groups. Obviously, the
harm associated with low doses should not be extrapolated
directly outside of these population groups.
Possible heterogeneity in the effects of
vitamins C and E
A common feature of the discussions of the physiological
effects of vitamins C and E has been the implicit assump-
tion that their effects are similar in all people. If such an
assumption was valid, it would allow extrapolation of any
study findings widely, given that the trial is well conducted
and so large that the results are accurate. The validity of
this assumption, that the effects of these vitamins are simi-
lar over the population, is thus of fundamental importance.
For example, Pauling (1971a; pp 35-6) assumed that the
findings of the Ritzel trial (1961) could be directly extrapo-
lated to the general population without considering that the
positive effects of vitamin C found in the trial may be valid,
but not appropriate for extrapolation because of the special
conditions of a trial with schoolchildren in a skiing camp.
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Similar careless extrapolation from the findings of a single
small trial (N = 617) was recently carried out by Hamer and
Meydani (2004), who calculated that "Given that 34 mil-
lion elderly people live in nursing homes, this would trans-
late into more than 5 million fewer elderly nursing home
residents contracting upper respiratory tract infections in a
year," with their estimate of the effect being based on a mar-
ginally significant finding of RR = 0.84 (95% CI: 0.69-1.00;
Meydani et al. 2004), whereas a much larger trial (N =
21,796) found that vitamin E supplementation had no over-
all effect on common cold incidence (Paper III; Hemilä &
Kaprio 2004). Another recent example of this implicit as-
sumption of similar effects is seen in the meta-analysis of
the potentially deleterious effect of vitamin E supplementa-
tion by Miller et al. (2005 [see Hemilä 2005f]), which was
based on the assumption that there is a universal threshold
level, so that higher intakes of vitamin E would progres-
sively increase the risk of harm in all people equally. Thus,
the implicit assumption of similar effects in all people is
common to many considerations of the effects of vitamins
C and E.
An important finding in the current thesis was that the
effects of daily vitamin C and E supplementation on the
incidence of the common cold and pneumonia seem to be
modified by various factors, so that the effects of these two
vitamins vary between different population groups. Conse-
quently, the assumption of similar effects in all people seems
not to be valid.
If the effects of daily vitamin C and E supplementation
vary substantially between different subpopulations, the het-
erogeneity of the effect evidently means a need for careful
consideration of goals when planning new trials on these vi-
tamins. Assuming heterogeneity, further trials should try to
identify and characterize the population groups or living con-
ditions in which these vitamins might be beneficial, rather
than re-examining the effects on ordinary Western people for
whom the studies already available have not found any mean-
ingful overall benefits from daily supplementation.
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CONCLUSIONS
1. A large number of studies with various animal species, and with a large diversity of
infectious agents have found that vitamins C and E affect the incidence and severity of
infections.
2. The potential effect of vitamin C on the common cold has been a controversial topic for
several decades. It has been shown in this thesis that since several major reviews on
vitamin C and the common cold present the findings of original trial results erroneously,
the conclusions of the reviews are unjustified. Two of these flawed reviews were used as
references in major textbooks on infectious diseases and in the US RDA nutritional rec-
ommendations as support for the claim that vitamin C has no effect on the common cold.
3. The most influential vitamin C common cold trial, carried out by Karlowski et al. (1975),
was re-analyzed in this thesis. It was shown that the original conclusions of the authors
were inconsistent with the published data. The Karlowski trial found, consistently with a
large number of other placebo-controlled trials, that regular vitamin C supplementation
shortens the duration of common cold episodes. However, if the main effect of vitamin C is
the alleviation of cold symptoms, it would appear more reasonable to administer it thera-
peutically, starting immediately after the first symptoms, rather than regularly. Neverthe-
less, only a few therapeutic trials have been carried out, and none were conducted with
children, for whom the regular vitamin C supplementation trials found substantially greater
benefit. Consequently, further therapeutic trials are needed to examine whether vitamin C
supplementation starting without delay after the first common cold symptoms might sub-
stantially reduce the duration and symptoms of colds.
4. Meta-analysis of the six largest vitamin C-common cold trials showed that the great ma-
jority of people in Western countries cannot lower common cold incidence by vitamin C
supplementation. Still, vitamin C may affect common cold risk in certain restricted groups
of people, such as those with heavy acute physical stress and/or cold stress, and young
males with low dietary vitamin C intakes, and these findings warrant further research.
5. In an analysis of the ATBC Study cohort of middle-aged male smokers, the intake level of
vitamin C in diet was not associated with the incidence of the common cold or tuberculosis.
6. Vitamin E supplementation had no overall effect on the risk of the common cold, pneu-
monia and tuberculosis in the ATBC Study. However, in the cases of the common cold
and pneumonia there was strong evidence indicating that the effect of vitamin E supple-
mentation differed between subgroups, so that certain restricted groups of people seemed
to derive benefit from supplementation. Vitamin E reduced common cold incidence in a
small group of elderly city-dwellers who smoked 5-14 cigarettes per day, and pneumonia
incidence in participants who initiated cigarette smoking late in life. Although both of
these effects were statistically highly significant, they were rather small. The assessment
of the practical importance of these findings requires further study.
7. The trials analyzed in this thesis suggest that there is no evidence that ordinary Western
people would derive benefit from daily supplementation of vitamin C or vitamin E as
regards the incidence of respiratory infections. Nevertheless, in both cases, there was
substantial heterogeneity in the effects between population groups. It is possible that
restricted population groups might experience benefit from daily supplements and fur-
ther study is warranted to investigate this possibility.
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Appendix 1. A brief history of vitamin C and its deficiency, scurvy
We were all hearty seamen, no cold did we fear
And we have from all sickness entirely kept clear
Thanks be to the Captain he has proved so good
Amongst all the Islands to give us fresh food.
Song of James Cook’s Sailors
(Kodicek & Young 1969)
Scurvy, vitamin C deficiency, was a serious occupational
disease of sailors in the Age of Sail. It has been estimated
that over two million sailors perished from scurvy (Carpen-
ter 1986; Harvie 2002; Bown 2003).
Vasco da Gama began his expedition to India in 1497
and when his ships arrived on southeast coast of Africa,
most of the crew were afflicted with scurvy. Da Gama re-
corded that "Many of our men fell ill here, their feet and
hands swelling, and their gums growing over their teeth so
that they could not eat." As they sailed farther up the east
coast of Africa, they met local traders, who traded them
fresh oranges, and within 6 days of eating them, the crew
recovered. Although da Gama recorded that "It pleased God
in his mercy that ... all our sick recovered their health for
the air of this place is very good," the crew were convinced
that the oranges that they had eaten were powerful curatives,
because they particularly asked for them the next time scurvy
appeared (Carpenter 1986 pp 1-3). It is thought that scurvy
was the cause of the deaths of 100 of Vasco da Gamas 160
men (Harvie 2002 pp 12).
The English sea captain Sir Richard Hawkins stated in
1622 that "In 20 years, since that I have used the sea, I dare
take upon me to give accompt of 10,000 men consumed
with scurvy" emphasizing the magnitude of the problem.
Hawkins "wished that some learned man would write of it,
for it is the plague of the sea, and the spoil of mariners." In
the 1780s, twenty-one British warships were stationed in
the West Indies, which had become the major theatre for
naval battles involving France, Spain, and England during
the War of American Independence. Sir Gilbert Blane, who
was the personal physician to the admiral, counted that,
during his first year in the West Indies, out of 12,019 mari-
ners only 60 died from enemy action, whereas 1,518 per-
ished from disease, with cases of scurvy outnumbering all
other illnesses combined (Bown 2003 pp 199-225; Carpen-
ter 1986 pp 91-7), corresponding to a mortality rate for
scurvy of about 1 per 10 person-years.
When Commodore George Anson set out with 8 ships
and 1,854 sailors to the South Seas in 1740, he returned in
1744 with only 1 ship and 188 men; the great majority of
the rest died of scurvy (Gordon 1984; Carpenter 1986
pp 46-51; Watt 1998). In contrast, during James Cook’s sec-
ond voyage towards the South Pole and round the World,
from 1772 to 1775, he lost no men to scurvy: "… the Reso-
lution performed a voyage of three years and eighteen days,
through all climates … with the loss of one man only by
disease, and who died of a complicated and lingering ill-
ness, without any mixture of scurvy. Two others were un-
fortunately drowned, and one killed by a fall; so that of the
whole number with which I set out from England I lost only
four" (Cook 1776). After this voyage, Cook was honored
with the Copley Medal of the Royal Society, Cook’s most
prestigious award. This was not for his navigational dis-
coveries, but for his success in maintaining a long sea voy-
age without a death from scurvy among the men in his crew
(Chick 1953; Kodicek & Young 1969). Still, Cook could
not receive the medal in person because he had already left
on yet another voyage, in which he was to be killed by na-
tives on a beach in Hawaii.
Paradoxically, Cook’s success in preventing scurvy, far
from hastening the cure of the disease, instead delayed the
identification of the actual cure (Lloyd 1961). Cook was
primarily a navigator and explorer and not a dietician, and
he did not examine specifically which of the numerous anti-
scurvy measures was the actual reason for its absence.
Cook’s experience could thus not be used to exclude use-
less treatments, and false explanations for the cause and
treatment of scurvy prevailed for a long period in spite of
his success in keeping his own sailors free of it (Table 1).
Strong observational evidence had shown that fruit had
been useful for treating and preventing scurvy since Vasco
da Gama’s voyage, and Hawkins (1622) commented that
"That which I have seene most fruitfull for this sicknesse, is
sower oranges and lemmons." The benefit of fruit was, how-
ever, forgotten for a long period and was rediscovered only
in the 1700s.
James Lind (1753) carried out a systematic review of all
the earlier literature on scurvy and wrote the classic mono-
graph A Treatise of the Scurvy. At the end of his treatise,
Lind wrote a brief summary of each of the earlier publica-
tions on scurvy ("Bibliotheca scorbutica"; Lind 1753 pp 249-
354). In the literature before Lind, the clinical definition of
scurvy had become highly ambiguous and, for example, one
of the earlier authors had stated "As this case cannot prop-
erly be referred to any other disease, it may justly be deemed
scorbutic" (p 36). Because of the imprecise definitions of
scurvy, and in many cases using the name for unrelated dis-
eases as we define it nowadays, Lind discarded most of the
earlier texts by eminent authors. Working for years as a sur-
geon on Navy ships, Lind had substantial personal experi-
ence with scorbutic patients, and his own clinical definition
was based on "putrid gums, swelled legs, and spots, accom-
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panying each other, and in their progress usually attended
with rigid tendons in the ham, are observed in no other dis-
temper" (p 53). In contrast to most earlier authors on scurvy,
Lind’s line of exploring the nature of the disease was em-
pirical: "I shall propose nothing dictated merely from theory;
but shall confirm all by experience and facts, the surest and
most unerring guides" (p 144).
In 1747, Lind carried out the first well described con-
trolled trial in medicine, on HMS Salisbury (1753 pp 145-
8). In this trial, Lind kept "12 patients in the scurvy … their
cases were as similar as I could have them," in the same
quarters; and he saw to it that they all had the same diet.
Groups of 2 men were then allocated to 6 different daily
treatments for a period of 14 days. One group was adminis-
tered 2 oranges and 1 lemon per day for 6 days only, when
the supply was exhausted. Other groups were administered
vinegar, sea-water, and other supposed anti-scurvy remedies.
From this trial, Lind concluded that "The most sudden and
visible good effects were perceived from the use of the or-
anges and lemons; one of those who had taken them, being
at the end of six days fit for duty" (p 146).
Lind’s trial was a milestone in medical research method-
ology (Dudley 1953; Thomas 1969, 1997; Hughes 1975;
McBride 1991; Dunn 1997; Friedman et al. 1998 p 1; Man-
chester 1998a; Sutton 2003; Currie 2003; Milne & Chalmers
2004). Hampton (2002) stated that "The elegant trial of the
use of oranges and lemons for the treatment of scurvy was
hardly bettered until the trial of streptomycin for tuberculo-
sis designed by Austin Bradford Hill [in 1948]."
Thus, Lind’s trial provided further empirical evidence
that citrus fruits could cure scurvy. However, most current
authors refer to this trial out of context, claiming that it
proved the essential role of fruit in preventing scurvy, and
establishing a way to understand deficiency diseases (Car-
penter 1986; Bartholomew 2002a,b). The trial is described
in just 3 pages of a book of some 350 pages. Lind himself
did not put as much weight on his trial as the current com-
mentators retrospectively do. In fact, he drew his own con-
clusions, which were completely false, about the etiology
of scurvy from observational data.
Lind was convinced that lack of fruit and vegetables was
not the primary etiological cause of scurvy, and argued at
length for this conclusion. "Before determining what are the
true causes of scurvy being so often epidemic at sea, it may
not be amiss to remark what they are not, although commonly
accused" (1753 p 71). "Others have supposed such to be the
constitution of the human body, that health and life cannot be
preserved long, without the use of green herbage, vegetables,
and fruits; and that a long abstinence from these, is alone the
cause of scurvy. But if this were truly the case, we must have
had the scurvy very accurately described by the ancients;
whose chief study seems to have been the art of war; and
whose manner of besieging towns was generally by a block-
age, till they had forced a surrender by famine. Now, as they
held out many months, sometimes years, without a supply of
vegetables; we should, no doubt, have heard of many dying
of the scurvy" (pp 73-4). "There are persons everywhere, who,
from choice, eat few or no green vegetables; and some coun-
tries are deprived of the use of them for five or six months of
the year; as is the case of many parts in the highlands of
Scotland, Newfoundland, etc., where, however, the scurvy is
not a usual malady" (p 74). Lind also describes his own ex-
perience while on board HMS Salisbury where he did not
observe a correlation between the consumption of greens and
the occurrence of scurvy, concluding that "although it is a
certain and experienced truth, that the use of greens and veg-
etables is effectual in preventing the disease, and extremely
beneficial in the cure … yet there are unquestionably to be
found at sea, other strong sources of [scurvy]; which we shall
hereafter distinguish by the name of the predisposing causes
to it." (p 76; Lind’s italics).
Thereafter Lind extensively describes his own notions
of the etiology of scurvy concluding that "I am certain it
will be allowed, by all who have had an opportunity of
making observations on this disease at sea, or will atten-
tively consider the situation of seamen there, that the prin-
cipal and main predisposing cause to it, is a manifest and
obvious quality of the air, viz. its moisture" (pp 84-5; Lind’s
italics; Martini 2004). Lind also argued "I will venture to
affirm, that, without any one exception, scurvy is unknown
in dry places" (p 98), "The lazy and indolent, and those of a
sedentary life … are most subject to scurvy; while hard la-
bourers … keep entirely free. … Those that are of a cheer-
ful and contented disposition, are less liable to it, than oth-
ers of a discontented and melancholy mind" (p 105). Fi-
nally, when discussing "the cure of the disease, and its symp-
toms" in the latter part of his treatise, Lind stated "All man-
kind have not the benefit of a pure wholesome air, warm
dry lodgings, with proper conveniences to guard against the
inclemency of different weather and seasons… Experience
shews, that the cure of the adventitious scurvy is very sim-
ple, viz. a pure dry air, with the use of green herbage or
wholesome vegetables, almost of any sort; which for the
most part prove effectual… Thus a free and pure country-
air, with such moderate exercise as at the same time conduces
to the agreeable amusement of the mind, is requisite"
(pp 178-9). "And by all faithful and accurate observations
made on this disease, moisture is experienced to be the prin-
cipal and main predisposing cause to it" (p 206). Although
proposing ‘moisture’ explicitly as the principal cause of
scurvy, Lind did consider that diet may have importance as
an ‘occasional cause’ of scurvy, i.e., secondary to moisture.
The correct explanation of the etiology of scurvy was
proposed in 1734, i.e., before Lind’s trial and monograph,
by John Bachstrom, a physician in Holland who claimed
that the cause of scurvy was the absence of fresh vegetable
food from the diet for a considerable time (Carpenter 1986
pp 44-5; Lind 1753 pp 314-7). Carpenter comments that
"Bachstrom’s treatise seems to the modern reader a straight-
forward argument and one that deserved at least a serious
consideration. But to the contemporary main-line physician
it was not impressive because it dealt with a single disease
in isolation and did nothing toward establishing a view of
the nature of ‘disease’ in general – an ideal which the medi-
cal profession had as its goals, by analogy with the univer-
sal laws being developed by the physicists at that time. In
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other words, Bachstrom was ‘a mere empirick’." Lind ex-
plicitly disagreed with Bachstrom’s proposal that "a long
abstinence from fruits and vegetables is alone the cause of
scurvy" (1753 p 73).
One hundred years later, John Elliotson (1831), profes-
sor of medicine in London, proposed specifically that
"scurvy is disease purely chemical. The body, structure, and
functions are not in the least in fault; in one sense, each part
of the system is ready to perform all its functions, but one
of the external things necessary for its doing so is taken
away. In the case of suffocation, the body is not at all in
fault, but it suffers from a want of fresh air; so in scurvy, the
functions are all right, but the food which the body by na-
ture requires is withheld from it… The case of scurvy is
exactly like the case of impending suffocation – the body
would be in good health if not deprived of its proper exter-
nal supply." A few years later, in 1842, George Budd also
suggested that scurvy was a deficiency disease: "From this
we must infer, that the ill effects of a diet consisting of sugar,
starch, oil, fat, do not result from want of protein only but
from want of other principles also requisite for the support
of the body. Perhaps the deficiency of each principle shows
itself in a particular way" (Hughes 1973; Carter 1977; Car-
penter 1986 pp 98-9, 249-51; Cook 2004). These were vi-
sionary considerations far ahead of their time.
The concept of necessary minor constituents started to be
accepted in main-line medicine over half a century after
Elliotson and Budd published their arguments, in the early
twentieth century. In 1906, Sir Frederick Hopkins wrote that
"The animal body is adjusted to live either upon plant tissues
or the tissues of other animals, and these contain countless
substances other than the proteins, carbohydrates, and fats.
Physiological evolution, I believe, has made some of these
well-nigh as essential as are the basal constituents of diet…
The field is almost unexplored; only is it certain that there
are many minor factors in all diets of which the body takes
account. In diseases such as rickets, and particularly in scurvy,
we have had for long years knowledge of a dietetic factor;
but though we know how to benefit these conditions empiri-
cally, the real errors in the diet are to this day quite obscure.
They are, however, certainly of the kind which comprises
these minimal qualitative factors that I am considering."
Hopkins was awarded the 1929 Nobel Prize in Medicine or
Physiology for his discovery of the growth-stimulating vita-
mins, which he called ‘accessory food factors’ and in 1931
he became the president of the Royal Society (Hopkins 1906,
1929; Harris 1947a,b; Needham 1962a,b; Kamminga 1997;
Carpenter 2003b, 2004; NF 2005a).
In 1912, Casimir Funk assembled all the various strands
of work supporting the deficiency theory of disease, con-
cluding that "The diseases mentioned above [in the title of
the paper] present certain general characters which justify
their inclusion in one group, called deficiency diseases. They
were considered for years either as intoxications by food or
as infectious diseases, and twenty years of experimental
work were necessary to show that diseases occur which are
caused by a deficiency of some essential substances in the
food. Although this view is not yet generally accepted, there
is now sufficient evidence to convince everybody of its truth,
if the trouble be taken to follow step by step the develop-
ment of our knowledge on this subject. This article is writ-
ten with the intention of giving a summary of the modern
investigations … there is perhaps no other subject in medi-
cine where so many contradictory and inexact statements
were made, which instead of advancing the research retarded
it by leading investigators in a wrong direction." Subsequent
research confirmed most of Funk’s opinions and vindicated
most of the arguments he provided in their support. Since
his paper, additional work on the deficiency diseases can be
thought of as elaboration of an existing theory (Carter 1977);
however, see footnote to Table 1. Funk (1912) also coined
the term ‘vitamine’ (‘vital’ substances that were chemically
‘amines’), but the letter ‘e’ was later dropped out when it
was found that not all these vital substances were ‘amines’,
so that the term for later use became ‘vitamin’ (Rosenfeld
1997; Carpenter 2004).
Nevertheless, as to the actual cure of scurvy, it took sev-
eral decades after Lind’s trial in 1747 before citrus fruits
were properly utilized in preventing it. Sir John Pringle be-
lieved that scurvy was caused by putrefaction, his own theory
being that ‘wort of malt’ was its cure and, because Sir John
happened to be the president of the Royal Society, ‘wort of
malt’ was a more respectable remedy for scurvy than lem-
ons long after Lind’s controlled trial (Table 1). In 1778,
Pringle resigned his position at the Royal Society, and in
1795, Sir Gilbert Blane, a follower of Lind, was able to
persuade the British Admiralty to issue a daily ration of
lemon juice to all sailors, which virtually eliminated scurvy
aboard Navy ships. It seems this defeat of vitamin C defi-
ciency was a major reason why the British Navy was able
to protect the country against Napoleon’s invasion and, in
particular, why Nelson was able to beat the French and Span-
ish fleets at the Battle of Trafalgar in 1805 when their mari-
ners were suffering from scurvy. Never before, and never
since, has vitamin C as a chemical substance had such a
crucial role in global politics (Bown 2003 pp 227-55).
Although scurvy caused its greatest evils on the long sea
voyages, it has also been a problem on land, sometimes
called the ‘land scurvy’ (Lind 1753 pp 52-63; Hess 1920
pp 1-22; Lorenz 1953, 1957; Wilson 1975; Carpenter 1986
pp 98-132; Hughes 1990; Bollet 1992; Harvie 2002 pp 225-
34). French explorer Jacques Cartier had winter on the Saint
Lawrence River in 1535-6 since his ships were frozen in the
ice, and most of his crew got scurvy. Local indians taught
them to prepare juice of white cedar and "after drinking it
two or three times, they recovered health and strength and
were cured of all the diseases they had ever had" (Carpenter
1986 pp 7-12; Martini 2002). Juice made of pine needles was
used also during the siege of Leningrad in the Second World
War to prevent scurvy (Shishkin 1943). Land scurvy has been
a problem in various circumstances. In the American Civil
War of 1861-1865, 7,000 Union army deaths were directly
attributed to scurvy, and another 45,000 deaths from dysen-
tery and diarrhea followed from severe scurvy. In the Cali-
fornia Gold Rush, some 10,000 men died from scurvy, half
of them succumbing in the first two winters alone. In the
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Irish Famine, caused by the failure of the potato crops in the
late 1840s, approximately one million people died of scurvy
and other diseases. Moreover, in the late 1800s, scurvy be-
came a pediatric problem when children were administered
heated milk and artificial foods which did not contain vita-
min C; this form of scurvy was called ‘the Barlow’s disease’
(Barlow 1894; Ylppö 1929; Aspin 1993; Rajakumar 2001;
Carpenter 1986 pp 158-72, 2003a). In Scandinavia, ‘land
scurvy’ was explicitly described in the 1500s, being largely
associated with wars (Olaus Magnus Gothus 1555). Nowa-
days, ‘land scurvy’ is a problem in the refugee camps, where
its prevalence has been up to 44% at the upper extreme (in
Somalia in 1985; WHO 1999), and in Afghanistan (Ahmad
2002). In the developed world, severe vitamin C deficiency
is currently rare; nevertheless, because its clinical features
are no longer familiar, even frank scurvy may remain undi-
agnosed (Sherlock & Rothschild 1967; Reuler et al. 1985;
Scully et al. 1986; Fain et al. 1998; Hirschmann & Raugi
1999; Weinstein et al. 2001; Akikusa et al. 2003; Bingham et
al. 2003; DeLuna 2003; Pimentel 2003).
Although there was strong observational evidence even
before Lind’s trial that citrus fruits were beneficial for scurvy,
there was no biological rationalization for fruit, and a large
number of false theories about scurvy prevailed long after
Lind’s controlled trial (Table 1). Since vitamin C is synthe-
sized by all mammals with the few exceptions of primates,
the guinea pig and fruit-eating bats, a reasonable animal
model for scurvy was not easy to find. Holst and Frölich
(1907; Johnson 1954) were able to produce scurvy in guinea
pigs by administering them a diet deficient in fruit, whereby
a suitable animal model for vitamin C deficiency was iden-
tified. Since then, the guinea pig has been the most impor-
tant animal model for studies examining the physiological
effects of vitamin C. Carpenter (1986 p 173, 2003a) con-
sidered that the Holst and Frölich paper has been the most
important in the whole history of vitamin C and scurvy;
however, see footnote to Table 1.
There were a few systematic efforts to isolate vitamin C,
but it was first isolated by chance by Albert Szent-Györgyi
(1933, 1963, 1971; Bendiner 1982; Hughes 1983; Edsall 1986;
Straub 1987; Grazer 1988; NLM 2005b), who had initially
considered that "Vitamins were, to my mind, theoretically
uninteresting. ‘Vitamin’ means that one has to eat it. What
one has to eat is the first concern of the chef, not the scien-
tist." Nevertheless, in 1928, while working in Frederick
Hopkin’s laboratory, Szent-Györgyi isolated a sugar-like
molecule from adrenals and citrus fruits. Since he did not
know much about the substance, he proposed the name
‘ignose’ (‘ignorant’ plus ‘-ose’ which is the suffix for sugar),
but the editor of the Biochemical Journal did not like jokes
and rejected the name. Thereafter Szent-Györgyi proposed
‘Godnose’ (‘God knows’ the purpose of the substance), but
the fate of this second proposal was the same, and the sub-
stance was finally named ‘hexuronic acid’ since it has 6 car-
bon atoms and is acidic.  In 1932, when Szent-Györgyi showed
that the substance cured scurvy in guinea pigs, the substance
was renamed ‘ascorbic acid’ (‘scorbutus’ is scurvy in Latin).
Szent-Györgyi spent the next several years "preaching vita-
min C" (as he put it) all over Europe, suggesting that it might
be valuable as a preventive or cure for the common cold and
other illnesses. He attempted to interest some of the British
biochemists in running some clinical trials, but they consid-
ered the idea crankish and refused to consider it. Vitamin C
proved disappointing as a miracle cure, however, and Szent-
Györgyi eventually got back to his basic research in other
areas (NLM 2005b). The Nobel Prize in Medicine or Physi-
ology was awarded to Szent-Györgyi in 1937 for identifying
vitamin C and for studies on energy metabolism (Szent-
Györgyi 1937; Simola 1937; Krebs 1970; Manchester 1998b;
NF 2005b). In parallel with Szent-Györgyi’s work, Charles
King identified vitamin C at nearly the same time and this
led to disagreements over who was first (King 1953, 1968,
1979; Szent-Györgyi 1938; Jukes 1988; Stare & Stare 1988;
NLM 2005c).
The chemical structure of vitamin C was solved by Sir
Norman Haworth, who was awarded the Nobel Prize in
Chemistry in 1937 (NF 2005c). In parallel with Haworth’s
vitamin C synthesis, Tadeus Reichstein developed a more
practical method of synthesizing vitamin C, which became
commercially useful, and patents allowed Reichstein to
amass considerable financial rewards. Although many peo-
ple were surprised that Reichstein did not receive the Nobel
Prize for the synthesis of vitamin C, he received the Nobel
Prize in Medicine or Physiology in 1951 for isolating and
identifying cortisone (Rothschild 1999; NF 2005d). The
Reichstein synthesis of vitamin C has been used to produce
it for decades, but currently there is a change to synthetic
processes involving genetically modified microbes. The
current world production of vitamin C is about 100,000,000
kg per year (Hancock & Viola 2002; Baier 2004).
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______________________________________________
Study
Animal
Infection
(Source of data)     Treatment P 1
____________________________________________________
Jungeblut-1937a Vit C Cont
Rhesus monkey
Intracerebral inoculation
of poliovirus
Tables II and III
Natural vitamin C
5 mg/d
Animal no. 33 38
Paralysis 17 36 .000,02
10-50 mg/d
Animal no. 19 38
Paralysis 16 36 .12
100-700 mg/d
Animal no. 10 38
Paralysis 10 36 .7
____________________________________________________
Jungeblut-1937b Vit C Cont
Rhesus monkey
Infection with poliovirus
Intracerebral inoculation
(Table II)
Synthetic vit C
5-100 mg/d
Animal no. 101 98
Paralysis 90 93 .07
Natural vit C
(2.5% impurities)
5-100 mg/d
Animal no. 181 98
Paralysis 123 93 <.000,001
Intranasal inoculation
(Table IV)
Natural vit C
(2.5% impurities)
5-25 mg/d
Animal no. 20 10
Paralysis 19 10 .5
50-100 mg/d
Animal no. 10 5
Paralysis 1 5 .001
____________________________________________________
Sabin-1939 Vit C Cont
Rhesus monkey
Intranasal inoculation
of poliovirus
Table I
Natural vit C
Series I
Vit C adequate diet
5 mg/d
Animal no. 6 10
Paralysis 5 8 .5
100 mg/d
Animal no. 10 10
Paralysis 9 8 .7
Series II
Vit C inadequate diet
Animal no. 7 5
Paralysis 7 4 .8
____________________________________________________
Jungeblut-1939 Vit C Cont
Rhesus monkey
Intranasal inoculation
of poliovirus
Natural or synthetic vit C
10-500 mg/d
Infected nasally by droplets
(Table IV)
Animal no. 56 20
Paralysis 23 15 .006
Infected nasally by pressure
(Table IV)
Animal no. 50 20
Paralysis 49 20 .4
____________________________________________________
Appendix 2. The effect of vitamin C on animal infections:
Administration of pure vitamin C to the ‘vitamin C group’
1 The 1-tailed P-value. In the case of dichotomous data, the mid-P-
value was calculated by the current author (see Table 7). The sur-
vival data, and the recovery time in Edwards (1968) and Naresh
(2002), and the number of tuberculin doses in Stein & Klein (1936)
were analyzed using the log-rank test. The score data, and the bacte-
rial count data of Wang et al. (2000), was analyzed using the
Wilcoxon test with normal approximation. Continuous data was
analyzed using the t-test. In the case of survival data and score data,
the number in parenthesis (n) indicates the number of animals with
the same outcome value; ‘+’ indicates censoring.
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Murphy-1974 Vit C Cont
Marmoset
Intranasal inoculation
of parainfluenza virus
Animal no. 14 7
Signs of infection
within 3 d 7 7 .015
Mortality 5 4 .2
Mean duration of sickness
in survivors (d) 9 20
__________________
Steinbach-1936 Vit C Cont
Guinea pig
Infected with M. bovis
Tuberculin injection
Animal no. 3 3
Mortality 0 3 .025
Tuberculin injection
Animal no. 8 8
No. of sequential 9+; 5+;9; .008
tuberculin doses 15+(4); 15(4);
before death 17; 17+;
(animals in pairs) 18+(2) 18
__________________
Birkhaug-1938, 1939,a,b Vit C Cont
Guinea pig
Infected with M. bovis
subcutaneous inoculation
to the left groin
Animal no. 12 12
Weight change in 49 d
Mean (g) +12 –40 .005
SD (g) 35 52
Size of tuberculin 2
reaction at 51 d
Mean (mm3) 575 4168 <.000,001
SD 228 1429
t(log-size)=12.9
Central necrosis
in tuberculin
reaction ≥140 mm3 3 12 .000,1
Overall score of
tuberculous 1(7); 2(7); .000,3
involvement 2(5) 3(5)
(scale 0 to 4)
Size of lymph glands:
Left superficial inguinal 2
Mean (mm3) 281 1885 .000,02
SD 252 1759
t(log-size)=5.07
Left tracheobronchial
Mean (mm3) 319 1212 .000,005
SD 183 514
Periportal
Mean (mm3) 554 1548 <.000,001
SD 236 436
Total size of lymph glands
Mean (% of body wgt) 1.21 2.37 <.000,001
SD 0.139 0.49
Size of spleen
Mean (mm3) 1421 2764 .001
SD 524 1220
Extensive caseonecrotic
lesions (no. of animals):
Lymph glands
Left deep inguinal 4 11 .003
Tracheobronchial 3 7 .063
Liver 3 9 .011
Spleen 5 9 .063
Tuberculous pneumonia 2 5 .11
__________________
Kleimenhagen-1941 3 Vit C Cont
Guinea pig
Infected with
M. tuberculosis
Young animals
Animal no. 6 8
Survival time (d) 68;75; 68;69; .018
182; 70;77;
190; 81;92;
197; 101;
259 107
Old animals
Animal no. 9 9
Survival time (d) 50;69; 43;46; .020
103; 54;58;
138; 81;114;
156+(5) 122;
136;
156+
__________________
2 Birkhaug (1939a,b) listed the data for the size of tuberculin reaction and the size of the left superficial inguinal lymph nodes per animal, and
these were log-transformed before the t-test by the current author. Birkhaug (1939b) listed mean and SD for the total size of lymphoid glands
and the size of the spleen; however, since he calculated the SD using ‘n’ as the denominator, the SD was corrected here to ‘sample SD’ using
‘n-1’ as the denominator.
3 Kleimenhagen (1941): survival data for young guinea pigs is from his table 6, and for old guinea pigs from his table 13. The current vitamin C
group is his group III (5 mg/day) and the control group is his group I (0.5 mg/day).
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Steinbach-1941 4 Vit C Cont
Guinea pig
Infected with M. bovis
Animal no. 13 6
Score of tuberculous 1(10); 1; .015
involvement 2;3; 2(3);
(scale 0 to 4) 4 4(2)
__________________
Gangadharam-1953 5 Vit C Cont
Guinea pig
Infected with
M. tuberculosis
Animal no. 4 4
Mean survival (d) 68 64
Mean weight change (g) –21 –70
Pathological lesions:
(scale 0 to 4)
Lungs, Mean 1.0 1.5
Liver, Mean 2.0 2.5
Spleen, Mean 1.0 1.5
__________________
Boyden-1956 6 Vit C Cont
Guinea pig
Infected with
M. tuberculosis
Animal no. 10 10
Survival time (d) 17;21; 13;21; .000,5
43;44; 22(2);
45;55; 24;26;
68;78; 27;29;
100; 30;35
120+
__________________
McCullough-1938 Vit C Cont
Guinea pig
Subcutaneous inj. of
Fusobacterium
necrophorum
Animal no. 50 50
Lesions at the site
of injection 0 31 <.000,001
Abscesses containing
F. necrophorum 0 16 .000,002
Animal no. 10 10
Abscesses containing
F. necrophorum
after 2 weeks 0 8 .000,2
__________________
Karel-1941 Vit C Cont
Guinea pig
Infection with
group C streptococcus
Animal no. 30 30
Mortality in 2 d 18 16 .7
Sulfanilamide groups
Animal no. 30 30
Mortality in 14 d 15 12 .8
__________________
Jones-1943 Vit C Cont
Guinea pig
Wound infection with
β-hemolytic Streptococcus
Animal no. 6 14
Mortality 1 10 .020
__________________
Peck-1991a 7 Vit C Cont
Guinea pig
Infected with E. coli
and S. aureus
Animal no. 13 15
Mortality 7 11 .2
__________________
Nelson-1992 Vit C Cont
Guinea pig
Burned animals,
S. aureus inj.
Animal no. 9 6
Bacteria in abscess (no.)
Mean 270 380 .2
SD 183 249
__________________
Sjunnesson-2001 Vit C Cont
Guinea pig
Infected with
Helicobacter pylori
Animal no. 12 14
H. pylori isolated after
5 weeks 5 6 .5
Gastritis score
(scale 0 to 3)
Mean 0.66 0.93 .3
SD 0.91 1.02
__________________
4 Steinbach & Klein (1941): data is from their table 3. The current vitamin C group is their group III (5 and 10 mg/day), and the control group is
their group IV.
5 Gangadharam & Sirsi (1953): the current vitamin C group is their group D, and the control group is their group C.
6 Boyden & Andersen (1956): the survival times were measured by the current author from their fig. 1. The current vitamin C group is their group
4 (hay-corn-beet + 140 mg/week vitamin C), and the control group is their group 1 (hay-corn-beet).
7 Peck & Alexander (1991a): data is from their table III. The current vitamin C group is the combination of their two low vitamin E groups (1×
and 3×RDA) administered high vitamin C (25×RDA) and the current control group is the combination of their two lower vitamin E groups
administered low vitamin C (1×RDA).
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Rogers-1983 Vit C Cont
Guinea pig
Infected with
Candida albicans
Fig. 1 (1×10exp[+5]) 8
Vit C 4 weeks
Animal no. 5 5
Log (no. of Candida
per kidney pair)
Mean 1.78 2.41 .036
SD 0.60 0.39
Vit C 6 weeks
Animal no. 5 5
Log (no. of Candida
per kidney pair)
Mean 1.87 2.61 .010
SD 0.43 0.41
Vit C 8 weeks
Animal no. 5 5
Log (no. of Candida
per kidney pair)
Mean 1.87 2.80 .004
SD 0.43 0.46
Fig. 2 (2×10exp[+6]) 9
Animal no. 6 6
Log (no. of Candida
per kidney pair)
Mean 3.63 4.70 .010
SD 0.65 0.69
__________________
Perla-1937 Vit C Cont
Guinea pig
Infected with
Trypanosoma brucei
–protozoa (sleeping sickness)
1. Experiment
vit C for 6 weeks
before infection
Animal no. 12 12
Mortality 2 12 .000,02
2. Experiment
vit C for 11 weeks
before infection
Animal no. 7 7
Mortality 7 5 .9
3. Experiment
vit C for 6 weeks
before infection
Animal no. 10 10
Mortality in 64 d 0 7 .000,8
__________________
Sadun-1951 Vit C Cont
Guinea pig
Infected with
Entamoeba histolytica
–protozoa (amebiasis)
Animal no. 14 10
Size of spleen
Mean (% of body wgt) 0.15 0.37 .000,02
(t = 5.314) 10
Animal no. 48 43
Lesions in cecal pouch
caused by infection 32 37 .017
Mortality 13 37 <.000,001
__________________
Banic-1975 Vit C Cont
Guinea pig
Infected with rabies virus
Animal no. 48 50
Mortality 17 35 .000,4
__________________
Greenwald-1935 11 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Animal no. 8 8
Survival time (d) 3;5;6; 3; .002
9;9+(2); 4(6);5
20;22
__________________
Jungeblut-1935 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Series II (Table III) 12
Animal no. 8 22
Mortality 4 22 .002
Series III (Table IV) 13
Animal no. 10 13
Local reaction to toxin 0;2(5); 4(4); .006
(scale 0 to 5) 4;5(3) 5(9)
__________________
Swanson-1936 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Animal no. 5 5
Broken incisors 0 5 .002
__________________
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Sigal-1937 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Table 3
Animal no. 13 14
Weight change in 18 d 14
Mean (g) +31 -68 .003
SD (g) 86 75
Mortality in 23 d 1 7 .012
__________________
Zilva-1937 15 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Animal no. 12 3
Survival time (d) 2;3.5; 2; .031
4(2); 3.5;
4.5(2); 4.5
5.5(2);
9+(3);
10+
__________________
King-1940 16 Vit C Cont
Guinea pig
Diphtheria toxin inj.
Animal no. 12 12
Injury to the odontoblasts
and dentin 0 12 <.000,001
__________________
Fuller-1971 17 Vit C Cont
Guinea pig
Endotoxin inj.
7-9 week old animals
Animal no. 10 12
Shock 3 12 .000,4
Survival time (h) 6; 1(11); .000,002
48+(9) 6
14-16 week old animals
Animal no. 10 14
Shock 3 14 .000,2
Mortality in 48 h 3 10 .031
__________________
Kuenzig-1980 18 Vit C Cont
Guinea pig
Endotoxin inj.
Animal no. 10 14
Signs of physical stress,
such as ocular exudate
and piloerection 1 7 .028
__________________
8 Rogers et al. (1983): data for 1×10exp(+5) inoculum is from their fig. 1. Vitamin C, 20 mg/day, was administered for 4, 6 or 8 weeks before
infection in separate groups, and the number of Candida in the kidneys was determined 3 days after infection. The mean and SD for the Log
(no. of Candida) were measured by the current author from their fig. 1. The number of animals was 5-8 per group, but the exact number is not
reported. The current calculation is based on the conservative assumption that the groups consisted of 5 animals.
9 Rogers et al. (1983): data for 2×10exp(+6) inoculum is from their fig. 2. Vitamin C, 100 mg/day, was administered before the inoculation, and the
number of Candida was determined 3 days after infection. The mean and SD for the Log(no. of Candida) were measured from their fig. 2. The
number of animals was 6-8 per group, and the present calculation is based on the conservative assumption that the groups consisted of 6 animals.
10 Sadun et al. (1951) calculated the t-test yielding the t-value in the parentheses but the SD-values for the size of the spleen were not reported.
11 Greenwald & Harde (1935): the current vitamin C group is the combination of two 4-animal groups administered 10-20 mg/day. The control group
is the combination of the corresponding two 4-animal control groups: in their first control group all animals died on the 4th day, whereas in their
second control group, the animals died at "3 to 5 days" and it is here assumed that the survival times are 3, 4, 4, and 5 days in the latter group.
12 Jungeblut & Zwemer (1935): the diphtheria toxin dose in series II was twice the minimal lethal dose (2×MLD). The current vitamin C group
consists of 8 guinea pigs administered 25 to 200 mg of the vitamin. The current control group refers to table I of the original paper, but not all
the control animals were concurrent with the vitamin-treated animals.
13 Jungeblut & Zwemer (1935): 0.02×MLD was injected intracutaneously, the score being recorded 3 days after the injection. Vitamin C doses
were 10 to 100 mg/day for 6 days.
14 Sigal & King (1937): data is from their table 3 with 0.6×MLD of diphtheria toxin. The range of weights on the 18th day was reported as from
436 to 608 g in the high vitamin C group and from 340 to 490 g in the low vitamin C group. The SD was estimated in the current table con-
servatively as half of the range, i.e., 86 and 75 g respectively. In the control group n=13 at 18th day.
15 Zilva (1937): the current vitamin C group is the combination of his groups D and E with a mixed diet supplemented with 100 mg/day of vita-
min C, and the control group is his group B with a mixed diet without additional vitamin C; all these animals were administered 1×MLD of
diphtheria toxin. When survival time of an animal was presented as a range, such as 3-4 days, the mean of the range (3.5) was used in the log-
rank test and is shown in the current table.
16 King et al. (1940): the current vitamin C group is the combination of their groups 2 to 7, and the control group is the combination of their
groups 9 to 14. The authors state that ‘two or more animals were taken from each group for examination of the teeth" and here the calculation
of the P-value has been based on the conservative assumption that each group consists of exactly 2 animals.
17 Fuller et al. (1971) administered E. coli lipopolysaccharide B. The methods are not described in detail, but reference is made to Schlumberger
(1959), which indicates that 4 mg/day of pure vitamin C was added to the vitamin C supplemented group.
18 Kuenzig et al. (1980) administered sublethal doses of E. coli endotoxin. In their brief abstract, only the percentage of animals with physical
distress is indicated: 57%, 43%, and 10% in the low, normal and high vitamin C level groups respectively. The lower estimate of the number of
animals was inferred from these percentages: 4/7, 3/7, and 1/10 respectively. The low and normal groups have been combined into the control
group of the current table (i.e., 7/14).
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Naresh-2002 Vit C Cont
Cow
Treatment of mastitis
Clinical mastitis 19
Animal no. 12 6
Recovery time (d) 4(10); 6(5); .000,02
5(2) 15
Subclinical mastitis 19
Animal no. 12 6
Recovery time (d) 5(8); 15+(6) .001
6(2);
15+(2)
__________________
Hamdy-1967 20 Vit C Cont
Lamb
Spontaneous pneumonia
Animal no. 44 92
Mortality before slaughter 14 12 .993
Pneumonia in
slaughtered lambs 3 48 <.000,001
__________________
Dwenger-1994 21 Vit C Cont
Sheep
Endotoxin inj.
Animal no. 8 8
Effect of vitamin C on:
Pulmonary arterial
   pressure .000,05
Arterial O2 saturation .005
Arterio-to-venous O2
   pressure difference .000,3
__________________
Büsing-1939 22 Vit C Cont
Rabbit
Intravenous inj.
S. pneumoniae (Table 1)
Animal no. 5 5
Survival time (h) 61;71; 30(2); .003
72; 45(2);
89(2) 61
S. aureus (Table 4)
Animal no. 12 12
Survival time (d) 21; 14(2); .026
24+(11) 15(2);
19;24+(7)
__________________
Locke-1937 Vit C Cont
Rabbit
Infected with
S. pneumoniae
Animal no. 11 12
Positive blood culture
after 30 min 4 9 .042
__________________
Locke-1939 23 Vit C Cont
Rabbit
Infected with
S. pneumoniae
Animal no. 11 10
Mortality 5 10 .005
__________________
Fukuda-1963 24 Vit C Cont
Rabbit
Endotoxin inj.
Liver glycogen depletion
Normal rabbits
Animal no. 5 5
Liver glycogen
Mean (% of liver wgt) 2.04 0.70 .000,5
SD 0.54 0.25
Adrenalectomized rabbits
Animal no. 5 6
Liver glycogen
Mean (% of liver wgt) 2.02 0.70 .001
SD 0.67 0.32
__________________
Edwards-1968 Vit C Cont
Cat
Duration of rhinotracheitis
(feline herpes virus)
Tylosin-treatment
Animal no. 15 19
Recovery time (d) 4(6); 4;7(6); .005
5(3); 8;9(5);
6(2); 10(2);
7(2); 11(2);
9;36 14(2)
No tylosin-treatment
(vit C alone)
Animal no. 26
Recovery time, Median (d) 4.5
__________________
19 Naresh et al. (2002) administered antibiotics to all cows with clinical mastitis, so that the effect of vitamin C was over and above that of antibi-
otics. For subclinical mastites, tables 2 and 3 are inconsistent, the latter being consistent with the text.
20 Hamdy et al. (1967): vitamin C was administered at birth and twice per week for 4-5 weeks.
21 Dwenger et al. (1994) administered E. coli endotoxin. This is a cross-over trial with 8 sheep. The P-values were calculated by the original
authors from the comparisons between several time points. In the current table, the P-values presented are those calculated in the time-range of
2 to 4 h after endotoxin administration.
22 Büsing (1939): the survival times were measured by the current author from their fig. 1 for S. pneumoniae, and their fig. 4 for S. aureus with
the kinin and non-kinin groups being combined.
23 Locke (1939): data is from table 2. Current vitamin C group is his group 6, and current control group his group 5.
24 Fukuda et al. (1963): the liver glycogen percentages were measured from the data points of fig. 1.
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Matsumoto-1992 Vit C Cont
Rat
Experimental
E. coli pyelonephritis
Oral vit C
Animal no. 8 8
Score of renal scarring 1(6); 1(2); .030
(scale 0 to 3) 2(2) 2(6)
Subcutaneous vit C
Animal no. 8 8
Score of renal scarring 0(2);1; 2(3); .036
(scale 0 to 3) 2(3); 3(5)
3(2)
__________________
Miyagatani-1998 25 Vit C Cont
Rat
Experimental peritonitis
Animal no. 27 28
Mortality in 2 d 6 14 .019
__________________
Armour-2001 26 Vit C Cont
Rat
Experimental peritonitis
Vit C 7.5 mg/100 g
Animal no. 5 16
Mortality in 1 d 0 4 .16
BP at 1 d
Mean (mmHg) 115.6 90.1 .000,5
SD 7.6 3.3
Density of perfused
capillaries
Mean (1/mm) 23.9 16.8 .010
SD 3.9 2.2
Vit C 76 mg/100 g
Animal no. 7 16
Mortality in 1 d 1 4 .3
BP at 1 d
Mean (mmHg) 111 90.1 .008
SD  12 3.3
Density of perfused
capillaries
Mean (1/mm) 27 16.8 .003
SD 4.5 2.2
__________________
Kastenbauer-2002 27 Vit C Cont
Rat
Experimental
S. pneumonia meningitis
Animal no. 4 10
Median intracranial
pressure (mmHg) 24 22 .5
Urate treated
Animal no. 6 8
Median intracranial
pressure (mmHg) 13 25 <.05 28
__________________
25 Miyagatani et al. (1998): rats were made septic by cecal ligation and puncture (CLP).
26 Armour et al. (2001): rats were made septic by cecal ligation and perforation (CLP). Blood pressure (BP) values were measured from their fig
5; there were 4-10 rats per group; the SE values for the groups were reported and here the SE value is transformed to SD assuming conserva-
tively that there were 4 rats per group.  Capillary density values were measured from their fig. 6; there were 4-7 rats per group; the SE values
for the groups were reported and here the SE value is transformed to SD assuming conservatively that there were 4 rats per group.  For the high
dose (76 mg/100 g) group, the results are described in text, and BP is based on n = 4, and capillary density on n = 5.
27 Kastenbauer et al. (2002): all animals were treated with ceftriaxone, so that the possible effect of vitamin C was over and above the effect of
the antibiotic.
28 Kastenbauer et al. (2002) calculated the P-value using a non-parametric test.
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Tyml-2005 29 Vit C Cont
Rat
Experimental peritonitis
Vit C 6 h after CLP  30
Animal no. 9 9
BP at 1 d
Mean (mmHg) 101 97 .3
SD 15 11
Density of perfused
capillaries at 1 d
Mean (1/mm) 19.5 11.3 .003
SD 4.2 3.5
Vit C 1 h after CLP  31
Animal no. 7 19
Mortality in 2 d 0 4 .13
Rectal temp at 2 d
Mean (°C) 33.9 37.8 .000,1
SD 0.23 1.34
Change in BP in 2 d
Mean (mmHg) 17 28 .15
SD 17 20
Density of perfused
capillaries at 2 d
Mean (1/mm) 18.0 10.4 .019
SD 5.0 4.6
Vit C 24 h after CLP 32
Animal no. 20 19
Mortality in 2 d 6 4 .7
Rectal temp at 2 d
Mean (°C) 35.1 37.8 .003
SD 0.90 1.34
Change in BP in 2 d
Mean (mmHg) 18 28 .12
SD 6 20
Density of perfused
capillaries at 2 d
Mean (1/mm) 16.1 10.4 .017
SD 2.1 4.6
__________________
Dey-1966 33 Vit C Cont
Rat
Tetanus toxin inj.
Vit C before or
simultaneously with toxin
Animal no. 10 5
Mortality 0 5 .000,2
Vit C after signs of
tetanus appeared
Animal no. 15 5
Mortality 0 5 .000,04
__________________
Feng-2004 34 Vit C Cont
Rat
Endotoxin inj.
Animal no. 6 6
Lung weight at 4 h
Mean (mg) 170 318 .000,004
SD 29.4 31.8
__________________
Kanter-2005 35 Vit C Cont
Rat
Endotoxin inj.
Animal no. 10 10
Diameter of glomeruli
Mean (µm) 70.13 43.84 <.000,001
SD 2.15 1.23
Vitamin A groups
Animal no. 10 10
Diameter of glomeruli
Mean (µm) 77.94 48.13 <.000,001
SD 3.46 1.26
__________________
29 Tyml et al. (2005): rats were made septic by cecal ligation and perforation (CLP).
30 Tyml et al. (2005): vitamin C 6 hours after CLP.  Blood pressure (BP) values were measured from their Fig. 2; there were 9-24 rats per group;
SE values for the groups were reported and here the SE value is transformed to SD assuming conservatively that there were 9 rats per group.
Capillary density values were measured from their Fig. 3; there were 6 rats per group.
31 Tyml et al. (2005): vitamin C was administered 1 hour after CLP. Rectal temperature was measured for 5 - 8 rats per group and the SE values
for the groups were reported in table 1; the SE value is transformed to SD assuming conservatively that there were 5 rats per group. Blood
pressure (BP) changes were measured from Fig. 4; there were 7-14 rats per group; SE values for the groups were reported and here the SE
value is transformed to SD assuming conservatively that there were 7 rats per group. Capillary density values were measured from their Fig. 5;
there were 5 rats per group.
32 Tyml et al. (2005): vitamin C was administered 24 hours after CLP. See footnote 31.
33 Dey (1966): 2×MLD of tetanus toxin was administered.
34 Feng et al. (2005): K. pneumoniae lipopolysaccharide.
35 Kanter et al. (2005): E. coli lipopolysaccharide. Statistical analysis inappropriate in the original paper, see Hemilä (2006b).
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Zhang-1997 36 Vit C Cont
Gerbil
Infected with H. pylori
Strain MCP37B
Animal no. 6 6
Log(CFU)
Mean 3.30 5.15 .000,007
SD 0.32 0.48
Strain ATCC43504
Animal no. 6 6
Log(CFU)
Mean 3.07 4.96 .000,007
SD 0.56 0.16
__________________
Garg-2004 37 Vit C Cont
Hamster
Inoculation of Leishmania
-protozoa
Prophylactic vit C
250 mg/kg
Animal no. 20 20
Parasite count
Mean 5.0 37.2 <.000,001
SD 2.5 17.4
Mortality in 90 d 0 20 <.000,001
100 mg/kg
Animal no. 30 30
Parasite count
Mean 8.6 36.2 <.000,001
SD 3.7 9.8
Mortality in 90 d 0 30 <.000,001
50 mg/kg
Animal no. 30 30
Parasite count
Mean 6.0 38.5 <.000,001
SD 1.2 6.3
25 mg/kg
Animal no. 20 20
Parasite count
Mean 55.4 56.1 .4
SD 7.6 8.7
Continuous vit C
250 mg/kg
Animal no. 20 20
Parasite count
Mean 37.0 37.0 .5
SD 14.1 17.2
__________________
Hastings-1976 Vit C Cont
Mouse
Inoculation of
M. leprae to foot pads
Table 1: 6 months follow-up
0.45% vit C in feed
Animal no. 6 6
No. of bacteria in
foot pad (10exp(+4))
Mean 4.44 13.5 .003
SD 1.45 6.2
0.15% vit C in feed
Animal no. 6 6
No. of bacteria in
foot pad (10exp(+4))
   Mean 5.21 13.5 .005
   SD 1.27 6.2
0.05% vit C in feed
Animal no. 4 6
No. of bacteria in
foot pad (10exp(+4))
   Mean 7.88 13.5 .058
   SD 0.90 6.2
__________________
Esposito-1986 38 Vit C Cont
Mouse
Infected with
S. pneumoniae
Animal no. 50 50
Survival time (d) 2; 2(4); .2
3(9); 3(10);
4(11); 4(11);
5(4); 5(3);
5+(25) 5+(22)
__________________
Fang-1990 39 Vit C Cont
Mouse
Burned animals,
infected with
Ps. aeruginosa
Low+Med vit C
Animal no. 59 26
Mortality 42 18 .6
High vit C
Animal no. 30 26
Mortality 27 18 .96
__________________
36 Zhang et al. (1997): data was measured by the current author from their fig. 2. CFU, colony forming units in stomach.
37 Garg et al. (2002): The parasite counts were calculated from their Fig. 1A. The number of animals is not quite clear. The materials and methods
state that "For each individual experiment a batch of 30 hamsters was equally divided into 3 groups [prophylactic vit C, continued vit C, con-
trol]" but it is not explicitly stated whether an "experiment" indicates Fig 1 or part of it, e.g. Fig. 1A. Here it is assumed that e.g. Fig. 1A
(250 mg/day) consists of "an experiment" which was replicated twice according to the legend of Fig. 1. Mortality is described in text [p 688]:
"animals given vitamin C prophylactically …survived until the day the experiment was terminated i.e. on day 90 p.i. [post infection], while the
animals of the other experimental groups died between day 50 and day 60 p.i.
38 Esposito (1986): the survival times were measured by the current author from their fig. 1.
39 Fang et al. (1990): data is for the group administered vitamin C on a single day at the time of infection, 1 day after the burn.
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Gallin-1979 40 Vit C Cont
Mouse
Infected with C. albicans
Normal mouse
Animal no. 16 19
Survival time (d) 3;4; 2.5; .025
5(2); 3(2);
5.5(5); 3.5(3);
6.5; 4(2);
7.5; 5(3);5.5;
8+(5) 6;6.5;
7;7.5;
8(2);8+
CHS mouse
Animal no. 16 19
Survival time (d) 1;1.5(6); 0.5(16); <.000,001
2(5); 1(3)
2.5(4)
__________________
Wang-2000 41 Vit C Cont
Mouse
Infected with
Helicobacter pylori
Animal no. 10 10
Bacterial count 0.7(4); 3.2(2); .000,5
Log (CFU) 1.3;2.2; 3.5(3);
2.3;2.4; 3.6;3.7;
3.0;3.7 4.0;4.2;
4.3
Inflammation score 1.2; 1.7(2); .000,1
(scale 0 to 3) 1.3(4); 1.8(2);
1.5(2); 2.0(3);
1.6(2); 2.3(2);
1.7 2.7
__________________
Wu-2003 42 Vit C Cont
Mouse
Experimental peritonitis
Animal no. 8 8
BP at 6 h
Mean (mmHg) 69.0 61.6 .023
SD 4.9 8.2
__________________
Wu-2004 43 Vit C Cont
Mouse
Experimental sepsis
Vit C 0.5 h before CLP
Animal no. 29 29
Survival time (h) 18(7); 18(20); .000,04
24(6); 24(6);
24+(16) 24+(3)
BP at 6 h
Mean (mmHg) 63 41 .000,003
SD 4 4
Vit C 3 h after CLP
Animal no. 6 6
BP at 6 h
Mean (mmHg) 39 40 .3
SD 10 5
__________________
Seah-1974 44 Vit C Cont
Mouse
Infected with
Toxoplasma gondii
–protozoa
A: Vit C 8 mg/d
Animal no. 12 24
Survival time (d) 5(3); 3; .000,001
6(4); 4(15);
7(4); 5(8)
9
B: Vit C 16 mg/d
Animal no. 12 24
Survival time (d) 4(3); 3; .000,5
5(4); 4(15);
6(3); 5(8)
8;9
__________________
Bourke-1980 Vit C Cont
Mouse
Infected with
Plasmodium berghei
–protozoa (malaria)
0.5 g vit C /kg body wgt
Animal no. ? ?
Survival time, Median (d) 18 9
1 g vit C /kg body wgt
Animal no. ? ?
Survival time, Median (d) 21 9
__________________
40 Gallin et al. (1979): the survival times were measured by the current author from their fig. 1. CHS; Chediac Higashi Syndrome mouse model.
41 Wang (2000): Half of the animals from each group were sacrificed 1 day after the cessation of treatment and the other half were sacrificed 10 days
after the cessation of treatment. The animals sacrificed at different times are combined in this table. The data for this table was measured from Figs
1 and 2 of the paper. Detection limit of bacterial growth was 0.7 Log units. CFU, colony forming units per ml of stomach homogenate.
42 Wu et al. (2003): mice were made septic by cecal ligation and puncture (CLP). Blood pressure (BP) values were measured from their Fig. 5.
43  Wu et al. (2004): mice were made septic by cecal ligation and puncture (CLP). Blood pressure (BP) values were measured from their Fig. 5 for
early vitamin C and from their Fig. 8 for late vitamin C; in both cases there were 6 animals per group.
44 Seah (1974) reported the mean and SD/SE for four groups; two were administered vitamin C (groups A and B) and two were controls (groups
C and D). The individual survival times were calculated from the published mean and SD (for groups A and B) or SE (groups C and D) values;
thereafter the control group data have been combined in the current table.
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Büller Souto-1939 45 Vit C Cont
Mouse
Clostridial toxins
1×LD50
Animal no. 125 62
Mortality in 2 d 27 29 .000,3
2×LD50
Animal no. 130 68
Mortality in 2 d 78 63 <.000,001
__________________
Hill-1955 46 Vit C Cont
Chicken
Infected with Salmonella
Table 5
Animal no. 40 40
Mortality 7 20 .002
__________________
Little-1971 Vit C Cont
Chicken
Infected with Eimeria
–protozoa (coccidiosis)
Table 3
Animal no. 80 80
Mortality 26 20 .8
Table 4
Animal no. 80 80
Mortality 56 48 .9
__________________
Gross-1988a Vit C Cont
Chicken
Infected with E. coli
Table 1
Animal no. 36 33
Pericarditis or dead 4 23 <.000,001
Table 3:
0.33-0.44 g vit C/kg feed
Animal no. 26 13
No. infected 13 12 .005
__________________
Gross-1988b 47 Vit C Cont
Chicken
Infected with E. coli
Experiment 1
Animal no. 22 21
Mortality 3 11 .005
__________________
Gross-1992 Vit C Cont
Chicken
Experiment 4
Infected with
Mycoplasma gallisepticum,
Newcastle disease virus,
and E. coli
Animal no. 26 42
Pericarditis or dead 9 32 .000,5
Experiment 5
Infected with
M. gallisepticum,
and Newcastle disease virus,
0.1 g vit C/kg feed
Animal no. 5 5
Lesion score, Mean 0.52 1.50 <.05 48
(scale 0 to 2)
Experiment 6
Infected with E. coli
0.1 g vit C/kg feed
Animal no. 8 8
Lesion score, Mean 0.50 2.90 <.05 48
(scale 0 to 4)
__________________
45 Büller Souto & Lima (1939) data was extracted by Clemetson (2002) to his table 1 and the current figures are from the latter source. Toxins of
four Clostridium species (C. welchii, C. septicum, C. oedematiens, C. histolyticum) were administered intramuscularly to different groups of
mice and the groups are combined to this table. LD50; dose leading to the death of 50% of animals.
46 Hill et al. (1955): data is from their table 5. There were 40 birds per treatment group, and the mortality was calculated from the percentages in
their table 5. The current vitamin C group is their ‘basal diet+vitamins+0.1%C’ and the control group is ‘basal diet+vitamins–C’ (excluding
vitamin C).
47 Gross (1988b): the results of HA and LA lines of chickens in their fig. 1 are combined. Comparison is between 0.4 g vitamin C/kg feed and no
supplementation.
48 Gross (1992) himself calculated the P-values for the lesion scores.
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Davelaar-1992 49 Vit C Cont
Chicken
Infected with avian coronavirus
(infectious bronchitis virus)
Experiment 1
0.33 g vit C/kg feed
Animal no. 20 20
Table 1
14 d: air sacculitis
no. of animals 0 12 .000,02
Table 2 50
10 d: tracheal lesion score 0(4); 1;2(5); .000,02
(scale 0 to 3) 1(8); 3(9)
2(3)
Experiment 2
0.3 g vit C/kg feed
Animal no. 24 24
Table 3
14 d: air sac lesion score 0(16); 0(9); .009
(scale 0,1,2,4) 1(3); 1(3);
2(5) 2(7);
4(5)
Table 4
10 d: tracheal lesion score 0(5); 0(2); .000,07
(scale 0 to 3) 1(18); 1(7);
2 2(15);
__________________
Amakye-2000 Vit C Cont
Chicken
Infected with
infectious bursal disease virus
Animal no. 30 30
Clinical signs 0 30 <.000,01
Mortality 0 9 .000,5
__________________
Hanzlik-1936 51 Vit C Cont
Pigeon
Diphteria toxin inj.
Animal no. 6 24
Mortality 1 15 .032
__________________
Durve-1982 Vit C Cont
Catfish
Infected with
Edwardsiella  tarda
Temperature 23° C
Animal no. 20 20
Mortality 4 20 <.000,1
Temperature 33° C
Animal no. 20 20
Mortality 2 10 .004
__________________
Li-1985 52 Vit C Cont
Catfish
Infected with
Edwardsiella ictaluri
Table 3
Animal no. 20 20
Mortality 0 20 <.000,1
__________________
Liu-1989 53 Vit C Cont
Catfish
Infected with E. ictaluri
2 g vit C/kg feed
Animal no. 300 60
Log(LD50)
(10exp[+5] cells/fish) 5.0 0.007
Vit C (g/kg feed)
0.1 5.2
0.5 5.8
1 6.8
2 7.1
4 7.1
__________________
Li-1993 54 Vit C Cont
Catfish
Infected with E. ictaluri
Table 5: Experiment 2
0.1 g vit C/kg feed
Animal no. 250 250
Mortality 151 195 <.000,1
2 g vit C/kg feed
Animal no. 250 250
Mortality 175 195 .020
__________________
49 Davelaar & Bos (1992) reported the mean and confidence limits of
the score values. The original score values per animal were inferred
by the current author from the published data. In the control groups,
the maximum harm caused by infection to the trachea was seen at
10 days and to the air sacs at 14 days, which are thus selected as
times for examining the effect of vitamin C in this table. In Table 2
for both groups n=15.
50 Davelaar & Bos (1992): In table 2 for both groups n = 15.
51 Hanzlik & Terada (1936): their vitamin C groups 2 and 3 have been
combined (n = 3 for both groups), and compared with the control
groups administered 9 µl and 10 µl of diphtheria toxin (n = 12 for
both groups). The mortality in the lower dose control group (9 µl)
was 50%, indicating that 6 of 12 pigeons died. The mortality in the
higher dose control group (10 µl) was 80%, which does not produce
an integer number of deaths, and the mortality is conservatively
rounded downwards (9 of 12). These two control groups were col-
lapsed to obtain the ratio 15/24 for the control group of the current
table.
52 Li & Lovell (1985): data is at 8 days after infection; the current
vitamin C group is fish administered 3 g vitamin C/kg feed, and the
control group is fish administered no vitamin C.
53 Liu et al. (1989): the P-value was calculated by the current author as
the test of slope in linear regression of Log(LD50) as a function of
the square root of vitamin C dosage.
54 Li et al. (1993): the cumulative mortality was calculated from the
mortality percentage and the total number of fish at the start (n = 50
in 5 aquaria per diet).
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Duncan-1993, 1994 Vit C Cont
Catfish
Spontaneous infection
by Flexibacter columnaris
0.2 vs. 0.02 g vit C/kg feed
Low folic acid
Animal no. 240 240
Total mortality 88 110 .021
Mortality caused by
F. columnaris 10 13 .3
Medium folic acid
Animal no. 240 240
Total mortality 30 121 <.000,1
Mortality caused by
F. columnaris 1 17 <.000,1
High folic acid
Animal no. 240 240
Total mortality 22 20 .6
Mortality caused by
F. columnaris 4 1 .9
Experimental infection
with E. ictaluri
Low folic acid
Animal no. 24 24
Mortality 18 21 .15
Medium folic acid
Animal no. 24 24
Mortality 9 15 .048
High folic acid
Animal no. 24 24
Mortality 7 7 .5
__________________
Lim-2000 Vit C Cont
Catfish
Infected with
E. ictaluri
50 mg vit C/kg feed
30 mg iron/kg feed
Animal no. 60 60
Mortality 30 40 .034
300 mg iron/kg feed
Animal no. 60 60
Mortality 20 49 <.000,1
__________________
Wahli-1986 Vit C Cont
Rainbow-trout
Infected with
Ichthyphthirius multifiliis
–protozoa
8800 tomites per fish
Animal no. 50 50
Mortality  1 26 <.000,1
11500 tomites per fish
Animal no. 50 50
Mortality 8 50 <.000,1
__________________
Navarre-1989 Vit C Cont
Rainbow-trout
Infected with
Vibro anguillarum
Fig 3
2×10exp(+4) bacteria/ml 55
Animal no. ? ?
Mortality  percentage
vit C g/kg feed
0.0 55% 0.005
0.1 46%
0.5 21%
1.0   1%
2.0   1%
1.4×10exp(+6) bacteria/ml 55
Animal no. ? ?
Mortality percentage
vit C g/kg feed
0.0 100% 0.005
0.1 84%
0.5 36%
1.0   8%
2.0   4%
2.8×10exp(+8) bacteria/ml
Animal no. ? ?
Mortality percentage
vit C g/kg feed
0.0 100% .5
2.0 100%
__________________
Wahli-1995 Vit C Cont
Rainbow trout
Infected with I. multifiliis
–protozoa
9 600 theronts/fish
Animal no. 40 40
Mortality 11 40 <.000,1
20 000 theronts/fish
Animal no. 40 40
Mortality 29 40 .000,2
__________________
55 Navarre et al. (1989): the P-value was calculated by the current author as the test of slope in linear regression of mortality percentage as a
function of the square root of vitamin C dosage.
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Wahli-1998 56 Vit C Cont
Rainbow trout
Infected with VHS virus
Low vit E
Animal no. 50 50
Mortality 10 13 .2
High vit E
Animal no. 50 50
Mortality 2 29 <.000,1
Infected with Yersinia ruckeri
Low vit E
Animal no. 50 50
Mortality 20 48 <.000,1
High vit E
Animal no. 50 50
Mortality 18 16 .6
Infected with I. multifiliis
–protozoa
Low vit E
Animal no. 50 50
Mortality 3 21 <.000,1
High vit E
Animal no. 50 50
Mortality 4 1 .9
__________________
Hardie-1991 57 Vit C Cont
Atlantic salmon
Infected with
Aeromonas salmonicida
Animal no. 25 25
Mortality  2 23 <.000,1
__________________
Waagbo-1992, 1993 58 Vit C Cont
Atlantic salmon
Infected with
A. salmonicida
Animal no. 50 50
Mortality  6 10 .14
__________________
Lygren-1999 59 Vit C Cont
Atlantic salmon
Infected with
infectious salmon anemia virus
Animal no. 90 90
Mortality in 43 d 84 90 .007
Fe added to feed
Animal no. 90 90
Mortality in 43 d 82 90 .002
__________________
Bell-1984 60 Vit C Cont
Sockeye salmon
Infected with
Renibacter salmoninarum
High Zn and Mn
Animal no. 30 30
Median survival time (d) 79 78 .5
Low Zn and Mn
Animal no. 30 30
Median survival time (d) 75 90 >.999
__________________
Sobhana-2002 Vit C Cont
Hamilton
Infected with
Aeromonas hydrophila
Animal no. 10 10
Mortality  2 7 .019
__________________
Martins-1998 61 Vit C Cont
Pacu-fish
Infected with
Anacanthorus penilabiatus
–protozoa
Animal no. 30 10
No. of parasites in gills
Mean 20.4 42.5 .003
SD 13.1 35.1
____________________________________________________________
56 Wahli et al. (1998): the current vitamin C group is fish administered
2 g vitamin C/kg feed. The low vitamin E group was not adminis-
tered additional vitamin E; the high vitamin E group was adminis-
tered 0.8 g vitamin E/kg feed. VHS, viral hemorrhagic septicemia
virus.
57 Hardie et al. (1991): data is from their fig. 5: the current vitamin C
group is fish administered 2.75 g vitamin C/kg feed.
58 Waagbo et al. (1993): data is from their fig. 2: the current vitamin C
group is fish administered 4 g vitamin C/kg feed, and the control
group was administered 40 mg vitamin C/kg feed. The cumulative
mortality at 55 days was calculated from the mortality percentage
and the total number of fish at the start (n = 50).
59 Lygren et al. (1999): data from their table 5 with 43 days follow-up.
The cumulative mortality at 43 days was calculated from the mor-
tality percentage and the total number of fish at the start (n = 90).
60 Bell et al. (1984): data for groups inoculated with bacterial dosage
5.69×10exp(+5) is presented in the current table. The survival times
were measured by the current author from their fig. 3. High Zn and
Mn comparison means comparison of groups 1 and 3, and low Zn
and Mn comparison means comparison of groups 4 and 6.
61 Martins et al. (1998): the current vitamin C group is the combina-
tion of their 50-200 mg/kg feed groups.
119
____________________________________________________
Study
Animal
Infection     Treatment P 1
____________________________________________________
Sabin-1939 Vit C Cont
Rhesus monkey (oranges)
Occurrence of
spontaneous infections
Animal no. 21 25
Mortality due to
pneumonia 0 5 .020
all infections 1 9 .006
__________________
Honjo-1969 Vit C Cont
Macaque monkey (sweet
Experimental Shigellosis potatoes)
Animal no. 4 7
Bloody stool 0 3 .10
__________________
McConkey-1933 2 Vit C Cont
Guinea pig (tomato
Infected with juice)
M. tuberculosis
by oral inoculation
Experiment I
Animal no. 5 10
Intestinal tract TB
at autopsy 1 7 .053
Experiment II
Animal no. 5 16
Intestinal tract TB
at autopsy 0 15 .000,2
Vit C Cont
(cabbage)
Experiment II
Animal no. 10 16
Intestinal tract TB
at autopsy 5 15 .010
__________________
De Savitsch-1934 3 Vit C Cont
Guinea pig (orange
Subcutaneous inoculation juice)
of M. tuberculosis
Animal no. 11 12
TB in the spleen score 0(6); 0;1(2); .008
(scale 0 to 4) 1(2); 2(5);
2(2);3 3(4)
TB in the liver score 0(9); 0(6); .038
(scale 0 to 4) 1(2); 1(2);
2(3);3
TB in the lungs score=0 8 3 .016
(scale 0 to 4)
__________________
Greene-1936 4 Vit C Cont
Guinea pig (orange
Infected with juice)
M. tuberculosis
Table 3:
Intraperitoneal inoculation
Animal no. 12 12
Survival time, Median (d) 81 60.5 .042
Table 7:
Subcutaneous inoculation
Animal no. 16 15
Survival time, Median (d) 152 80 .000,6
Table 9:
Subcutaneous inoculation
Animal no. 9 12
Survival time, Median (d) 67 46 .016
Table 15:
Oral administration
Animal no. 17 17
Mortality in 150 d 1 8 .005
Table 20:
Oral administration
Animal no. 12 11
Survival time, Median (d) 171 107 .011
Table 22:
Sputum fed animals
Animal no. 17 14
Survival time, Median (d) 168 121 .002
__________________
Appendix 3. The effect of vitamin C on animal infections:
Difference between the groups not specific to vitamin C
3 De Savitsch et al. (1934): TB, tuberculosis.
4 Greene et al. (1936) reported the survival data of their guinea pigs, but the data is not reproduced here; the median survival time was estimated
using the Kaplan-Meier method. Since the survival of uninoculated vitamin C deficient guinea pigs was over 200 days, the shorter survival
time in infected vitamin C deficient guinea pigs is not caused by vitamin C deficiency per se.
1 The 1-tailed P-value. In the case of dichotomous data, the mid-P-
value was calculated by the current author (see Table 7). The sur-
vival data was analyzed using the log-rank test. In the case of sur-
vival and score data, the number in parenthesis (n) indicates the
number of animals with the same outcome value; ‘+’ indicates
censoring.  The score data was analyzed using the Wilcoxon test
with normal approximation.
2 McConkey & Smith (1933): TB, tuberculosis. Experiment I: com-
parison of groups E and G. Experiment II: comparison of groups I
and K (tomato juice) and M (cabbage leaves).
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Boyden-1955 5 Vit C Cont
Guinea pig (fresh
Infected with alfalfa,
M. tuberculosis grass)
Animal no. 10 10
Survival time (d) 53(3); 20;21; <.000,1
61;67; 22(2);
74(2); 25(2);
99+(3) 29;32;
36;50
__________________
Findlay-1923 Vit C Cont
Guinea pig (orange
Infected with juice)
S. pneumoniae
Intraperitoneal inj. 6
(Table II: 1-2×10exp[+9])
Animal no. 16 8
Survival time, Median (d) 6.5 2 <.000,1
Subcutaneous inj.
Table III
Animal no. 8 4
Mortality 3 4 .036
__________________
Werkman-1924 Vit C Cont
Guinea pig (lemon
juice)
S. pneumoniae (Table 1)
Animal no. 8 8
Mortality in 3 d 1 4 .077
S. pneumoniae
or Bacillus anthracis
(Table 4) 7
Animal no. 43 34
Mortality in 4 d 23 28 .005
__________________
Takahashi-1935 Vit C Cont
Guinea pig (juice of
Infected with Daikon
Staphylococcus -radish)
Table 7
Animal no. 6 11
Osteomyelitis in the ribs 0 9 .002
Table 8
2 or 3 week vit C deficiency
in the control group
Animal no. 9 18
Osteomyelitis
in the ribs 0 18 <.000,1
in the long bones 0 8 .010
__________________
Taylor-1937 8 Vit C Cont
Guinea pig (orange
Intradermal inj. of juice)
S. haemolyticus
Animal no. 7 10
Bacteria stained
in the mitral valve 0 7 .003
__________________
Grant-1926 Vit C Cont
Guinea pig (orange
Salmonella typhimurium juice)
(B. aertrycke)
Spontaneus infection
caused by intestinal bacteria
(Table 1: cod-liver oil)
Animal no. 12 20
Infected 0 10 .002
Inoculation by mouth
(Table 2: cod-liver oil)
Animal no. 4 6
Infection of spleen 0 6 .003
__________________
Höjer-1924 9 Vit C Cont
Guinea pig (orange
Spontaneous juice)
acute infections
Animal no. 45 72
Signs of infections 9 34 .002
Animal no. 40 24
Mortality due to infections 8 13 .004
__________________
Schmid-Weyland-1928 Vit C Cont
Guinea pig (lemon
Inhalation of fowl cholera juice)
(Pasteurella)
and S. pneumoniae
Table 4: series III
Animal no. 10 10
Infected with fowl cholera 0 8 .000,2
__________________
Karel-1941 Vit C Cont
Guinea pig (green
Infection with group C food)
streptococcus
Animal no. 30 20
Mortality in 2 d 16 9 .7
Sulfanilamide groups
Animal no. 30 20
Mortality in 14 d 12 12 .091
__________________
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King-1935 Vit C Cont
Guinea pig (orange
Diphtheria toxin inj. juice)
Table 1
Animal no. 15 15
Mortality in 26 d 5 10 .043
Subcutaneous hemorrhagic
necrosis at the site
of injection 0 15 <.000,1
Figure 1: B-groups
Animal no. 5 5
Mortality 0 5 .002
Subcutaneous hemorrhagic
necrosis at the site
of injection 0 5 .002
__________________
Schultz-1936 Vit C Cont
Guinea pig (orange
Infection with group C juice,
streptococcus cabbage)
Control group:
3 ml/week orange juice
Animal no. 26 6
Mortality 7 6 .001
Control group:
6-9 ml/week orange juice
Animal no. 26 17
Mortality 7 9 .051
___________________________________________________________
5 Boyden & Anderson  (1955): the survival times were measured by the current author from their fig. 1.
6 Findlay (1923) reported the survival data of his guinea pigs but the data is not reproduced here; the median survival time was estimated using
the Kaplan-Meier method.
7 Werkman et al. (1924): data is from their table 4 which "summarized the results of 4 final series of experiments using the pneumococcus or B.
anthracis."
8 Taylor (1937): the current vitamin C group is the combination of groups 3 (normal diet) and 5 (scorbutic diet before infection and normal diet
after infection), and the control group is the combination of groups 2 (scurvy) and 4 (subacute scurvy).
9 Höjer (1924 pp 37-38, 120): the current vitamin C group consists of his animals with a ‘complete diet’, and the control group of his guinea pigs
with marginal scurvy (‘scorbut mitior’).
122
123
___________________________________________________
Study
Animal
Infection     Treatment P 1
___________________________________________________
Smith-1984 2 Vit E Cont
Cows
Spontaneous mastitis
Animal no. 41 39
No. of quarters: 164 156
Clinical mastitis 43 60 .010
__________________
Weiss-1997 3 Vit E Cont
Cows
Spontaneous mastitis
Animal no. 19 22
No. of quarters 76 88
Infected quarters 9 28 .002
Clinical mastitis 2 22 .000,02
__________________
Stephens-1979 Vit E Cont
Lamb
Inoculated with Chlamydia
Animal no. 10 10
Chlamydia isolated
in lungs at 11 d 0 4 .022
Weight gain in 11 d (kg) 4
Mean 2.32 1.37 .023
SD 0.66 1.23
__________________
Teige-1978 5 Vit E Cont
Pig
Treponema hyodysenteriae
Table 3
Animal no. 12 12
Days before diarrhea 8(3); 3(2); .4
9(3); 4;
10(2); 8(3);
11; 10(2);
13(2); 11;15;
30+ 17;30+
__________________
Teige-1982 6 Vit E Cont
Pig
T. hyodysenteriae
Table 3
Animal no. 12 12
Days before diarrhea 6(6); 6(3); .029
7;8(2); 7;8;
9;11; 9(2);
12; 10;12;
22+(3)
__________________
Peck-1991a 7 Vit E Cont
Guinea pig
Infected with E. coli
and S. aureus
Medium dose vit E
Animal no. 15 15
Mortality 7(46%) 14 .004
High dose vit E
Animal no. 14 15
Mortality 10(71%) 14 .08
__________________
Appendix 4. The effect of vitamin E on animal infections:
Administration of pure vitamin E to the ‘vitamin E group’
1 The 1-tailed P-value. The mid-P-value was calculated for dichotomous data by the current author (see Table 7), and the t-test was used for
continuous data. The survival data and the days before diarrhoea were analyzed using the log-rank test. In the case of survival and score data,
the number in parenthesis (n) indicates the number of animals with the same outcome value; ‘+’ indicates censoring.
2 Smith et al. (1984): data on the incidence of mastitis is from their table 3: the no-selenium and selenium groups are combined in this table.
3 Weiss et al. (1997): data on the incidence of mastitis: the current vitamin E group is treatment 3 (2,000 IU/day vitamin E during lactation) and the
control group is treatment 1 (100 IU/day vitamin E). The number of quarters with mastitis has been calculated from the published percentages.
4 Stephens et al. (1979) used the t-test to calculate that P < 0.05. The measure of variation in their table apparently thus refers to "SD" and not
"SE" as stated in the paper.
5 Teige (1978): the no-selenium and selenium groups are combined in this table.
6 Teige (1982): the no-selenium and selenium groups are combined in this table.
7 Peck & Alexander (1991a): data is from their table III. The groups of the current table are the combinations of the two low vitamin C groups
(1× and 5×RDA). Current high vitamin E refers to 9×RDA and medium vitamin E to 3×RDA.
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Tvedten-1973  8 Vit E Cont
Rat
Infected with
Mycoplasma pulmonis
Animal no. 5 5
Mycoplasma in the lungs 0 4 .012
__________________
Powell-1989 9 Vit E Cont
Rat
Experimental peritonitis
Animal no. 10 10
Survival time (d) 1(2); 0.5(5); .000,1
1.5(3) 1(5)
3;4;7+(3)
__________________
Powell-1991 10 Vit E Cont
Rat
Experimental peritonitis
Animal no. 10 32
Survival time (d) 1(2); 1(30); .000,03
1.5(3); 1.5;3+
3;3+(4)
__________________
Soybir-2002 11 Vit E Cont
Rat
Experimental peritonitis
Animal no. 28 30
Mortality 9 16 .057
__________________
Özlü -1999 12 Vit E Cont
Rat
Injection of bacterial
suspension to trachea
Animal no. 10 10
CFU in lavage at 3 d
Mean 208 4849 .002
SD 358 4798
__________________
Yoshikawa-1982 13 Vit E Cont
Rat
Endotoxin inj.
Rat model of DIC
Animal no. 10 12
Glomeruli with fibrin
deposits (% of glomeruli)
Mean 4.2% 75.2% <.000,001
SD 1.5% 9.7%
Fibrinogen
Mean (mg/ml) 0.37 <0.2
SD 0.10
Fibrin degradation products
Mean (µg/ml) 5.1 43.1 <.000,001
SD 1.0 5.4
__________________
Yoshikawa-1984 14 Vit E Cont
Rat
Endotoxin inj.
Rat model of DIC
Animal no. 18 19
Glomeruli with fibrin
deposits (% of glomeruli)
Mean 40.2% 57.3% .000,002
SD 9.1% 9.3%
Fibrinogen
Mean (mg/ml) 0.62 0.37 .000,002
SD 0.11 0.16
Fibrin
degradation products
Mean (µg/ml) 10.1 13.8 .028
SD 5.2 6.1
__________________
McKechnie-1986 15 Vit E Cont
Rat
Endotoxin inj.
Animal no. 15 15
Survival time (d) 1(7); 1(13); .000,6
4+(8) 3(2)
__________________
Kunimoto-1987 16 Vit E Cont
Rat
Endotoxin inj.
Animal no. 20 30
Survival time (h) 3(3); 3(8); .062
6(8); 6(14);
12(2); 12(2);
24+(7) 24;
24+(5)
__________________
8 Tvedten et al. (1973): data is from their table 4: the current vitamin
E group is conventionally maintained ‘vitamins A and E supple-
mented’ group and the control group is their ‘vitamin E deficient’
group.
9 Powell et al (1989): sepsis caused by cecal ligation and puncture
(CLP). Three rats in vitamin E group remained alive 1 week after
the study was completed. Thus, there was 1 death between 3 and 7
days.
10 Powell et al. (1991): sepsis caused by cecal ligation and puncture
(CLP). The current vitamin E group is the PRE-AT group with 3
days pretreatment prior to CLP.
11 Soybir et al. (2002): the current vitamin E group consists of group 5
(vitamin E) and group 7 (antibiotics and vitamin E) and the control
group consists of group 1 (control) and group 6 (antibiotics).
12 Özlü et al. (1999): 0.1 ml of a suspension containing 6 bacterial
species was instilled into the tracheal lumen by trans-tracheal injec-
tion. P-value calculated using Mann-Whitney U-test by the original
authors. CFU, colony forming units.
13 Yoshikawa et al. (1982) administered E. coli lipopolysaccharide B.
DIC, disseminated intravascular coagulation.
14 Yoshikawa et al. (1984) administered E. coli lipopolysaccharide B.
DIC, disseminated intravascular coagulation.
15 McKechnie et al. (1986) administered E. coli lipopolysaccharide.
16 Kunimoto et al. (1987) administered E. coli lipopolysaccharide. The
highest vitamin E group has been compared with the group pre-
treated with saline.
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Ashorobi-1995 17 Vit E Cont
Rat
Endotoxin inj.
Animal no. 40 40
Survival time (h) 5(13); 5(29); .000,3
12(2); 24(4);
24(3); 48+(7)
48;
48+(21)
Indomethacin treated
Animal no. 20 20 .004
Survival time (h) 5(2); 5(5);
48+(18) 12(4);
24;
48+(10)
__________________
Suntres-1996 18 Vit E Cont
Rat
Endotoxin inj.
Lung edema
Vit E 2 h after endotoxin
Animal no. 5 5
Lung weight increase in 1 d
Mean 31% 61% .021
SD 12% 25%
Vit E 4 h after endotoxin
Animal no. 5 5
Lung weight increase in 1 d
Mean 33% 62% .005
SD 12% 15%
__________________
Suntres-1998 19 Vit E Cont
Rat
Endotoxin inj.
Lung edema
Animal no. 5 5
Lung weight increase in 2 h
Mean 18% 37% .034
SD 9% 18%
__________________
Heinzerling-1974a 20 Vit E Cont
Mouse
Infected with S. pneumoniae
Nonimmunized mice
Medium vit E
Animal no. 20 20
Mortality 7(35%) 16 .003
High vit E
Animal no. 30 20
Mortality 16(53%) 16 .031
Immunized mice
Medium vit E
Animal no. 20 20
Mortality 6(30%) 15 .003
High vit E
Animal no. 30 20
Mortality 16(53%) 15 .07
__________________
Marubayashi-1989 21 Vit E Cont
Mouse
Endotoxin inj.
Animal no. 35 12
Survival time (d) 1(3); 1(3); .002
2(17); 2(9)
2+(15)
__________________
Fang-1990 22 Vit E Cont
Mouse
Burned animals,
infected with
Ps. aeruginosa
Animal no. 51 25
Mortality 23 21 .000,7
__________________
17 Ashorobi et al. (1995) administered E. coli lipopolysaccharide. The current vitamin E group is the combination of groups VII and VIII and the
control group is the combination of groups III and IV. The current indomethacin control group is group VI, and the indomethacin+vitamin E
group is group XII.
18 Suntres et al. (1996) administered E. coli lipopolysaccharide. The current control group is their liposome group. Data is measured from their
Fig. 1.
19 Suntres et al. (1998) administered E. coli lipopolysaccharide. The current control group is their ‘plain liposome group’.
20 Heinzerling et al. (1974a): data for nonimmunized mice is from their fig. 1. The current control group is the combination of 0 and 60 mg/kg,
the vitamin E(medium) group of 120 and 180 mg/kg, and the vitamin E(high) group of the 240, 300 and 360 mg/kg diet groups. Data for im-
munized mice is from their fig. 2 with the same collapse of categories.
21 Marubayashi et al. (1989) administered E. coli lipopolysaccharide.
22 Fang et al. (1990): data is for their group administered vitamin E on 4 consecutive days starting 2 days preceding the burn. The current vitamin
E group is the combination of their MED and HI groups.
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Peck-1991b Vit E Cont
Mouse
Burned animals,
infected with
Ps. aeruginosa
Low vit E
Animal no. 30 30
Mortality 20 21 .4
High+Med vit E
Animal no. 60 30
Mortality 51 21 .94
__________________
Beck-1994 23 Vit E Cont
Mouse
Infected with
coxcackievirus
Strain CVB3/20
Lard diet
Animal no. 5 5
Virus detectable
in myocardium at 14 d 0 5 .002
Menhadden oil diet
Animal no. 5 5
Virus detectable
in myocardium at 14 d 0 5 .002
Strain CVB3/0
Lard diet
Animal no. 5 5
Virus detectable
in myocardium at 14 d 0 5 .002
Menhadden oil diet
Animal no. 5 5
Virus detectable
in myocardium at 14 d 0 5 .002
__________________
Beck-2003 Vit E Cont
Mouse
Infected with
coxcackievirus
Se deficient
Animal no. 4 4
Log(cardiac virus titre) 24
Mean 5.6 9.5 .007
SD 1.3 1.9
Log(liver virus titre) 24
Mean 4.6 7.9 .006
SD 1.6 0.8
__________________
Hayek-1997 Vit E Cont
Mouse
Infected with
influenza virus
Young mice
Animal no. 9 7
Log(virus titre)
in the lungs at 5 d
Mean 2.95 3.50 .024
SD 0.53 0.46
Animal no. 5 6
Log(virus titre)
in the lungs at 7 d
Mean 0.88 0.91 .5
SD 0.70 0.73
Old mice
Animal no. 6 4
Log(virus titre)
in the lungs at 5 d
Mean 2.35 3.61 .001
SD 0.43 0.45
Animal no. 6 5
Log(virus titre)
in the lungs at 7 d
Mean 1.05 2.08 .024
SD 0.73 0.75
__________________
Han-2000 Vit E Cont
Mouse
Infected with
influenza virus
Animal no. 5 5
Weight loss in 5 d
Mean (g) 1.84 6.78 .009
SD 2.03 3.11
__________________
Sugino-1987 25 Vit E Cont
Mouse
Endotoxin inj.
Animal no. 35 21
Survival time (d) 1(3); 1(12); .000,003
2(17); 2(9);
2+(15)
__________________
23 Beck et al. (1994): There were 5 or 10 animals per group. Here it is assumed conservatively that there were 5 animals per group.
24 Beck et al. (2003) published the cardiac and liver virus titers for 4 mice per treatment group in their table 1. It is not stated whether these are
the same mice as the 5 mice used for histopathologic analysis. In the current table, the titers were log-transformed before the t-test. One of the
4 liver virus titers was "not detectable" which was replaced with 10 units, which is the lowest reported titer in their table.
25 Sugino et al. (1987) administered E. coli endotoxin.
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Mayorga-2004 26 Vit E Cont
Mouse
Endotoxin inj.
Fig. 3 vit E 22 h before LPS
4 mg LPS/kg
Animal no. 10 10
No. viable embryos
Mean 15.4 9.5 .000,5
SD 4.0 2.5
10 mg LPS/kg
Animal no. 10 10
No. viable embryos
Mean 18.6 7.2 <.000,001
SD 4.6 2.2
Fig. 4 vit E 5 d before LPS
4 mg LPS/kg
Animal no. 10 10
No. viable embryos
Mean 19.0 9.5 <.000,001
SD 1.0 2.6
10 mg LPS/kg
Animal no. 10 10
No. viable embryos
Mean 13.7 7.1 .000,2
SD 2.6 3.8
__________________
Sell-1997 Vit E Cont
Turkey
Infected with E. coli
Table 3
Animal no. 23 24
Mortality 7 3 .92
__________________
Zhu-2003 Vit E Cont
Turkey
Infected with
Listeria monocytogenesis
Experiment 1
Animal no. 25 24
Days of cloacal 1(8); 1(2); .026
swabs becoming 4(16); 4(20);
clean of Listeria 4+ 4(2)+
__________________
Huff-2004 27 Vit E Cont
Turkey
Infected with E. coli
Animal no. 60 60
Mortality 0 8 .002
Isolation of E. coli
from the liver 0 10 .000,4
__________________
Hill-1955 28 Vit E Cont
Chicken
Infected with Salmonella
Animal no. 40 40
Mortality 7 15 .026
__________________
Heinzerling-1974b 29 Vit E Cont
Chicken
Infected with E. coli
Animal no. 151 78
Mortality 7 22 <.000,001
__________________
Tengerdy-1975 30 Vit E Cont
Chicken
Infected with E. coli
Animal no. 30 30
Mortality 2 12 .000,2
__________________
Tengerdy-1977 31 Vit E Cont
Chicken
Infected with E. coli
Animal no. 42 39
Mortality 10 19 .011
__________________
Likoff-1981 32 Vit E Cont
Chicken
Infected with E. coli
Animal no. 22 22
Mortality in 2 d 8 18 .002
Aspirin groups
Animal no. 22 22
Mortality in 2 d 0 9 .000,4
__________________
26 Mayorga et al. (2004) administered S. typhimurium lipopolysaccharide (LPS).
27 Huff et al. (2004): data is from their figs. 2 and 4. There were 60 birds per group, and the mortality was calculated from the percentages in the
figures.
28 Hill et al. (1992): data is from their table 5. There were 40 birds per treatment group, and the mortality was calculated from the percentages in
their table. The current vitamin E group is their group with ‘basal diet+vitamins’ and the current control group is their group with ‘basal
diet+vitamins–E’ (vitamin E excluded).
29 Heinzerling et al. (1974b): data is from their table 1. Trials 1 and 2 are combined, and two vitamin E groups (150 and 300 mg/kg diet) are
combined to the current vitamin E group.
30 Tengerdy & Nockels (1975): data is from their Table 3. Mortality is calculated from mortality percentage and the total number of chicken
(n=30).
31 Tengerdy & Brown (1977): data on experiment 1 (table 4: groups IE2 vs. IC) and experiment 2 (table 6: groups IE2 vs. IC) has been combined
in the current table.
32 Likoff et al. (1981) reported the mortality percentage in their table 5. The number of chickens per group is inferred from their table 1 footnote.
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Downs-2000 33 Vit E Cont
Chicken
Experimental E. coli
cellulites
Animal no. 200 200
Chickens with
cellulites lesions 84 102 .036
__________________
Yang-2000 Vit E Cont
Chicken
Infected with E. coli
HAS-chicks
Animal no. 50 50
Weight loss in 1 d
Mean 6.4% 8.5% .027
SD 5.7 5.0
LAS-chicks
Animal no. 50 50
Weight loss in 1 d
Mean 4.4% 3.5% .8
SD 6.4 5.0
__________________
Schildknecht-1979 Vit E Cont
Chicken
Infected with
Histomonas meleagridis
–protozoa (histomoniasis)
Animal no. 24 24
Mortality 19 20 .4
Ipronidazole-treatment
Animal no. 18 18
Mortality 7 11 .11
__________________
Allen-2002 34 Vit E Cont
Chicken
Infected with
Eimeria maxima
-protozoa
Trial 1: strain ESS
Animal no. 15 15
Intestinal lesion score
Mean 1.87 2.80 .015
SD 1.05 1.16
Trial 2: strain Guelph
Animal no. 10 10
Intestinal lesion score
Mean 3.6 3.3 .7
SD 1.27 0.63
__________________
Furones-1992 35 Vit E Cont
Rainbow trout
Infected with Y. ruckeri
Animal no. 90 90
Mortality 28 39 .047
__________________
33 Downs et al. (2000): data was measured by the current author from their fig. 1, which gives the percentage of broilers with lesions. Since there
were 800 broilers in the study with 4 study groups, it is assumed that there were 200 broilers per group.
34 Allen et al. (2002): the current vitamin E groups are their 153 and 200 ppm groups, and control groups are their 13.2 and 13 ppm groups in
their trials 1 and 2 respectively.
35 Furones et al. (1992): data is for injected fish: the number of diseased fish was calculated from the mortality percentage.
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Wahli-1998 36 Vit E Cont
Rainbow trout
Infected with VHS virus
Low vit C
Animal no. 50 50
Mortality 29 13 .9993
High vit C
Animal no. 50 50
Mortality 2 10 .008
Infected with Y. ruckeri
Low vit C
Animal no. 50 50
Mortality 16 48 <.000,1
High vit C
Animal no. 50 50
Mortality 18 20 .4
Infected with I. multifiliis
–protozoa
Low vit C
Animal no. 50 50
Mortality 1 21 <.000,1
High vit C
Animal no. 50 50
Mortality 4 3 .6
__________________
36 Wahli et al. (1998): the current vitamin E group refers to fish administered 0.8 g vitamin E/kg feed. Low vitamin C groups were not ad-
ministered any additional vitamin C; high vitamin C groups were administered 2 g vitamin C/kg feed. VHS, viral hemorrhagic septicemia
virus.
37 Thorarinsson et al. (1994): data was measured by the current author from their fig. 3. The cumulative mortality at 324 days was calculated
from the mortality percentage and the total number of fish at the start (n = 150).
Thorarinsson-1994  37 Vit E Cont
Chinook salmon
Infected with
R. salmoninarum
Low selenium
Animal no. 150 150
Mortality 4 46 <.000,1
High selenium
Animal no. 150 150
Mortality 0 5 .015
__________________
Ito-1999 Vit E Cont
Yellowtail-fish
Infected with the bacterium
causing fish jaundice
Animal no. 10 10
Mortality 4 0 .98
__________________________________________________
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1 The 1-tailed mid-P-value was calculated by the current author (see
Table 7). The days before diarrhoea were analyzed using the log-
rank test. Continuous data was analyzed using the t-test. The number
in parenthesis (n) indicates the number of animals with the same
outcome value; ‘+’ indicates censoring.
2 Sabin and Duffy (1940): data on maternal diet is from their table I,
and on prematurely weaned mice from their table II. The ‘control
group’ was administered casein, yeast, cod liver oil, and the ‘vitamin
E group’ was administered wheat germ oil in addition to the basic
diet. VSV, vesicular stomatitis virus.
3 Broner et al. (1989) administered vitamin E along with superoxide
dismutase, sodium thiosulphate, sodium diethylthiocarbamate, and
desferoxamine to the antioxidant group.
4 Sjunnesson et al. (2001): data was measured by the current author
from their fig. 2. The current vitamin E group refers to diet 3: vita-
mins A, C and E, and selenium supplementation.
Appendix 5. The effect of vitamin E on animal infections:
Difference between the groups not specific to vitamin E
____________________________________________________________
Study
Animal
Infection     Treatment P 1
____________________________________________________
Sabin-1940 2 Vit E Cont
Mice (wheat
Infected with VSV virus germ oil)
at 4 weeks of age
Table I
Effect of maternal diet
Animal no. 15 15
Fatal paralysis 4 8 .08
Table II
Prematurely weaned mice
Animal no. 16 15
Fatal paralysis 6 12 .011
__________________
Teige-1977 Vit E+Se Cont
Pig
Experimental
swine dysentery
Animal no. 8 8
Days before diarrhea 8;10; 7(3); .004
11;12; 8(3);
13; 11;
14(2); 12
25+
__________________
Teige-1978 Vit E+Se Cont
Pig
T. hyodysenteriae
Table 2
Animal no. 6 6
Days before diarrhea 15;22; 5;7; .002
23;30; 10;15;
30+(2) 19;20
Cod liver oil groups
Animal no. 6 6
Days before diarrhea 30+(6) 6;8;9; .000,3
13;17;
21
__________________
Broner-1989 3 Vit E+ Cont
Rabbitt
Experimental E. coli sepsis
Moxolactam-treatment
Animal no. 12 12
Mortality 9 8 .6
__________________
Bennett-1999 Vit E+A Cont
Rat
Infected with E. coli
Ciprofloxacin-treatment
Animal no. 8 8
Renal inflammation 1 8 .000,4
__________________
Umar-1999 Vit E+C Cont
Rabbit
Infected with T. brucei
Animal no. 5 5
Log(parasites in blood/ml) 7.9 7.9 .5
SD 0.2 0.1
__________________
Sjunnesson-2001 4 Vit E+ Cont
Guinea pig
Infected with
H. pylori
Animal no. 12 14
Gastritis score
(scale 0 to 3)
Mean 0.33 0.93 .047
SD 0.66 1.02
___________________________________________________
